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Abstract
 Activation of the NF-κB transcription factor during cellular infection establishes 
an anti-viral state via upregulation of proinflammatory proteins.  Wild-type vaccinia virus 
(VV) strains subvert the immune response by expressing proteins that interfere with 
nuclear translocation of NF-κB.  In contrast, infection with an attenuated strain, MVA, 
results in host cell NF-κB activation.  
 Inclusion of the M2 gene of VV into the attenuated MVA virus was shown to 
reduce NF-κB activation, and also ERK1/2 activation, an early event in MVA infection.  
Understanding the molecular basis for M2- mediated inhibition of NF-κB and ERK1/2 
activation was the primary goal of this dissertation.
 Characterization of the M2 protein began with an examination of its expression 
profile during infection.  Much like other immunomodulators, M2 is expressed early 
during infection.  Analysis of the M2 amino acid sequence revealed an N-terminal signal 
peptide sequence, 4 putative glycosylation residues, and endoplasmic reticulum (ER) 
retention/retrieval sequences, indicative of an ER-localized protein. 
 Confocal microscopy analysis confirmed localization of M2 to the ER.   It was 
found that M2 requires a signal peptide cleavage site to confer proper localization and 
targeting across the ER membrane and that M2 is N-linked glycosylated.  Mutant M2 
proteins that are missing either a putative N-terminal signal peptide (∆sp) sequence or a 
C-terminal ER  (∆ERret) localization sequence no longer localize to the ER, and have a 
reduced ability to inhibit NF-κB activation and ERK1/2 activation.  As such, ER 
localization is critical for full NF-κB and ERK1/2 inhibitory activity for the M2 protein.  
 An M2 mutant lacking the signal peptide lost proper ER targeting and was not 
glycosylated.  This M2 mutant also lost NF-κB and ERK1/2 inhibitory activity.  It 
remained unclear whether loss of NF-κB or ERK1/2 inhibitory function was the result of 
impaired ER localization, trafficking, or post-translational modification.  
 Using site directed mutagenesis, mutant viruses expressing M2 proteins that were 
impaired in targeting or modification via the secretory pathway revealed functional 
consequences. 
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 Four mutant viruses expressing M2 with each of the four putative glycosylation 
sites abolished (N49Q, N79Q, N118Q, N154Q), and two mutant viruses (S17I and S17F) 
which prevent recognition by the signal peptidase present in the ER lumen were 
constructed.  Of the amino acid residues tested, 17,49,79,118,154 contribute to ERK1/2 
inhibitory activity, while residue 118 contributes the most for NF-κB inhibitory activity.   
It was also found that the level of M2 protein expression is influenced by the level of 
glycosylation conferred to the protein.  
  Data presented in this dissertation establish that M2 is not only cell associated, 
but transits the classical secretory pathway into the cellular medium as evidenced by 
sensitivity to Brefeldin A treatment.  Alteration to the signal peptide cleavage site 
impaired the time of cellular secretion of M2.  Most intriguing was that a point mutation 
within the second glycosylation site (N79Q) resulted in a non-detectable protein which 
still had function, indicating that transient expression of N79Q is sufficient to inhibit 
cytoplasmic signaling pathways.  
 This dissertation elaborates on M2’s molecular functioning as a viral 
immunomodulator to inhibit both the ERK1/2 and NF-κB pathways, which is reliant on 
its glycosylation status and proper cellular trafficking within the infected cell.  As M2 has 
no homology to any known viral or cellular protein, this suggests a novel 
immunoregulatory function.  Data contained within this dissertation provides insight into 
the molecular mechanism of an ER-localized protein, and its impact on cytoplasmic 
signaling pathways within the context of an anti-viral immune response.
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Chapter I: Introduction
Poxvirus History and Modern Relevance 
 Poxviruses are among the largest and most complex of animal viruses.  They are 
distinguished from other classes of DNA viruses in that its replication cycle occurs only 
in the cytoplasm for the duration of the infectious cycle, from viral entry until progeny 
viruses exit through the plasma membrane (49).  With a DNA genome of approximately 
200 kilobases (kb), they encode nearly 200 proteins.  Due to their large genomic size, 
most genes encode the replicative machinery, which is independent of the host-cell 
nucleus.  
 Poxviruses are significant due to their devastating impact on public health, both 
past and present.  They are still relevant today because of the variety of diseases of both 
veterinary and medical importance,  emergence of wild poxvirus strains, and fear of 
bioterrorism.  Their large size has also been exploited to deliver therapeutics, such as 
oncolytic vectors for drug delivery.  Thus, poxviruses have a important role in not only 
the diseases they cause, but also for their potential to be used as vectors in the treatment 
of other diseases.  
 Poxviruses can be categorized into different genera and species which infect a 
large variety of vertebrates and invertebrates.  The Poxviridae family consists of two 
subfamilies, Chordopoxvirinae, which infects vertebrates, and the Entomopoxvirinae, 
which infect arthopods. The vertebrate subfamily Chordopoxvirinae consists of eight 
different genera, four of which, Orthopoxviridae, Parapoxviridae, Yatapoxviridae, and 
Molluscipoxviridae, are able to infect and cause disease in humans.  The Orthopoxvirus 
genus is especially of interest to the scientific community, as four species, variola (the 
causative agent of smallpox), monkeypox, cowpox, and vaccinia virus cause human 
disease.  Many poxviruses genomes have been sequenced and are highly similar.  
 Variola virus, the causative agent of smallpox, is the best-known poxvirus.  
Historically, poxviruses have been instrumental in understanding pathogenesis.  The 
deliberate inoculation of smallpox, variolation, was believed to be initiated by a Buddhist 
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nun some time between 1022 and 1063 AD, a practice spreading to China, India and 
Turkey, and by the late 1700s, used by European physicians.  Variolation involved 
various methods, such as inhalation of powdered scabs into the nose, or inoculation of 
pus into the skin.    Although a 1% chance of contracting smallpox was likely, the benefit 
of gaining lifelong immunity against smallpox was worth the risk.  Edward Jenner’s 
demonstration in 1796 that human inoculation of cowpox virus protected against 
smallpox, ushered in the concept of cross-protective immunity.  Jenner noted that 
milkmaids who developed cowpox, a less serious disease, did not develop the deadly 
smallpox disease.  Using fluid from a cowpox pustule on a dairymaid’s hand, he 
inoculated an 8-year-old boy.  Six weeks later, when the boy was challenged with 
smallpox, he did not develop smallpox, indicating Jenner’s vaccination was effective.  
This form of “vaccination,” a phrase coined by Jenner to pay homage to the cow, 
appeared to be safer than the method of variolation.  Although the complications from 
Jenner’s vaccination method was less than that of variolation, its protective effects lasted 
only 5-10 years.  Ultimately, the cowpox vaccine was replaced by vaccinia virus.       
 
Variola (Smallpox) Virus
 Smallpox, the most notorious poxvirus disease, is caused by the variola virus, 
which exclusively infects humans.  Smallpox was a devastating disease which afflicted 
people across nearly all continents and throughout centuries.  Collectively, smallpox has 
killed more people than all collective wars and diseases combined (40).  The eradication 
of variola virus in the wild had a large impact on the modern practice of vaccination.  
 In 1967, a global campaign under the supervision of the World Health 
Organization (WHO) succeeded in eradicating smallpox in 1977.  The WHO declared 
smallpox eliminated from natural settings in 1980, and recommended that all countries 
cease vaccination.  Surprisingly, little was known about the cellular and immune-based 
mechanism by which vaccinia virus afforded protection to the host immune system.  
Despite smallpox eradication, research on poxviruses continued.  Advances in modern 
techniques in the different fields of virology, immunology, and molecular biology has 
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allowed for the study of viral proteins and functions, and has contributed to our current 
understanding of how poxviruses cause disease. 
 Several factors contributed to why smallpox was able to be eradicated.  First, the 
natural host was strictly humans.  Thus, it was not spread by animal vectors and 
contained it within the human population.  Second, it was a severe disease causing high 
morbidity and mortality, creating a public health need for eradication efforts.  Third, and 
most importantly, vaccination against variola virus was obtainable with the related 
vaccinia virus.  This allowed for protection of uninfected individuals against the disease.  
Fourth, the ability of a cheap and effective, heat-stable vaccine and committed 
governments around the world also factored in the success of the smallpox eradication 
campaign (40).  Collectively, these circumstances favored the elimination of variola virus 
from the wild.  
 Naturally occurring variola virus has been eliminated worldwide.  Stocks of 
variola virus legally exist only at the Center for Disease Control in Atlanta, Georgia, and 
at the State Research Center of Virology and Biotechnology, also known as the Vector 
Institute in Koltsovo, Russia.  Variola virus destruction was considered in 1993, 1999, 
and 2002 (33, 35).  Also, the WHO called for countries that harbored smallpox strains to 
destroy them due to fears of weaponization of smallpox, and intentional or accidental 
release of the virus to the wild.  The WHO considered destroying these laboratory 
samples, a topic that divided the scientific community, with those for and against 
destroying smallpox stocks.  
 Ultimately, the WHO ruled that retaining existing viral stocks was important to 
aid in the possible develop of a more attenuated, safer smallpox vaccine, and the 
establishment of potential antiviral drugs to treat patients with smallpox.  Also, fears that 
stocks of smallpox still exist today in rogue nations such as Iran, Iraq, and North Korea, 
prevent the ultimate destruction of variola virus (23).  As these uncertain threats still 
remain, considerations for the continuation of variola research are still relevant.  This 
includes not only using the actual variola stock itself, but also to continue research with 
its related virus, vaccinia virus (40).    
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 There is increased concern that since smallpox vaccination ended over 20 years 
ago, the majority of today’s population possess no immunity to smallpox, and are 
susceptible to an emerging orthopoxvirus or smallpox.  In 2003, an outbreak of 
monkeypox occurred in the United States, due to handling of monkeypox virus infected-
animals imported from Central and West African countries (76).  Genomes of monkeypox 
and variola virus are 96% similar (76).  Because the clinical features of smallpox and 
monkeypox are similar, a laboratory diagnosis is needed to confirm the existence of such 
an infection.  There are continuous outbreaks of human monkeypox in Africa, so studying 
this orthopoxvirus and the related vaccinia is relevant in terms of understanding emerging 
diseases.   
Disease Progression of Smallpox 
 The disease caused by poxviruses, and the outcome of infection, is a result of both 
host and viral factors.  Poxviruses infect their host via a number of different routes 
including through the respiratory tract, and skin abrasions (71).  Smallpox infection in 
humans was commonly spread through inhalation of virus in aerosolized form via 
excretions of the mouth and nose of infected individuals.   It could also be spread with 
direct contact with infected bodily fluids or contaminated objects such as bedding or 
clothing (21). 
 The progression of  smallpox is as follows.  Upon inhalation of virus aerosols 
produced by an infected individual, respiratory tract cells serve as the initial factories for 
variola virus replication.   The incubation period lasts from 7-17 days.  During this 
period, individuals have very little symptoms and are not contagious.  After this time 
period, the onset of initial symptoms begins, which includes a fever and general malaise.  
Due to replication of the virus, respiratory tract cells die, releasing virus, which 
subsequently infects respiratory macrophages.  The infected respiratory macrophages 
enter the bloodstream and lymphatic system, allowing the virus to be transported 
throughout the body.   
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 The most contagious phase followed that of  viral replication in lymphoid organs, 
consisting with a oropharyngeal enanthema eruption.  Large amounts of virus were 
spread from the oral sores that broke open, resulting in spread via the respiratory route.   
Eventually the rash in the mouth resolves into a bumpy rash on the skin, due to cell 
associated virus localizing to dermal blood vessels.  This accounts for the centrifugal 
spread of the virus from the face to the arms and legs, and then to the hands and feet.  The 
pox pustular lesions change into scabs and the individual remains contagious until all 
scabs had fallen off of their body.   The exudate from the lesions was infectious, but 
accounted for a lesser percentage of transmission as compared to the respiratory route 
(21).  
 In human and animal models, the participation of humoral and cellular immunity 
types are crucial to overcoming a poxvirus infection.   After infection occurs, the affected 
individual has mounted a biphasic immune response to clear their current infection and to 
protect against subsequent infections.   The initial innate immune response includes 
effectors such as interferons, natural killer cells and macrophages.  This serves to 
diminish virus spread by preventing the virus from reproducing to high enough titers to 
overtake the host.  The second wave of protection is adaptive immunity, involving both 
specific B and T cells responses, critical for lasting immunity.  It has been reported that T-
cell immunity remains stable for decades (18).  B cell memory to smallpox has been 
found to persist for up to 90 years after vaccination with the DryVax vaccine (13, 58).  
Vaccinia Virus
 Vaccinia virus (VV) is the prototypic member of the genus Orthopoxvirus.  
Presently, research with VV is of continued interest because it is a model system for 
variola virus, the causative agent of smallpox.  Most of the knowledge concerning 
poxvirus biology and pathogenesis is derived from vaccinia virus.  
  Viruses within the Orthopoxvirus genus, such as VV and variola, share at least 
97% nucleotide identity, with the most conserved region in the central region of the 
genome (51).  In contrast, genes located in the terminal regions are more variable, and 
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encode proteins that are non-essential for virus replication, but affect virulence, host 
range, and modulation of the host response to infection (51, 53).  The majority of these 
immunomodulatory genes are expressed early during infection acting either intra- or 
extracellularly to provide the virus with a substantial defense against the host immune 
system.  In many instances, the removal of one or more of these immunomodulatory 
genes from VV results in a mutant virus that causes an attenuated disease in laboratory 
animals (44, 51).    
 VV genes are identified by their location in the genome, including the letter of the 
HindIII restriction fragment (A-O), the number of the gene from the 5’ end of the 
fragment (1-36), and the transcriptional orientation , with R indicating right to left, and L 
indicating left to right (17).  Thus, M2L is the second gene from the left end of the 
HindIII M restriction fragment and is transcribed in a leftward (on the reverse/bottom 
strand) orientation.  
Morphology and Vaccinia Virus Entry Into the Host Cell  
 Poxviruses are some of the largest viruses known to man and historically were the 
first to be seen microscopically.  Morphologically, poxviruses, including VV, appear as 
large brick-shaped particles. These particles contain a covalently closed, dsDNA genome 
ranging in size from 170 to 240 kilobase pairs.  Virus morphogenesis begins in 
cytoplasmic factories that are devoid of cellular organelles (14).  
 There are two infectious forms of VV, named intracellular mature virions (IMVs) 
and extracellular enveloped virions (EEVs).  IMV particles represent the majority of 
infectious progeny and most remain within the infected cell until cell lysis. The virion of 
VV consists of a complex core structure surrounded by a lipoprotein envelope.  The 
poxvirus virion possesses a DNA-dependent RNA polymerase, which is in close 
association with viral DNA. 
 The nature of the membrane envelope surrounding the IMV remain controversial.  
There is disagreement as to whether or not one or two closely opposed lipid bilayer 
membrane form the outer envelope (51).  Negative staining electron micrographs reveal 
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that the IMV envelope forms the outer bounder layer that surrounds the inner core, which 
often appears dumbbell-shaped.  The outer row of “knobs” on the core wall is termed the 
palisade (51).
 The core itself contains the dsDNA genome and virion enzymes, including DNA-
dependent RNA polymerase and RNA-processing enzymes.   The viral DNA and viral 
proteins comprise what is called the viral nucleosome.  
 Poxvirus virions do not possess an obvious helical or icosahedral nucleocapsid.  
The brick shaped IMV is released only upon cell lysis, yet can acquire a second, double 
membrane from a trans-Golgi or early endosomal compartment which forms the 
intracellular enveloped virion (IEV).  These IEVs can move to the cell surface on 
microtubules where fusion with the plasma membrane form cell-associated virions 
(CEV).  These CEV can induce an actin polymerization that promotes direct transfer and 
infection of surrounding cells.  If the IEV is released and is not retained on the cell 
surface as a CEV, it is termed an EEV.  EEV  particles contains an additional lipid bilayer 
membrane that is wrapped around the entire IMV particle.  
This is followed by morphogenesis of virus particles.
 Upon entry into a host cell, the virus must replicate to produce more viral progeny 
(see Figure 1).  It is now known  that vaccinia utilizes macropinocytosis and apoptotic 
mimicry to gain entry into the cytoplasm (46).  Recent evidence demonstrates that 
vaccinia virus also employs a cell “surfing” method to rapidly infect neighboring 
uninfected cells.  A cell which has already been infected with vaccinia virus, displays 2 
viral proteins on its surface which produce actin tails. This prevents incoming virions 
from being able to enter the cell.  This repels the incoming virus to other neighboring 
uninfected cells (20).  It is thought that this ability for cell-to-cell travel contributes to 
poxvirus infection rapidly spreading in vivo.  VV also preferentially infects antigen-
presenting cells (dendritic cells, monocytes/macrophages, B cells) and activated T cells, 
but not resting T cells (10).  This implies that VV has a limited tropism of primary human 
cells of hematolymphoid origin.  This implies a mechanism by which VV disseminates in 
activated T cells throughout the lymphatic system.   Also, the recruitment of cells which 
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will collectively secrete antiviral and inflammatory cytokines is diminished,  this will 
reduce the magnitude of the immune response by the host.  
 Once the virus enters the cell, the core is partially uncoated in the cytoplasm (see 
Figure 1).  Early VV mRNAs are transcribed here immediately.   Vaccinia virus mRNAs 
are synthesized in the cytoplasm of the infected cell in three highly coordinated temporal 
phases: early, intermediate, and late.  Each temporal phase requires completion of the 
previous one. 
 Vaccinia virus is a model for transcriptional regulation in all poxviruses, because 
these mechanisms appear to be conserved across the Poxviridae (8).  All viral proteins 
necessary for transcription of the early class of genes are packaged along with the 
genome in the core.  Genes of this early class of proteins include DNA-dependent RNA 
polymerase, an early transcription factor, capping and methylating enzymes, and a poly
(A) polymerase.  Upon infection, early transcription initiates, and early mRNA proteins 
are detected within the first hour.  These early mRNA are processed similar to other 
eukaryotic mRNAs.  They are capped, methylated, and polyadenylated.  For poxviral 
gene transcription, there has been no evidence for alternative splicing or other kinds of 
processing involving RNA cleavage.  
 Vaccinia virus early, late, and intermediate promoters are well-characterized.  
Early vaccinia virus promoters contain a consensus “AAAAAATGAAAAAAAA” region 
(16).  This 16 base-pair critical region (which is highly sensitive to mutation) is further 
separated by 11 base-pairs of a less critical T-rich sequence from a seven base-pair region 
within which initiation with a purine usually occurs (16). 
 Early viral genes are not synthesized beyond ~ 6 hrs post infection (unless an 
inhibitor of DNA replication such as cytosine arabinoside (AraC) is added).  Once early 
viral gene expression has finished, DNA replication begins.  The viral genome encodes 
for all of the proteins necessary for DNA replication and transcription, due to its 
cytoplasmic location.  Early gene products include proteins that stimulate viral DNA 
replication machinery and, important to our studies, immunoevasion genes. Temporally, 
replication begins approximately 1 to 2 hours post infection and generates 10,000 copies 
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of the viral genome per cell.  These genome copies are then packaged into virions for 
subsequent infection of other cells.   
 After DNA replication is completed, intermediate gene transcription continues the 
gene expression cascade, producing late transcription factors that stimulate transcription 
of late genes.  The final wave of late transcription produces virion proteins, including 
envelope proteins and transcription machinery that is packaged into nascent virus 
particles. 
 The promoters associated with intermediate and late genes differ in sequence from 
early promoters and have different transcription factor requirements.  Intermediate factors 
are synthesized early in order to facilitate transcription of newly replicated viral DNA. 
Some of the late proteins produced are products of intermediate genes, and hence are 
made and used after viral DNA replication.  Intermediate genes are expressed for a 
relatively short period after DNA replication.  Late promoters produce more protein than 
those of early or intermediate promoters, possibly due to promoter strength, DNA copy 
number or prolonged expression (52).  
Poxvirus Immunomodulators
 The host has evolved complex defense mechanisms to control and clear virus 
infection, and protect against subsequent infections.   Poxviruses are under selective 
pressure to evade the immune response of their host and actively manipulate the host 
immune system to survive and replicate.  
 Poxviruses encode immunomodulators, proteins that enable, facilitate, or 
modulate infection by preventing anti-viral host cell responses.  Poxviruses evade host 
immune responses by targeting many of the primary mediators of innate immunity.  They 
use a number of strategies, including secreting decoy cytokine or chemokine receptors, 
regulating apoptosis (28), and preventing complement-mediated lysis.  Some of these 
proteins are illustrated in Figure 3 and work at both the transcriptional and translational 
levels.  Proteins in this category usually act by interfering with cellular processes or by 
modulating virus-host interaction at the level of the organism.  Viral host specificity is 
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also defined by these effective immune evasion strategies (9).  The majority of these 
immunomodulatory genes are expressed early during infection acting either intra- or 
extracellularly to provide the virus with a substantial defense against the host immune 
system.  In many instances, the removal of one or more of these immunomodulatory 
genes from VV results in a mutant virus that causes an attenuated disease in laboratory 
animals (44, 51).  
 
The NF-κB Transcription Factor 
Since its discovery in 1986, nuclear factor-kappa B (NF-κB) has remained one of 
the most widely studied eukaryotic transcription factors due to its critical role in 
controlling expression of numerous genes, which are involved in diverse processes, 
including inflammatory and immune responses (31, 64).  NF-κB was first identified by 
Sen and Baltimore as a protein that bound to a specific DNA sequence (5’ -
GGGACTTTCC-3’) within the intronic enhancer of the immunoglobulin kappa light 
chain gene in mature B and plasma cells, but not pre-B cells (64).  NF-κB is known to 
exist in a majority of cell types and is the central mediator of immune and inflammatory 
responses.  Genes that are regulated by NF-κB allow the organism to respond 
appropriately to conditions of infection or stress.  This finding is exemplified by the 
finding that laboratory mice lacking functional NF-κB dimers are more susceptible to 
virus infection than normal mice (31) .
 The activation of NF-κB is a classic paradigm for the regulation of a transcription 
factor by subcellular compartmentalization.  In the majority of cell types, NF-κB exists in 
the cytoplasm as homo- or heterodimers of a family of structurally related proteins.  The 
DNA-binding NF-κB family members share a Rel homology domain that enables DNA 
binding, nuclear localization, and protein dimerization.  DNA-binding members of NF-
κB/Rel include p50 (NF-κB1), p65(RelA), c-Rel, p52 (NF-κB2 or Lyt-10), RelB (I-Rel), 
and dorsal.  p50 and p52 are actually precursors of p105 and p100, respectively, that are 
proteolytically processed to generate active DNA-binding p50 and p52.  NF-κB members 
exist as either homo- or hetero- dimers in the cytoplasm, with the most abundant forms 
  10
being the p65:p50 heterodimer (24, 31).   Rel homology domains (RHD) are 
characteristic of NF-κB proteins, and are instrumental in mediating dimerization, 
interaction with inhibitors of NF-κB (IκBs), and binding to DNA(31).
    The intracellular localization and post-translational activity of NF-κB/Rel 
proteins are regulated by the ankyrin repeat containing IκB proteins (IκBα, IκBβ, IkBγ, 
IκBε, Bcl-3, p105, and p100) (31).   The NF-κB/Rel proteins are sequestered in the 
cytoplasm in an inactive from (NF-κB complex) through their association with an 
inhibitory protein called IκB, or an inhibitor of NF-κB (77).  Each of the IκBs contain 
between five to seven ankyrin repeats, and these ankyrin repeats are motifs responsible 
for mediating protein-protein interactions, allowing for the binding to the dimerization 
domain of NF-κB dimers (31).  IκBα is the best characterized member of the family, and 
is most commonly bound to the p65 subunit of the p65:p50 homodimer (68).  
 Activation of most forms of NF-κB, including the prototypic p65-p50 
heterodimer, depends on phosphorylation induced ubqituitination of the IκB proteins.  
This event depends on two protein complexes: the IκB kinase (IKK) complex and the E3 
IκB ubiquitin ligase complex.  Once poly-ubiquitinated, the IκBs undergo degradation at 
the 26S proteasome, freeing the NF-κB dimers where they translocate to the nucleus and 
participate in transcriptional activation of specific target genes.  
 Figure 2 outlines the NF-κB activation pathway.  Since constitutive NF-κB 
activation results in inflammation, NF-κB is inactive in resting cells.  The multitude of 
biological factors and environmental conditions known to induce NF-κB activity are 
large and diverse.  These include extracellular and intracellular signals.  In general, these 
signals represent states of infection or stress.  These activating agents can be viruses, 
phorbol esters, cytokines, growth factors, UV irradiation, radical oxygen intermediates, 
and bacterial lipopolysachcharide, which promote the dissociation of the cytosolic NF-
κB/IκB complexes, in part by activating cellular kinases that phosphorylate IκB.  This 
ultimately results in a rapid degradation of IκB, exposing a nuclear localization sequence 
present in NF-κB.  Although different signal transduction pathways involve distinct 
scaffolding and signaling proteins, all pathways converge upon activation of the IκB 
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kinase (IKK) complex.  IKK phosphorylates IκBα at N-terminal serine residues, resulting 
in its subsequent polyubiquitnation, which then targets it to the 26S proteasome for 
degradation (73).  This allows translocation of the NF-κB/Rel proteins to the nucleus 
where they can activate the transcription of target genes containing the decameric κB 
binding site.  These different NF-κB dimers bind to variant NF-κB sites, termed “κB 
sites” with the consensus being 5’- GGGANNYYCC -3’ present in the promoter regions 
of many genes.  As part of an autoregulatory loop, NF-κB also binds to the IκBα 
promoter, allowing IκBα to be re-synthesized (11).  Nascent IκBα physically removes 
NF-κB from the DNA, and terminates the transcriptional response.
  
Poxviruses and Their Role in Inhibiting NF-κB 
 NF-κB activation upregulates anti-viral immune and inflammatory molecules.  As 
NF-κB activation is an immediate early step of immune activation, interference of NF-κB 
activation represents a strategy that many viruses, including VV, use to inhibit the innate 
immune response (63).  As poxviruses perform their lifecycle within the same 
cytoplasmic compartment in which NF-κB resides, they are well suited to interact and 
modulate NF-κB activity during infection.   
 VV encode various intracellular inhibitors of NF-κB (50).  VV A46R and A52R 
proteins have been shown to act as dominant negative inhibitors of TIR signaling by the 
Toll-like receptor family.  A46R associates with MyD88, TRIF, and TRAM and interferes 
with the activation of NF-κB and MAP kinases (70).  A52R associates with IRAK2 and 
TRAF6, disrupting signaling complexes containing these proteins and blocks NF-κB 
activation signaled through multiple TLRs (6, 30).  The N1L VV protein targets the IKK 
complex, inhibiting signaling to NF-κB by TNF-α receptors, and also disrupts signaling 
from TLRs, inhibiting NF-κB and IRF3 signaling (19).  VV K1L is an ANK-repeat 
containing protein that prevents IκBα degradation in  RK-13 cells, and this mechanism is 
not related to its host range function due to the observation that inhibition is observed in 
both permissive and nonpermissive cells (66).  VV B14R has a three dimensional 
structure that resembles that of Bcl-2 proteins, which usually function to regulate 
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apoptosis, but does not modulate the apoptotic pathway (27).  Instead, B14R prevents 
IKKβ activation and consequently the cellular pathway leading to activation of NF-κB is 
not induced.  To identify more vaccinia virus proteins that inhibit NF-κB activation, we 
utilized a genetic approach in which a strain of vaccinia virus (MVA) has been 
demonstrated to activate NF-κB activity.  
MVA
 Modified Ankara Virus, or MVA, an attenuated and replicative virus was used as 
the vaccine against smallpox in Germany at the end of the vaccination campaign (45).  
MVA presents immunological advantage over that of wild-type vaccinia because it did 
not express soluble homolog receptors for IFNγ, IFNα-β or CC type chemokines, yet 
enhanced cellular genes implicated in the immune response such as IL-6, IL-7, and IL-15 
(29).  The immunogencity of MVA is largely attributed to loss of immune evasion genes, 
but as most genes encoding structural proteins are retained, this preserves antigenic 
determinants. The host-restricted MVA can replicate efficiently only in chick embryo 
fibroblast and BHK-21 cells, but viral and recombinant protein expression occurs in all 
cell lines infectable by standard strains.  
  MVA was derived from its parental virus, Chorioallantois vaccinia virus Ankara 
(CVA) by more than 570 serial passages in chicken embryo fibroblasts (CEF) (45, 48).   
As a result, MVA has lost six major regions of DNA reducing the size of Ankara from 
208 kb to 178 kb (48).   This accounted for the loss of over 30% of the parental genome, 
especially proteins which encode for immunomodulatory function (48).  It is believed 
that deletions and/or mutations in MVA relative to CVA and other wild-type vaccinia 
virus strains account for the diminished virulence and success as a vaccine against 
smallpox (Upton, Slack, Hunter, Ehler, Roper, 2003).   Sequence comparison of Ankara 
and MVA revealed that many immunoregulatory genes are missing in MVA (4, 25). 
 In our laboratory, it has been shown that MVA activates NF-κB in 293T cells (42).  
Others have reported that MVA is able to activate NF-κB within different cell types (39, 
56).  As MVA is an attenuated strain of vaccinia virus, wild-type strains of vaccinia virus 
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retain the ability to inhibit the NF-κB transcription factor. In contrast to MVA, infection 
of 293T cells with the wild-type WR inhibits cellular NF-κB activation (56, 66).  One 
explanation for this change in phenotype is that WR possesses NF-κB inhibitory genes 
that are missing from MVA.  If this were true, then the re-insertion of NF-κB inhibitory 
genes from the wild type parental genome into MVA would restore the virus’ ability to 
inhibit NF-κB activation (66).  Indeed, our lab identified several recombinant MVA 
viruses that negatively impacted NF-κB induction, when parental DNA from wild-type 
virus was stably re-introduced into the MVA genome.  
MVA/5.2kb
 A crucial virus in terms of understanding the basis of viral proteins that inhibit 
activation is the MVA/5.2kb.  MVA/5.2kb is appropriately named since a 5.2kb fragment 
of wild-type DNA was inserted into the MVA genome (66).  This fragment contains three 
genes absent in the MVA genome: M2L, M1L, and K1L (4).  Thus, it was hypothesized 
that either one or more of these genes was responsible for NF-κB inhibition.  Further, 
given that the MVA strain of VV utilizes the MEK/ERK pathway, one possibility is that 
one of these products would inhibit this pathway (either directly or indirectly) to mediate 
its inhibitory effects.  The goal of my thesis was to assess whether the M2L protein 
inhibits the NF-κB and MEK/ERK pathway.  
M2L 
 The M2L gene, which is 663 bp, codes for a protein of 25 kDa.  The M2L protein  
does not have homology to any other known cellular or viral proteins (22, 34).  Thus, a 
prediction of the function of M2L was difficult.  Because the M2L gene was present in 
wild-type vaccinia strains but not MVA,  it was suggested that it may act as an 
immunomodulatory protein.  Also,  the M2L gene’s presence in poxvirus genomes from 
many genera implies that it serves a valuable function in vivo.  The promoter sequence of 
M2L predicts that it is expressed early in infection, much like other poxviral 
immunomodulators.     Analysis of the M2L amino acid sequence reveals that it contains 
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a putative signal peptide sequence, putative ER retention/retrieval sequences, four 
putative glycosylation sites, and five potential casein-kinase II sites.   Primary goals of 
the thesis project focused on determining if M2L localized to the ER and if the protein 
received post-translational modifications, as the observed molecular weight on M2L by 
immunoblot analysis was higher than that of it predicted theoretical molecular weight.  
The significance of M2L ER localization will also be assessed by attempts to identify 
ER-resident binding partners as a means for M2L functioning.  ER-based signaling 
pathways such as the unfolded protein response and ER overload pathway were also 
candidate signal transduction pathways that M2L could act on.  As M2L possesses a 
signal peptide, clarification was needed if M2L was trafficked outside the cell through the 
secretory pathway as well.  The contribution of  the glycosylation and casein-kinase II 
motifs present in M2L were investigated to determine if they might contribute to 
inhibiting cellular pathways leading to NF-κB or ERK 1/2 activation.  
Poxviral Modulation of the ERK 1/2 Activation Pathway
 Like NF-κB, the mitogen-activated protein kinases (MAPK) are another important 
group of signaling mediators in the cell.  The evolutionarily conserved signaling cascade 
consists of three sequentially activated kinases: a MAP kinase kinase kinase (MEKK), a 
MAP kinase kinase (MEK), and a MAP kinase (MAPK).  To date, four different MAP 
kinase pathways can be functionally distinguished, leading to the activation of the 
different MAP kinases: ERK 1/2, p38, JNK and ERK5 (54, 57, 61).  Unfortunately, these 
different signaling cascades have not been well characterized in the context of a poxvirus 
infection.  The MAPK/ERK 1/2 (mitogen activated protein kinase/extracellular signal 
regulated kinase 1/2) pathway plays a critical role in transmission of mitogenic and 
survival signals in response to a variety of extracellular stimuli.  Since cell survival is 
vital for virus multiplication, it is not surprising that many viruses, including VV, choose 
to manipulate this pathway.  
 Dr. Claudio Bonjardim’s group has demonstrated that VV infection triggers the 
MAPK/ERK 1/2 and protein kinase A pathway, and disruption of these pathways results 
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in decreased viral protein expression, DNA replication, and VV multiplication (3).   
Although VV and cowpoxvirus are of the Orthopoxvirus genus, siRNA knockdown of an 
early growth response gene 1 (EGR-1) downstream of the MEK/ERK signaling 
diminished VV replication, but not that of cowpoxvirus replication (67).  These findings 
demonstrate that the host MEK/ERK pathway and EGR-1 is stimulated by 
orthopoxviruses, allowing for the most favorable outcome of infection.  In our laboratory, 
Roderick Gedey demonstrated that the phosphorylation (and hence activation) of ERK 
1/2 is partially required for MVA- induced NF-κB activation: MVA-infected cells 
incubated in the presence of either PD 98059 or U0126, compounds known to prevent 
ERK1 and ERK2 phosphorylation, demonstrated impaired nuclear NF-κB translocation 
and lowered expression of an NF-κB-regulated luciferase gene (22).  A similar repression 
was also noted in cells that contained a dominant, non-active form of ERK2, confirming 
the above findings (22).  The focus of my research is to resolve if M2L acts to inhibit 
both ERK 1/2 activation and NF-κB activation, and if these two pathways are mutually 
exclusive or dependent on one another.  
 
The Endoplasmic Reticulum
 Eukaryotic cells are unique in that different membranous compartments exist and 
protein trafficking through them is regulated and monitored.  The endoplasmic reticulum  
(ER) is a main player in the secretory pathway, and is an organelle containing 
interconnected tubules, vesicles and sacs.  It is estimated that one-third of all cellular 
proteins are translocated into the lumen of the ER (32).  Within the ER exists a 
specialized environment where biosynthesis of sterols, lipids, membrane-bound and 
soluble proteins, and glycosylation occurs. These events take place before proteins are 
either retained in the ER or further transported to other components of the secretory 
pathway.   This organelle is also critical for the proper functioning of the cell as a whole, 
since insults to the cell and ER homeostasis activate pathways meant to cope with such 
stress. 
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Glycosylation
 Proteins that are translocated into the ER lumen frequently receive the post-
translational modification of glycosylation.  Acquisition of glycans to a protein promotes 
proper folding of newly synthesized proteins in the ER, allowing eukaryotic cells to 
produce and secrete large, complex, proteins.  It is clear that glycosylation can have a 
wide range of effects on normal enzymatic activities, cellular trafficking, ligand binding, 
or downstream signaling (41).  The presence of glycosylation residues improves 
solubility in water, contributing to proper orientation of the molecule, protects it from 
proteases, and in some cases, is required for efficient intracellular transport.  A wide 
variety of  proteins are modified by glycosylation, including antibodies, enzymes 
involved in lipid metabolism, insulin receptors, proteoglycans, the surface layer and 
flagellar proteins of archaea (37), and human gut pathogens such as Campylobacter (1).  
Glycosylation is known to play a role in numerous processes and is conserved throughout 
eukaryote evolution.
 The addition of an oligosaccharide to a protein can occur through N-linked or O-
linked glycosylation.  Attachment of an asparagine residue of secreted or membrane 
bound proteins are termed N-linked (5).  N-linked glycoforms can be categorized as high 
mannose, hybrid, or complex.      
 The process of N-linked glycosylation begins with the transfer of a presynthesized 
oligosaccharide comprising GlcNAc2Man9Glc3.   The Dol-P-GlcNAc2Man9Glc3 is 
cotranslationally added en bloc to the amide group of an asparagine residue.  N-linked 
glycosylation occurs on the asparagine within the sequon, N-X-S/T, where X is any 
amino acid except proline.  Addition of a glycan precursor is due to the enzyme 
oligosaccharyltransferase, which is closely associated with the translocon and thought to 
have access only to nascent chains as they emerge from the ribosome at the lumenal face 
of the ER.   The ability to form hybrid or complex N-glycans differs during different 
eukaryotic systems and during development within a given system or cell type.  The 
consensus motif of N-X-S/T is a prerequisite, but this is not sufficient to confer 
glycosylation (5).  Other factors such as protein length, cell type, and amino acids in the 
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vicinity of the consensus motif influence the addition of a sugar moiety to an asparagine.  
Noncanonical Asn-linked glycosylation can occur as well.   This occurs on Asn residues 
in the context of an atypical Asn-X-Cys sequence.  This has been observed in the 
recombinant epidermal growth factor receptor, the T cell activation antigen CD69, and 
several other proteins (62, 74).  
 O-linked glycosylation occurs when the protein has an addition of an 
oligosaccharide to a serine or threonine residue.  There is no consensus sequence for this 
type of modification, but it typically occurs in close proximity to proline residues, with 
the acceptor site  in a beta-conformation.  O-linked glycosylation occurs within the 
lumina of the Golgi cisternae, and more recently, within the nucleus and cytoplasm of 
cells (5).  Drugs such as tunicamycin or Endo H block N-linked glycosylation, whereas 
monensin blocks O-linked glycosylation.  Mutagenesis of potential glycosylation sites 
within the primary sequence also ablates this post-translational modification.  When 
proteins are resolved using SDS-PAGE, those that were subjected to glycosidase 
treatment are seen as single bands, corresponding to the unglycosylated polypeptides. 
 Loss of glycosylation may affect a protein in various ways.  This is due to the 
disruption of altering the carbohydrate groups, which control conformation, folding, and 
thus stability of the altered protein.  If glycoproteins fail to fold or oligomerize, they are 
retained in the ER and eventually degraded.  The degradation process, termed ER-
associated degradation (ERAD), is important because it prevents accumulation of 
unsalvagable, misfolded proteins in the ER.   Impaired glycosylation has also been 
implicated in disease progression.   These include inborn errors of lipid metabolism, 
Wolman disease, and cholesteryl ester storage disease (78).  
 Evidence has shown that loss of glycosylation at one site can cause a protein to 
retain function in one signaling pathway but lose its function in another pathway.  The 
nuerokinin 1 receptor, a G protein-coupled receptor involved in pain and inflammation, 
when glycosylated at only one of its N-linked glycosylation sites, lost its ability to 
modulate IL-8 secretion, but the double glycosylation mutant was minimally impacted in 
its ability to activate MAPK pathways  (72). 
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  As of this writing, there has been no evidence that viruses intrinsically encode 
enzymes required for the biosynthesis of N-linked oligosaccharides (60).  Therefore, 
viruses, like other processes during their life cycle, are reliant on the host cell’s 
glycosylation system.  As a number of viral proteins are glycosylated, it reasons that such 
a modification serves an important function for the proteins themselves.
 N-linked glycosylation of envelope or surface proteins of viruses can promote 
proper folding and subsequent trafficking using host cellular chaperones and folding 
factors.  It is well known that glycosylated proteins are an essential component of 
enveloped viruses.  Cotranslational modification of these proteins by addition of N-linked 
oligosaccharidees provides increased solubility and possible interaction with chaperones 
in the ER.   This supports the process of folding and stabilizes the native conformation.   
Alternation of a site or sites of glycosylation can have dramatic impacts on survival and 
transmissibility of the virus.  Small changes can alter folding and conformation, affecting 
portions of the entire molecule (36, 47, 69).  The Rabies Virus RGP protein expression at 
the cell surface is altered by glycosylation residues (65).  Mutation of glycosylation sites 
in the capsid protein of Hepatiits E Virus prevents the formation of infectious virus 
particles (26).  
 Two interacting poxvirus glycoproteins, VV B5R and A34R are involved in the 
formation of extracellular enveloped virions during morphogenesis.  Recently, it was 
shown that mutated forms of B5R cannot associate with A34R, and actually alters the 
glycosylation status of A34R, leading to A34R’s conformational instability and thus 
degradation (7).   
Signal Peptides
 N-terminal signal peptides can be thought of as transient “zip codes” between 13 
to 36 amino acid residues in length.  They contain a tripartite structure that contains a 
central hydrophobic region, flanked by the amino and carboxy segments of the signal 
peptide  (12).  These sequences mediate the transport of eukaryotic secretory proteins 
where they can be retained within the ER, or trafficked out of the ER and secreted outside 
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of the cell to act.  Upon translocation across the ER lumen,  the signal peptide is then 
excised by the membrane-bound type I signal peptidases during translocation across the 
cell membrane.  At the cleavage site, defined by Von Heijne’s “-3-1 rule” for signal 
peptides, the -1 position is critical for recognition by a signal peptidase and is generally 
occupied by an uncharged amino acid with a small side chain (75).
    Numerous studies have highlighted the adverse effects caused by mutations to 
signal peptides.  Mutant proteins that retain their signal peptide have been described in 
humans (15, 59).  These proteins remain attached to the luminal face of the ER membrane 
and fail  to proceed through the secretory pathway.  
 Besides targeting, signal peptides have been reported to exhibit regulatory 
function in immune surveillance (38), to promote effective translocation by preventing 
the premature or misfolding of secretory preproteins, to control the amount of proteins to 
their destination, and other functions as more literature emerges over time.  Alteration of 
signal peptides thus presents an opportunity to regulate a protein’s function.   
ER Retention and Retrieval Sequences
 Many proteins are selectively retained in the compartments in which they 
function. Maintenance of resident proteins within the ER compartment means that they 
are distinguished from the secretory cargo.  C-terminal ER retention -K/HDEL and ER 
retrieval signals for membrane bound proteins-KKXX are responsible for maintaining 
these proteins within the ER.  These signals are recognized by membrane bound receptors 
that continually retrieve proteins from a later compartment of the secretory pathway and 
return them to the ER.  Alterations to canonical and noncanonical variants of these motifs 
results in mislocalization of proteins and also impaired function (55).   
Importance of M2L Research
 At the beginning of my thesis project, it was unknown what role the VV M2L 
served during infection.  The only information available on VV M2L was that it did not 
interact with any other poxviral protein through a yeast-two hybrid screen (43).  This 
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thesis project has characterized this novel VV protein and explains its functional 
importance.
 More than ever, a detailed understanding of virus-host interactions is important.  
Increases in world travel and population have led to an increased spread and threat from 
infectious pathogens such as viruses.  Emerging poxviruses in the wild have also been of 
concern, and any information regarding viral proteins can contribute to a better focus on 
development of antiviral strategies.  Molecular medicine is increasingly turning to viruses 
for use as tools to deliver foreign genes and macromolecules, and an oncolytic myxoma 
virus has the potential for targeted elimination of cancer cells.  Viral proteins serve as 
continuous sources in understanding tools and model system to aid in the discovery of 
new concepts in molecular, structural, and cell biology.  
 Understanding how the previously uncharacterized M2L mechanistically inhibits 
NF-κB activation is crucial in understanding poxviral immunomodulators in general.  
There is no known shared immunomodulatory protein shared across all poxviral species, 
and thus the outcome of infection is dependent on the virus species and the 
immunomodulatory proteins expressed by the virus (71).  Many different VV proteins 
inhibit signaling pathways leading to NF-κB activation, but these proteins have non-
redundant functions because when the gene encoding each inhibitor is deleted 
individually, the deletion mutant displays an in vivo phenotype (2, 6, 30, 70).  
 By inhibiting NF-κB activation, VV M2L may ultimately alter recruitment of 
inflammatory cells to sites of infection and so diminish the ability of the host to fight 
infection.  Whereby other poxviral NF-κB inhibitors are known to selectively inhibit 
known NF-κB pathways as sensed by extracellular inflammatory signals as sensed by toll 
like receptors and cytokine receptors, M2L is able to inhibit NF-κB activation as 
triggered by MVA-induced viral infection.   
 The following chapters will detail the characterization and theorized function of 
M2L in the context of a viral infection.  The importance of these discoveries will be 
discussed along with with their implications for poxvirus biology. 
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Figure 1.1  Single-cell replicative cycle of vaccinia virus infection (adapted from Harri-
son, 2001 and McFadden, 2005).  The intracellular mature virus (IMV) and extracellular  
enveloped virus (EEV) virions bind to the host cell and viral mRNA and protein synthesis 
occurs at early, intermediate, and late times during infection.  Please see text for detailed 
explanation.
  22
IgB_
p50p65
p50p65
Cytoplasm
Nucleus
Extracellular space
ER
p50p65
IKK complex 
_ `
a
IgB_
p50p65
P P
Ub
UbUb
Ub
Ub
UbUb
Ub
      26S 
proteasome
IgB_
Degradation
MVA
TNF
TNFR
Inflammatory 
  Cytokines
Growth Factors
      MitogensVirus Infection
Bacterial Products
TLR
Cell stress
(UV, drugs)
Figure 1.2 Representation of NF-ѣB activation. NF-ѣB heterodimers are 
sequestered in the cytoplasm by association with IѣB inhibitory proteins (IѣBa).  
Various stimuli (viral and bacterial pathogens, stress-inducing agents, exposure to 
inflammatory cytokines, mitogens) activate the IKK complex through many different 
signaling components.  Once activated, IKK phosphorylates IѣBa at serines 32 and 36 
(as denoted by “P”).  Next, IѣBa is recognized by the ћ-TrCP-like component of a specific 
ubiquitin-protein ligase that results in the polyubiquitination (as denoted by “Ub”) of IѣBa 
at lysines 21 and 22.  This targets IѣBa for degradation by the 26S proteasome.  IѣBa 
degradation exposes the nuclear localization sequence on NF-ѣB, allowing freed NF-ѣB 
to be translocated to the nucleus, where it binds to a conserved consensus sequence in 
cellular DNA.  The endoplasmic reticulum (ER) is represented as a grey structure as 
“ER.”
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Chapter II:  Characterization of Wild-Type and Mutant 
Vaccinia Virus M2L proteins’ Abilities to Localize to the 
Endoplasmic Reticulum and to Inhibit NF-κB and 
ERK1/2 Activation During Infection
 Portions of this chapter have been published in the Journal of Virology, 80 (17): 
8676-85, 2006 and Virology, 373 (2): 248-62.
Introduction
 Poxviruses are complex viruses, possessing large double-stranded DNA genomes 
and the ability to replicate cytoplasmically in their host cell (28), with vaccinia virus 
being the best-characterized member of this family. Wild types strains of vaccinia virus 
code for myriad products that inhibit inflammatory and immune responses, including 
ones that prevent NF-κB activation (12, 42). In contrast, the genome of attenuated 
vaccinia virus strain MVA lacks many of the wild type immunomodulatory genes (2), and 
infection of cells with this strain will render the activated form of this transcription factor 
(32, 41).  As would be expected, stable re-introduction of wild type genes whose products 
inhibit NF-κB activation, such as the M2L ORF, reverses this phenotype (9).
 A similar repression was also observed in cells that contained a dominant, 
nonactive form of ERK2 but not in cells where ERK1 phosphorylation was inhibited via 
overexpression of a dominant-negative mutant MEK1 protein. Presumably, proteins 
expressed from a wild-type VV that block ERK2 activity would also inhibit MVA-
induced NF-κB activation. Indeed, the expression of one such open reading frame, M2L, 
supported this prediction. First, ectopic M2L expression hampered ERK2 
phosphorylation induced by exposure to phorbol myristate acetate. Second, viral M2L 
expression via infection of cells with a recombinant MVA construct that stably expressed 
M2L decreased the phosphorylation of ERK2 compared to that in cells infected with the 
parental MVA strain. Finally, the recombinant M2L-expressing virus restored the “wild-
type” NF-κB-inhibitory phenotype, as indicated by decreased NF-κB migration to 
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infected cell nuclei and interference in transcription. Thus, in 293T cells, VV apparently 
utilizes its M2L protein to interfere with a step(s) that would otherwise enable ERK2 
phosphorylation and the consequential activation of an NF-κΒ response.
 Little is known about the M2L protein: its expression is dispensable for virus 
replication in cell culture (43), and no portion of the M2L protein possesses regions of 
homology to other proteins with known biological properties. Delineating the molecular 
mechanism for the M2L protein’s inhibitory effect is important for understanding viral 
regulation of the host immune response. Further, since the M2L protein is unique to 
poxviruses, its mode of action may enable the identification of new anti-viral drug 
targets. Additionally, the M2L protein itself may be useful as a biological tool to regulate 
proinflammatory processes. Upon close examination of the M2L protein, several motifs 
indicative of endoplasmic reticulum (ER) localization were found to be present. To 
understand the involvement of the M2L protein, the goal of these studies was to define its 
intracellular location and examine the importance of this site to its function. As shown 
here, the M2L protein was found to be produced early during infection, a characteristic 
shared with other poxviral immunomodulatory gene products, and to be sequestered to 
the ER. Using mutational analysis of the M2L ORF, the relationship between ER location 
and the inhibitory effect on NF-κB activation was investigated.
Materials and Methods
Cells and Viruses
 The human HEK293T (293T) and monkey BS-C-1 kidney fibroblast cell lines 
were obtained from the American Type Culture Collection, while chicken embryo 
fibroblast (CEF) cells were purchased from Charles Rivers Laboratories. All cells were 
cultivated in EMEM supplemented with 10% fetal calf serum (FCS; Hyclone). The wild 
type vaccinia virus strain Western Reserve (WR) and the attenuated strain modified 
vaccinia Ankara (MVA)(23) were used in these studies. MVA/M2L is a recombinant virus 
in which the WR M2L transcriptional unit was stably inserted into the MVA del III region 
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(9). BS-C-1 and CEF cells were utilized to amplify the WR- and MVA-based vaccinia 
viruses, respectively.
 An MVA virus containing a DNA sequence encoding a V5 epitope tag fused to the 
C-terminus of the WR M2L transcriptional unit (MVA/M2L-V5) was produced by 
homologous recombination in CEF cells. To accomplish this, the M2L ORF and its linked 
promoter were PCR amplified from WR viral DNA, using two sequential PCR reactions 
to add DNA coding for a V5 epitope tag to the C-terminus of the M2L ORF. To this end, 
oligonucleotide primers M2LFOR 
(5′TGCGCATGCACGAGCTGTACAAGTAAGCGGCCGCAACTAATT-3′) and 
M2LREV1 (5′-CAGCAGGGGGTTGGGGATGGGCTTGCCCTCTCTATAACA-3′) were 
utilized. DNA coding for the V5 epitope product is underlined. This PCR product was gel 
purified to remove excess, unincorporated oligonucleotide primers. Next, DNA encoding 
the remainder of the V5 epitope was engineered onto the C-terminus of the 
aforementioned M2L amplicon in a second, sequential PCR amplification reaction that 
utilized primers M2LFOR and M2LREV2 
(5′-GTACTGCAGTTAGGTGCTGTCCAGGCCCAGCAGGGGGTT-3′). The DNA 
sequence coding for the V5 epitope in M2LREV2 is underlined. The resultant M2L-V5 
amplicon was inserted into the EagI and PstI sites of a modified pLW44 (provided by 
Drs. Linda Wyatt and Bernard Moss) to create plasmid M2L-V5/pLW44. This modified 
plasmid no longer possesses an H5 promoter directly upstream of the inserted M2L-V5 
amplicon, thereby allowing M2L-V5 to be expressed only during the early times post-
infection, under the control of the naturally occurring M2L promoter. M2L-V5/pLW44 
also retains the green fluorescent protein (GFP) gene linked to the vaccinia p11 promoter, 
allowing for GFP fluorescence to be utilized as a stable screening marker during isolation 
of recombinant MVA viruses (described below). Sequence analysis of a representative 
plasmid demonstrated the presence of the C-terminal V5 epitope tag and the absence of 
mutations in the wild type M2L promoter and ORF.
 To create a recombinant MVA virus expressing M2L-V5, CEFs were infected with 
MVA and transfected subsequently with plasmid M2L-V5/pLW44. At 48 h post-infection, 
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cells were harvested and lysed. Virus-containing lysates were incubated with fresh CEF 
monolayers, and cells infected with recombinant MVA/M2L-V5 viruses were identified 
based on their ability to express GFP. GFP-expressing foci were plaque purified at least 
four times and pure stocks were amplified in CEF cells. The presence of the M2L-V5 
ORF in the MVA del III region, as well as the absence of contaminating parental viral 
DNA, was verified by PCR analysis of the isolated viruses’ genomes, using primers 
recognizing sequences that either flanked the MVA del III region or were present within 
the M2L ORF. Expression of the M2L-V5 protein in virus-infected cells was confirmed 
via probing immunoblotted lysates of infected cells with polyclonal rabbit anti-M2L 
antibodies raised against M2L residues 130–145 (9) (diluted 1:1000 in TBS-T), followed 
by incubation of membranes with horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (Fisher Scientific), which was diluted 1:20,000 in TBS-T. Immunoblots were 
then washed to remove excess antibodies and developed by using the SuperSignal West 
chemilluminescence reagents, as per manufacturer’s directions (Pierce).
 Similar to above, an MVA construct expressing a mutant M2L protein lacking 
residues 2–13 (MVA/M2L-V5 Δsp), thereby removing most of the predicted N-terminal 
peptide sequence, was produced by using homologous recombination in CEF cells. For 
this purpose, the mutated M2L amplicon was PCR amplified from plasmid M2L-V5/
pLW44 using primers ΔSPFOR (5′-TCGGCATGCACGAGCTGT-3′) and ΔSPREV (5′-
CTAATTTGTACCCGAGCATCTTAC-3′). An AvaI restriction enzyme site was present 
in primer ΔSPFOR (underlined), allowing for the introduction of a unique AvaI site into 
the mutant M2L amplicon. Next, the gel-purified PCR product was ligated into the AvaI 
and EagI sites of the modified pLW44. Stable introduction of this mutant ORF into the 
del III region of the MVA genome, as well as the selection, purification and amplification 
of recombinant viruses, and the detection of the inserted modified M2L DNA, were 
performed as described above. Expression of M2L-V5 Δsp mutant proteins during 
infection was assessed by immunoblotting, where infected-cell lysates were 
electrophoretically separated, transferred to a polyvinylidene difluoride (PVDF) 
membrane (Millipore) and incubated first with polyclonal rabbit anti-M2L antiserum (9), 
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and then with HRP-conjugated goat anti-rabbit IgG (Fisher Scientific), using the dilutions 
mentioned above. Immunoblots were then washed to remove excess antibodies and 
developed by using the SuperSignal West chemilluminescence reagents (Pierce).
 A recombinant MVA construct expressing a mutant M2L product deleted of 
residues 179–220 (MVA/M2L-V5 ΔERret) was created by homologous recombination in 
CEF cells, similar to the methods utilized above. To begin, the C-terminal truncated M2L 
amplicon and its natural promoter was PCR amplified from plasmid M2L-V5/pLW44. 
Two sequential PCR reactions were performed to allow for the addition of DNA coding 
for a V5 epitope tag onto the C-terminus of the truncated M2L ORF. The first PCR 
reaction utilized oligonucleotides ERFOR 
(5′-TCT CGGCATGCACGAGCTGTACAAGTAAGCGGCCGCAACTAA TT-3′) and 
ERREV1 (5′-GGGGATGGGCTTGCCGGGGTGTAGGTAATGGGG-3′), while the 
subsequent PCR reaction utilized primers ERFOR and 
ERREV2 (5′-CTTCTGCAGTTAGGTGCTGTCCAGGCCCAGCAGGGGGTT 
GGGGATGGG-3′). DNA sequences coding for the V5 epitope are underlined in 
oligonucleotides ERREV1 and ERREV2. The purified amplicon, which has EagI and PstI 
sites engineered into the N- and C-termini, respectively, was inserted into the same sites 
of a modified pLW44 vector, creating plasmid M2L-V5 ΔERret/pLW44. The stable 
introduction of this mutant ORF into the MVA genome, the identification of recombinant 
viruses expressing GFP, the purification of recombinant viruses away from parental MVA 
viruses, and the verification of the presence of the modified M2L ORF in the del III 
region of the MVA genome, was performed as described above. Expression of M2L-V5 
ΔERret mutant proteins during infection was assessed by immunoblotting as described 
above, using polyclonal rabbit anti-M2L antiserum (9) and HRP-conjugated goat anti-
rabbit IgG (Fisher Scientific). Dilutions of antiserum used for immunoblotting are 
mentioned above.
 A WR construct deleted for the M2L ORF (ΔM2L) was produced by using 
homologous recombination in BS-C-1 cells. For this purpose, a 4.2 kb DNA segment 
containing the M2L ORF and flanking sequences was PCR amplified from the WR 
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genome, using oligonucleotides M2A (5′-GACTTCATCATGAATTCCCG- 3′) and M2B 
(5′-CAATAATTCGGATCCCTTCATTC-3′). The resultant PCR amplicon possessed 
EcoRI and BamHI restriction enzyme sites at the 5′ and 3′ ends, respectively, since these 
DNA sequences were present in primers M2A and M2B, as denoted by the underlined 
regions in the above oligonucleotides. The purified PCR products were then ligated into 
pNEB193 (New England Biolabs) at the EcoRI and BamHI sites. The resultant construct 
was named pNEB/M2L, and was sequenced to verify that no mutations had been 
introduced into the viral DNA. The pZIPPY-NEO/GUS plasmid (8) was digested with the 
BglII and HindIII restriction enzymes, and the neo-gus cassette was isolated from this 
plasmid by using agarose gel electrophoresis. This DNA segment contains the 
Escherichia coli neomycin resistance gene (neo) under the control of the vaccinia p7.5 
promoter, and the E. coli gusA gene under the control of a modified vaccinia H5 
promoter. Thus, when this cassette is stably inserted into the WR genome, recombinant 
viruses are identified based on their ability to form plaques in the presence of geneticin 
(G418) and to produce β-glucuronidase, an event measurable by the production of a blue 
color when virus-infected cells are incubated with the X-glucuronidase (X-glu) reagent 
(Clontech Laboratories). Next, the neo-gus cassette was blunt-end ligated into the StyI 
and AgeI restriction enzyme sites in pNEB/M2L, resulting in plasmid pNEB/ΔM2L/neo-
gus. Using this process, most of the M2L ORF was removed from pNEB193, and 
replaced with the neo-gus cassette. However, enough viral DNA flanking the M2L ORF 
was retained in the plasmid to allow for successful homologous recombination.
 BS-C-1 cell monolayers were transfected with pNEB/ΔM2L/ neo-gus using the 
FuGene6 transfection reagent (Roche) and then infected with WR. At 24 h post-infection, 
cells were harvested by scraping, lysed by freeze-thawing three times, and sonicated. 
Virus-containing cellular lysates were incubated with fresh BS-C-1 cellular monolayers 
that had been pre-incubated in medium containing 1 mg/ml G418 (Invitrogen 
Corporation) for 24 h. After a 1-h adsorption phase, virus-containing medium was 
removed, and cellular monolayers were incubated in medium containing 1.0% low-
melting point agarose and 1 mg/ml G418. At 48 h later, a second layer of medium 
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containing 1.0% low-melting point agarose and 0.2 mg/ml X-glu (Clontech Laboratories) 
was added. Recombinant viruses that produced blue-colored plaques were identified and 
collected. These plaques were further purified to remove contaminating parental virus 
using the same techniques, for a total of four rounds of plaque purification. The absence 
of the M2L ORF in the recombinant WR-based viruses was verified by PCR analysis of 
the genomes of plaque-purified viruses, and by immunoblotting lysates from ΔM2L-
infected cells. For immunoblotting, infected-cell lysates were electrophoretically 
separated, transferred to a PVDF membrane (Millipore) and membraneswere incubated 
with polyclonal rabbit anti-M2L antiserum (9) in TBS-T, followed by incubation with 
HRP-conjugated goat anti-rabbit IgG (Fisher Scientific), using dilutions of antibodies 
mentioned above. Immunoblots were developed as discussed above.
Western Immunoblotting for M2L Protein Expression
 Cytoplasmic proteins were extracted from infected-cell lysates, according to a 
modified version of methods described previously (9, 32). Briefly, 293T cellular 
monolayers were infected with indicated viruses at an MOI of 10. In some experiments, 
40 µg/ml cytosine arabinoside (Ara C) (Sigma-Aldrich) was present in the medium 
during the absorption phase of infection and post-infection. At either 2, 4, 8 or 16 h post-
infection, cell monolayers were scraped from the cell culture plates and pelleted during 
centrifugation for 1 min at 14,000×g at 4 °C. Alternatively, cellular monolayers were 
incubated in medium containing either tunicamycin (10 µg/ml; Sigma-Aldrich) or 
monensin (1 µM; Sigma-Aldrich) 30 min prior to infection, and were continuously 
incubated in supplemented medium during and after the absorption phase of virus 
infection. For these experiments, infected cell mono-layers were harvested from cell 
culture substrates by scraping at 20 h post-infection. As above, cells were collected and 
pelleted by centrifugation (1 min at 14,000×g). For both protocols, supernatants were 
removed, and cellular pellets were resuspended and lysed in CE buffer (32) containing 
HALT protease inhibitors (Pierce) for 5 min at 4 °C. After a brief centrifugation (1 min at 
14,000×g), the resultant supernatants were collected, and the protein concentration in 
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each preparation was determined by using the BCA Protein Assay kit (Pierce). An 
equivalent amount of protein (25 µg) from each sample was mixed in a 1:1 ratio with 2× 
Laemmli buffer (Fisher) containing 10% 2-mercaptoethanol, boiled for 5 min, and loaded 
into separate wells of a SDS-12% polyacrylamide gel. Proteins were separated 
electrophoretically and transferred to a polyvinylidene difluoride (PVDF) membrane 
(Millipore). Membranes were incubated in blocking buffer (TBS containing 5% 
powdered milk and 0.1% Tween-20) for at least 1 h. Next, membranes were incubated at 
4 °C overnight with the primary antibodies in TBS-T (TBS containing 0.1% Tween-20 
and 0.5% milk). For detection of M2L proteins, blots were incubated with polyclonal 
rabbit anti-M2L antiserum (9) diluted 1:1000 dilutions in TBS-T. After washing the 
membranes in TBS-T to remove unbound primary antibodies, blots were incubated with 
TBS-T containing a 1:20,000 dilution of HRP-conjugated goat anti-rabbit IgG (Fisher 
Scientific). Immunoblots were then washed to remove excess antibodies and developed 
by using the SuperSignal West chemilluminescence reagents, as per manufacturer’s 
directions (Pierce). In some cases, the same immunoblots or identical, duplicate 
immunoblots were probed with either polyclonal rabbit anti-actin antiserum (Sigma-
Aldrich) or polyclonal rabbit anti-A11R antiserum (40) diluted 1:1000 in TBS-T, 
followed by incubation with HRP-conjugated goat anti-rabbit IgG (Fisher Scientific) 
diluted 1:10,000 in TBS-T before being developed using the SuperSignal West 
chemilluminescence reagents (Pierce).
Confocal Microscopy
 293T cells were seeded onto glass cover slips (Fisher Scientific) and incubated 
overnight at 37 °C. Cellular mono-layers were infected with the indicated vaccinia 
viruses (MOI=10). At 1 to 2 h post-infection, infected-cell monolayers were washed with 
PBS, incubated in a 4% paraformaldehyde solution (Fisher Scientific) for 25 min, washed 
with PBS, and then incubated in a 0.1% Triton X-100 solution for 10 min (Bio-Rad) to 
allow for permeabilization. Next, fixed cells were washed with PBS and incubated in 
confocal blocking buffer (PBS containing 3% bovine serum albumin; BSA) (Fisher 
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Scientific) for 1 h. Fixed monolayers were then incubated for at least 1 h with either 
monoclonal rabbit IgG (Jackson ImmunoResearch), monoclonal mouse anti-V5 IgG 
(Invitrogen), rabbit polyclonal anti-BiP IgG (Abcam), rabbit polyclonal anti-M2L IgG 
(9), or rabbit polyclonal anti-PDI IgG (Stressgen). These primary antibodies were diluted 
at 1:250 or 1:500 in blocking buffer. Next, cellular monolayers were washed with excess 
volumes of confocal blocking buffer, and subsequently incubated with either Alexa Fluor 
488 dye-conjugated donkey anti-mouse IgG or Alexa Fluor 647 dye-conjugated goat anti-
rabbit IgG antibodies (Molecular Probes) for 30–45 min (1:1000–1:2000 dilutions), 
washed with confocal blocking buffer to remove unbound antibody and then mounted on 
microscope slides. All of these incubations proceeded at room temperature. Images were 
acquired by using a Leica SP2 laser scanning confocal microscope, and processed using 
the Leica SP2 software (Leica).
Gel Electromobility Shift Assays
 Electromobility shift assays were performed as previously described (9). Briefly, 
subconfluent 293T cellular monolayers in 6-well plates were infected with the indicated 
viruses (MOI=10). At 1 h post-infection, cells were harvested by scraping, and pelleted 
by centrifugation (1 min at 14,000×g) at 4 °C. Pellets were lysed in CE buffer (32) 
containing HALT protease inhibitors (Pierce) to disrupt the cytoplasmic, but not the 
nuclear membranes. Nuclei were then separated from the lysates by centrifugation (5 min 
at 14,000×g at 4 °C) and washed in excess CE buffer to remove contaminating 
cytoplasmic proteins. Nuclei were then resuspended in NE buffer (32) to disrupt their 
nuclear membranes. Samples were centrifuged to separate soluble and insoluble proteins. 
Soluble proteins were collected to new tubes and their concentrations were determined by 
using the BCA Protein Assay Kit (Pierce). 5 µg of each extract was incubated with 0.35 
pmol of 32P-labeled double-stranded oligonucleotides containing binding sites for the NF-
κB transcription factor (Promega) in Gel Shift Assay System Binding buffer (Promega) as 
per manufacturer’s directions. In some reactions, 1 µg of monoclonal mouse anti-p65 IgG 
(Santa Cruz Biotechnology), and antibody recognizing the p65 subunit of the p65:p50 
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NF-κB heterodimer, was present. Following incubation at room temperature, reactions 
were resolved electrophoretically in a 6% acrylamide gel (Invitrogen) under non-
denaturing conditions. Afterwards, the gel was dried onto filter paper, exposed to a 
phosphorimager plate (Molecular Devices), and images were developed and analyzed 
using the ImageGauge and ImageReader programs, respectively (Fuji).
Immunoprecipitation and EndoH Treatments
 293T cellular monolayers were infected with MVA-based viruses at an MOI of 
10. At 2 h post-infection, cells were harvested by scraping, and collected by 
centrifugation. Cellular pellets were re-suspended in IP lysis buffer (140 mM NaCl, 10 
mM Tris (pH 7.2), 2 mM EDTA (pH 8.0), 1% NP40) containing HALT protease 
inhibitors (Pierce). Clarified lysates were incubated with Protein G-Sepharose 4B beads 
(Invitrogen) previously conjugated to monoclonal anti-V5 antibodies (Invitrogen). The 
reaction was incubated at 4 °C with constant rotation for at least 2 h. Next, 
immunoprecipitates were collected by centrifugation, and beads were washed with large 
volumes of IP lysis buffer three times. Next, collected beads were subjected to EndoH 
digestion, as per the manufacturer’s directions. Briefly, 3 µl of the EndoH 10X denaturing 
solution (New England Biolabs) was added to each tube containing beads, and tubes were 
heated to 100 °C for 10 min, and then incubated on ice for 2 min. Samples were 
centrifuged at 13,000×g for 5 min at room temperature. Supernatants were collected, and 
incubated with 1000 U EndoH in G5 buffer (New England Biolabs) for 2 h at 37 °C. 
EndoH digestion was halted when samples then received 2× loading buffer and 2-
mercaptoethanol. Next, samples were incubated at 100 °C for 5 min, cooled on ice, and 
samples analyzed by SDS-12% PAGE. Immunoblotting for M2L protein expression was 
performed as described above
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Results
The M2L Product is Expressed Early During Vaccinia Virus Infection
 Given the role of the M2L protein in altering host-mediated immune responses 
(9), it was likely that M2L was produced early during infection, a time in which most 
other known poxviral immune-modulating proteins are expressed (28).  Bolstering this 
hypothesis is the fact that the nucleotide sequence of the M2L ORF promoter resembles 
that of transcriptional regulatory elements for other confirmed early genes (Moss, 2007), 
and that the transcriptional termination sequence (TTTTTNT) is not embedded within the 
M2L ORF, a characteristic of other early genes (28).
 To assess temporal expression during infection, M2L protein levels were 
examined at early and late times post-infection by probing infected-cell lysates with 
polyclonal anti-M2L antiserum (Fig. 2.1).  In lanes containing WR-infected cell lysates, a 
31 kDa protein was detected as early as 2 h post-infection (Fig. 2.1).  As infections 
progressed over time, additional higher molecular weight proteins of 33 kDa were 
recognized by the anti-M2L antiserum, with the proteins most abundant at 4 h post-
infection, but still detectable at 8 and 16 h post-infection.  These bands most likely 
represent M2L proteins since reactive proteins of identical molecular masses were not 
detected in mock-infected cell lysates or lysates from cells infected with a mutant WR 
virus lacking the M2L ORF (ΔM2L) (Fig. 2.1).  Likewise, 31–33 kDa proteins were not 
detected when MVA-infected cell lysates were probed (Fig. 2.1), consistent with the fact 
that the M2L ORF is absent from the genome of this attenuated vaccinia virus (2). In 
contrast, M2L protein expression in recombinant MVA/M2L-infected cells, in which the 
M2L ORF is present, was similar to that observed with lysates from WR-infected cells: 
31–33 kDa M2L proteins were detected as early as 2 h post-infection (Fig. 2.1).  Detected 
proteins of similar molecular weight also were observed in lysates from MVA//M2L-
infected cells at 4 h post-infection, while an additional different-sized protein was 
detected in cells at 8 and 16 h post-infection. Since similar amounts of actin were present 
in each sample (Fig. 2.1), as detected by the presence of a 42 kDa band, the differences 
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observed in M2L levels at different times were not due to varying amounts of proteins in 
a lane.
 The presence of Ara C during virus infection did not prevent M2L protein 
expression in either WR- or MVA/M2L-infected cell lysates (Fig. 2.1), since the lower- 
and higher-molecular weight forms of M2L proteins were readily detected at all time 
points. Cytoplasmic extracts from infected cells were analyzed concomitantly for the 
presence of the known late vaccinia virus protein, A11R (40) to ensure that the 
concentration of Ara C utilized in these experiments inhibited poxviral genome 
replication and late gene expression.  As previously reported (40), A11R proteins were 
detected at very low levels at 4 h post-infection, and in greater amounts at 8 and 16 h 
post-infection, when WR infections proceeded in regular medium (Fig. 2.1). Likewise, 
A11R proteins were detected also in ΔM2L, MVA- and MVA/M2L-infected cells at 4, 8 
and 16 h post-infection, consistent with the presumed expression of the A11R ORF (Fig. 
2.1).  However, when infections proceeded in medium containing Ara C, A11R proteins 
were not detected at any time post-infection.  This absence of A11R proteins was not due 
to low protein levels in cytoplasmically extracted samples since similar amounts of actin 
were detected in each immunoblotted sample (Fig. 2.1).  Since Ara C, a pyrimidine 
nucleoside analog, inhibits vaccinia virus DNA replication (19) and also prevents 
poxviral intermediate and late gene expression, it appears that the M2L protein is an early 
protein.
 The M2L protein sequence possesses motifs associated with ER localization and 
retention.  Previously, expression of the vaccinia M2L product was reported to greatly 
diminish MVA-mediated NF-κB activation in 293T cells (9).  Since no other organisms 
possess analogs to the M2L protein, its sequence was analyzed for other known motifs 
that would indicate potential function.
 The predicted amino acid sequence of the M2L protein contains several motifs 
that infer a possible localization of the M2L protein to the endoplasmic reticulum (ER) 
during infection (Fig. 2.2).  For instance, analysis of the M2L protein by using the 
SignalP 3.0 algorithm software predicted the presence of a signal peptide at N-terminal 
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residues 1–19 (Fig. 2.2) (46).  Signal peptide sequences, especially those containing a 
cluster of hydrophobic residues like those present in the M2L signal peptide, often direct 
proteins to the ER (46).  Further suggestive of ER localization was the presence of four 
consensus sites for N-linked glycosylation (N–X–S/T, where X can be any amino acid 
except proline), with the motifs located at residues 49–51, 79–81, 118–120 and 154–156 
(Fig. 2.2).  Since one of the major biosynthetic functions of the ER is to covalently add 
sugars to proteins (reviewed by (1)), the presence of these sites suggested that the M2L 
protein may locate to the ER for this modification to occur.  While many glycosylated 
proteins traffic to other cellular structures, or become secreted (38, 48), the presence of 
two ER retention signal motifs (XDEL) at residues 199–202 and 209–212, implies that 
M2L remains in the ER (30).  Interestingly, the C-terminus of the viral product also 
possesses a di-lysine KXKXX motif (residues 178–182) that directs Golgi-to-ER retrieval 
(16).  Based on these motifs, a working hypothesis is that the M2L product is directed to 
the ER by its signal sequence.  Next, the M2L protein is N-linked glycosylated and may 
briefly traffic to the Golgi apparatus before returning to the ER for the duration of 
infection.
The M2L Product is N-linked Glycosylated
 M2L proteins of various molecular weights were observed in WR- and MVA/
M2L-infected cells at later times post-infection (Fig. 2.1).  These proteins were larger 
than the predicted 25 kDa molecular weight for the M2L protein. Since N-linked 
glycosylation adds approximately 2.5 kDa of molecular mass to a protein (21), one 
hypothesis is that these M2L proteins with a size greater than 25 kDa represent 
glycosylated forms of M2L.  To test this possibility, the electrophoretic mobility of M2L 
proteins from cells infected in the presence of glycosylation inhibitory drugs were 
compared to M2L proteins expressed under normal conditions.  As before (Fig. 2.1), 
when either WR or MVA/M2L infections proceeded in unmodified medium, the 
molecular weights of the M2L proteins were between 31 and 33 kDa (Fig. 2.3A).  In 
contrast, when infections proceeded in the presence of tunicamycin, a drug that prevents 
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N-linked glycosylation (15), the size of detected M2L proteins decreased to 25 kDa. In 
contrast, when infections proceeded in the presence of monensin, a drug that prevents 
Golgi-mediated O-linked glycosylation (45), the mobilities of the M2L proteins remained 
similar to that observed for untreated, WR- or MVA/M2L-infected cells (Fig. 2.3C).  As 
expected, exposure to either tunicamycin or monensin did not affect the lack of M2L 
protein expression by the MVA or ΔM2L virus, nor did it affect the expression of cellular 
genes, since actin levels were similar in untreated versus treated cells.
The M2L Protein Localizes to the ER During Vaccinia Virus Infection
 The presence of the signal peptide sequence, the N-linked glycosylation sites, and 
the ER retention and ER retrieval motifs in the M2L protein suggested that it would 
localize to, and remain in, the ER.  However, the M2L product prevents NF-κB activation 
(9), an intracellular signaling event, making M2L secretion unlikely.  Additionally, when 
incubating media from virus-infected cells with anti-M2L antiserum and Protein G 
sepharose beads, M2L proteins were not detected in these immunoprecipitates, inferring 
that the M2L protein remained cell-associated (data not shown).
 To directly test the hypothesis that the M2L protein localizes to the ER during 
infection, confocal microscopy was utilized to assess the cellular location of a C-
terminally V5-epitope tagged version of the M2L protein.  Since the biological function 
of the M2L protein had been elucidated in HEK293T cells, we chose to study M2L 
protein cellular location in this cell line.  As shown in Fig. 2.4A, a low level of diffuse 
fluorescence was observed when either mock- or MVA-infected cells were incubated with 
monoclonal mouse anti-V5 IgG antibodies. In contrast, staining of fixed MVA/M2L-V5-
infected cells with anti-V5 antibodies resulted in fluorescence next to and surrounding 
part of the nucleus, a pattern typical of ER localization.  Similar results were observed 
when fixed MVA/M2L-V5-infected cells were instead incubated with polyclonal rabbit 
anti-M2L protein antiserum (Fig. 2.7C), inferring that the addition of a V5 epitope tag did 
not appear to influence the cellular location of the M2L protein.
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 As further evidence that M2L proteins were being retained in the ER, virus-
infected cells expressing M2L protein also were co-incubated with antiserum specific for 
the ER luminal resident protein disulfide isomerase (PDI) (11).  As shown in Fig. 2.4, 
there was a co-localization of the M2L-V5 proteins with PDI in MVA/M2L-V5-infected 
cells, and this co-localization remained constant when these double-labeled, stacked 
images were viewed by Z-series (data not shown).  Similar results also were observed 
when antiserum against another known cellular ER-localizing protein, BiP, was 
substituted for anti-PDI antiserum (data not shown).  When comparing PDI location in 
mock- versus virus-infected cells, PDI staining patterns were similar, indicating that virus 
infection was not obviously affecting ER structure at early times post-infection (Fig. 
2.4A).  Similar results were observed if COS-7 cells were instead utilized as the host cell 
for infection (Fig. 2.4B).  Staining of fixed MVA/M2L-V5-infected cells with anti-V5 
antiserum resulted in fluorescence surrounding the nucleus, a pattern similar to that 
observed when the same fixed, infected cells were stained with anti-PDI.
The Signal Peptide Sequence at the N-terminus of M2L is Responsible for ER 
Localization of the M2L Protein
 Previously, the M2L protein was reported to prevent virus-induced NF-κB 
activation (9).  To examine if M2L ER location is important for this function, a modified 
M2L protein, in which the N-terminal signal sequence was removed, was created.  This 
altered M2L protein was predicted to no longer possess a functional signal peptide motif, 
as predicted by the SignalP 3.0 software program, and therefore should not localize to the 
ER.  After verifying the aberrant cellular location, this mutant M2L protein would then be 
assessed for its ability to inhibit virus-induced NF-κB activation to ascertain the 
importance of ER location for NF-κB inhibitory function.  To this end, the M2L ORF was 
engineered such that residues 2–13 were deleted from the encoded protein, and residues 
encoding a V5 epitope tag were engineered onto its C-terminus.
 Analysis of the molecular weight of the modified M2L protein (“M2L-V5 Δsp”) is 
shown in Fig. 2.5A.  While the wild-type M2L protein is expressed as 31–33 kDa 
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products in cells infected with vaccinia strain WR, the addition of a V5 epitope tag is 
estimated to increased the molecular weight of the M2L protein by approximately 1.4 
kDa.  In agreement with this prediction, the M2L-V5 protein expressed during infection 
of cells with MVA/M2L-V5 results in the expression of proteins that are 32.4–34.4 kDa 
(Fig. 2.5A).  It was predicted that the removal of M2L residues 2–13 would result in a 
reduction of the M2L molecular mass by 1.5 kDa, resulting in 30.9–32.9 kDa M2L-V5 
Δsp proteins.  If, however, this mutation affected the ability of M2L proteins to localize to 
the ER, thereby disrupting the normally occurring post-translational modifications of the 
M2L protein, then the altered M2L protein’s molecular weight would be expected to be 
decreased further.  Indeed, when cells were infected with MVA/M2L-V5 Δsp, 25 kDa 
M2L proteins were detected (Fig. 2.5A), the predicted molecular weight of an epitope-
tagged mutant protein that received no post-translational modifications.  The relative 
quantity of the modified M2L protein compared to wild type M2L protein detected in 
either MVA/M2L-V5-infected cells was lower, whether detection of the mutant protein 
was assessed at either 1, 2 or 4 h post infection (data not shown).  However, unlike MVA/
M2L-V5-infected cells, where the M2L protein localized to the ER, the modified M2L 
protein in MVA/M2L-V5 Δsp-infected cells was spread throughout the cytoplasm (Fig. 
2.5B).  Moreover, whereas the intact M2L protein co-localized with cellular PDI, there 
was little, if any, similar placement of PDI and the M2L-V5 Δsp protein (Fig 2.5B).  
Further examination of M2L-V5 Δsp protein location also revealed that small populations 
of this protein were localizing to the nucleus.  Similar results were obtained if virus-
infected cells were instead incubated with anti-M2L antiserum, instead of anti-V5 
antiserum to detect M2L protein location (Fig. 2.7).
 As further proof that the M2L-V5 Δsp protein did not localize to the ER, its 
sensitivity or resistance to endoglycosidase H (Endo H) was assessed.  Endo H cleaves 
mannoses and some hybrid oligosaccharides from N-linked glycoproteins.  Therefore, 
proteins that are Endo H sensitive imply that protein localized to the ER, where it 
received the N-linked glycosylation.  To determine the Endo H sensitivity of wild-type or 
mutant M2L proteins, epitope-tagged M2L proteins from virus-infected 293T cells was 
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immunoprecipitated with anti-V5 antiserum.  Immunoprecipitates were incubated with 
Endo H, and reactions were analyzed for M2L protein mobility by using immunoblotting.  
Results are shown in Fig. 5C. While the wild-type M2L-V5 protein’s mobility was 
approximately 35 kDa, Endo H treatment of immunoprecipitates decreased the mobility; 
M2L was represented as an intense 25 kDa band, and as less intense bands ranging from 
25 to 35 kDa.  Thus, wild-type M2L proteins were EndoH sensitive, and present in the 
ER. In contrast, the 25 kDa M2L-V5 Δsp protein’s mobility remained the same in the 
presence or absence of Endo H, indicating that this mutant protein did not localize to the 
ER.
The Ability of the M2L Protein to Prevent NF-κB Activation is Lost When its Signal 
Peptide Sequence is Deleted
 To assess the importance of ER location for the ability of the M2L protein to 
inhibit NF-κB activation, 293T cells were infected with MVA constructs expressing either 
wild type or mutated M2L proteins.  NF-κB activation was then determined by incubating 
nuclear-extracted proteins from these virus-infected cells with radiolabeled 
oligonucleotides containing consensus NF-κB binding motifs.  If NF-κB had translocated 
to the nucleus, an event that occurs when this host protein is activated, then it would bind 
to the radiolabeled oligonucleotides, and reduce their electrophoretic mobility.  
 As previously reported (9), MVA was apparently unable to prevent NF-κB nuclear 
translocation (Fig. 2.6, lane “MVA”).  That the novel high molecular weight band did 
indeed represent an NF-κB-oligonucleotide complex was verified by it being shifted to a 
higher molecular weight due to reaction with a specific anti-NF-κB antibody (Fig. 2.6, 
lane “MVA+anti-p65”).  A similar complex was also observed when a lysate from cells 
infected with MVA/M2L-V5 Δsp was used.  In contrast, both the unmodified WR and the 
parental MVA/M2L-V5 exhibited the inhibitory phenotype, with no band detected in 
lanes containing extracts from WR-infected cells, and only a faint band observed when 
testing extracts from MVA/M2L-V5-infected cells.  Thus, elimination of the leader 
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sequence of the M2L protein was associated with the loss of the ability to prevent NF-κB 
nuclear translocation.
A Mutant M2L Protein Lacking the Putative ER Retention and Retrieval Motifs 
Localizes to the ER and to the Cytoplasm, and No Longer Prevents NF-κB Nuclear 
Translocation
 To rule out the possibility that the decreased detection levels of the M2L-V5 Δsp 
protein as compared to wild type M2L protein was due to the anti-M2L antibodies 
preferentially recognizing the glycosylated forms of M2L proteins, a second mutant M2L 
protein expressing only residues 1–178, and thereby retaining its glycosylation sites, was 
created.  Since this C-terminal deletion mutant protein (M2L-V5 ΔERret) lacked the 
regions containing the two putative ER retention motifs and the ER retrieval signal, it 
was predicted that the M2L-V5 ΔERret proteins, while initially localizing to the ER, 
would egress from the ER during infection.  Similar to M2L-V5 Δsp, M2L-V5 ΔERret 
also possessed a C-terminal V5 epitope tag.  The predicted molecular weight of this 
protein, if it received no N-linked glycosylation and if the signal peptide sequence was 
cleaved, was 19.5 kDa. As shown in Fig. 2.7A, infection of cells with MVA/M2L-V5 
ΔERret resulted in the detection of 25 kDa products.  Additionally, the relative quantity 
of the C-terminal deleted M2L protein was similar to the V5-epitope tagged wild-type 
protein (Fig. 2.7A).
 To assess if the differences in observed versus theoretical molecular weights was 
due to N-linked glycosylation, infected cells were incubated in medium containing 
tunicamycin.  Similar to before, the 34 kDa wild-type M2L-V5 protein was represented 
by a 25 kDa band (Fig. 2.7B), indicating that the wild-type protein received N-linked 
glycosylation, an event which occurs in the ER.  When studying the mobility of M2L-V5 
ΔERret, its mobility in the absence of tunicamycin is 25 kDa.  However, when 
tunicamycin is present during infection, the mobility of the mutant M2L protein changes 
to 18–19 kDa (Fig. 2.7B), suggesting that this mutant M2L protein migrates to the ER 
and receives some N-linked glycosylation modifications.
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 Next, the cellular location of the M2L-V5 ΔERret protein during infection was 
assessed by using confocal microscopy.  Similar to patterns found when utilizing anti-V5 
antiserum to identify M2L proteins (Fig. 2.4 and Fig. 2.5), staining fixed cells with anti-
V5 antiserum resulted in detection of the V5 epitope tagged form of the wild-type M2L 
protein in areas next to and around the nucleus, whereas the M2L-V5 Δsp protein 
appeared to be distributed throughout the cellular cytoplasm (Fig. 2.7C).  As shown in 
Fig. 2.7C, M2L-V5 ΔERret also localized to areas next to and surrounding the nucleus, as 
detected by using anti-V5 antiserum, suggesting ER localization.  However, when 
comparing the cellular location of the M2L-V5 ΔERret proteins with that of the PDI 
cellular resident ER proteins, it was observed that a population of these mutant M2L 
proteins no longer co-localized with PDI (Fig. 2.7C).  Thus, it appears that that there is 
not complete localization of this mutant M2L protein to the ER.
 To assess the effect of this mutant protein on MVA-mediated NF-κB activation, 
293T cells were infected with MVA constructs expressing either wild-type or mutated 
M2L proteins.  Similar to above, NF-κB activation was determined by the migration of 
freed, and presumably active, transcription factor to the nucleus.  When incubating 
nuclear-extracted proteins from uninfected cells with radiolabeled oligonucleotides 
containing consensus NF-κB binding motifs, there was no detectable shift in the mobility 
of the radiolabeled oligonucleotides, suggesting that NF-κB was absent from the nuclei of 
these resting cells (Fig. 2.8, lane “uninfected”).  In contrast, MVA infection was 
apparently triggering NF-κB nuclear translocation (Fig. 2.8, lane “MVA”), as was 
evidenced by the appearance of a unique mobility-shifted band.  The addition of 
antibodies specific for the p65 subunit of the NF-κB heterodimer super-shifted this 
unique complex (Fig. 2.8, lane “MVA+anti-p65”), confirming that the MVA-induced 
mobility-shifted band contained NF-κB.  A band of similar intensity was observed when 
analyzing nuclear extracted proteins from cells infected with MVA/M2L-V5 ΔERret, but 
this band was not present when proteins from cells infected with WR were analyzed.  A 
band of lesser intensity was present when extracts from MVA/M2L-V5-infected cells 
were used, an event not surprising given that this genome lacks ORFs that code for other 
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NF-κB inhibitory proteins, namely K1L (41).  These trends are noted when cells were 
harvested at either 1 or 2 h post-infection. Thus, the removal of the ER retention and 
retrieval sequences from the M2L protein yielded the same NF-κB activation phenotype 
as when the N-terminal signal sequence of the M2L protein was absent, even though 
some of these mutant M2L proteins still localized to the ER.
The VV M2L Protein Prevents Phosphorylation of ERK1/2
 It was reported previously that the stable insertion of a 5.2-kb region of parental 
Ankara DNA into the MVA genome produced a recombinant virus that no longer fully 
activated NF-κB in 293T cells (41). Since this fragment contains three intact ORFs 
(M2L, M1L, and K1L) that are either absent or fragmented in the MVA genome (25), one 
hypothesis is that one or more of the encoded products inhibits NF-κB activation by 
interfering with at least one step in the pathway requiring ERK2 phosphorylation. We 
tested this hypothesis by examining the effect of expression of the three individual ORFs 
on phosphorylation of ERK2 in stimulated 293T cells. To this end, the status of ERK2 in 
stimulated 293T cells that had been transfected previously with expression vectors 
containing the VV K1L gene (K1L/pCI), M1L gene (M1L/pCI), or M2L gene (M2L/pCI) 
was examined.
 Rather than use MVA for induction, the phorbol myristate acetate (PMA) 
compound, which activates the MEK/ERK pathway and triggers the formation of P-
ERK2 in 293T cells (17), was included in the medium. As shown in Fig. 2.9, a 2-h 
exposure to PMA was sufficient to induce ERK2 phosphorylation, an event not detected 
in any of the untreated transfected cells. No decrease of ERK2 phosphorylation was 
noticed in the PMA-treated cells transfected with K1L/pCI, M1L/pCI, or the unmodified 
parental pCI vector. In contrast, ectopic expression of the M2L protein resulted in a 
discernible decrease in the presence of P-ERK1 and P-ERK2 in PMA-exposed cells. This 
loss was not due to ERK protein degradation in M2L/pCI-transfected cells since ERK1 
and ERK2 quantities were similar in all lysates, regardless of whether the cells had been 
transfected or activated with PMA.
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 To test if the presence of the M2L gene had a similar effect on MVA-induced 
activation of MEK/ERK interactions, we examined the effect of insertion of the VV M2L 
transcriptional unit into the MVA genome on the resultant recombinant's ability to trigger 
ERK2 phosphorylation.  Both P-ERK1 and P-ERK2 were present in greater amounts in 
lysates from MVA-infected cells than in those from mock-infected cells (Fig. 2.10) For 
comparison, the levels of both phosphorylated proteins were dramatically reduced in 
lysates from cells infected with MVA/M2L or the M2L ORF-possessing WR strain of VV. 
This inhibition was specific for the M2L protein, as ERK2 phosphorylation was not 
diminished in cells infected with a different MVA recombinant whose DNA contained a 
novel VV K1L transcriptional unit insert (MVA/K1L). Moreover, the M2L protein did not 
cause ERK2 degradation, since the relative amount of ERK2 remained constant, 
regardless of whether the cells were mock infected or infected with any of the four 
viruses.
 
Discussion
 The vaccinia M2L protein was characterized as a means of understanding how it 
functions molecularly to inhibit virus-induced NF-κB activation.  Here, we demonstrate 
that the M2L protein is expressed early during virus infection, a trait shared with other 
poxviral immunomodulatory agents (28).  Also, the M2L protein remains intracellular 
and is N-linked glycosylated, indicative of its localization to the ER.  Moreover, 
microscopic analysis confirmed that M2L proteins traffic to the ER, with this organelle 
location dependent on its N-terminal signal peptide sequence and, to a lesser extent, on its 
C-terminal retention motifs.  Finally, either leaderless M2L proteins or M2L proteins 
lacking their putative ER retention and retrieval motifs lose their ability to deter NF-κB 
activation at early times post-infection.
 The M2L protein is expressed as a 31–33 kDa product during the course of 
infection.  There are two scenarios that would explain the detection of this doublet: either 
the M2L protein is cleaved during infection or the protein is post-translationally 
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modified.  Since expression of the M2L protein in the presence of tunicamycin, a drug 
that inhibits N-linked glycosylation, renders the production of a single 25-kDa M2L 
protein, it appears that the later possibility is most likely, with the 31 kDa and 33 kDa 
proteins representing high- versus low-glycosylation forms.  It was unlikely that the wild-
type M2L proteins localized to the Golgi apparatus, a hypothesis that was supported with 
the observation that M2L protein mobility was unaltered when infected cells were treated 
cells with monensin, a drug that inhibits Golgi apparatus-mediated O-linked 
glycosylation (45).  Additionally, M2L proteins did not co-localize with other known 
Golgi apparatus-associated proteins as determined by using confocal microscopy (data 
not shown).
 Motifs present in the M2L protein suggested that it entered the ER.  Indeed, 
analysis of a mutant M2L-V5 protein missing the putative N-terminal signal peptide 
sequence (M2L-V5 Δsp) revealed that the modified protein no longer localized to the ER.  
Coincident with this data was the observation that the M2L-V5 Δsp protein was of a 
molecular weight that indicated it had not received N-linked glycosylation modifications, 
biochemical events that occur in the ER.
 It was observed that the mutant M2L-V5 Δsp protein was detected at lower levels 
than the wild-type M2L-V5 protein when using immunoblotting (Fig. 2.6).  One 
possibility for this difference in detection levels may be that the avidity of the anti-M2L 
antiserum for the unglycosylated form of M2L is lower than for the glycosylated form.  
Thus, a construct expressing mutant M2L proteins that still allow for glycosylation, while 
losing predicted ER location signals, M2L-V5 ΔERret, was created and tested for its 
ability to inhibit NF-κB activation. Unlike M2L-V5 Δsp proteins, M2L-V5 ΔERret 
protein detection was similar to that of wild-type M2L proteins.
 The C-terminal region of the M2L protein contains 2 ER retention motifs (XDEL) 
and an ER retrieval motif (KXKXX), implying that M2L proteins, after post-translational 
modifications, would remain in the ER for the duration of infection.  Removal of these 
motifs, then, was expected to result in M2L-V5 ΔERret proteins that would initially enter 
the ER, but ultimately migrate out of the ER.  Since the mobility of this mutant protein 
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decreased when cells were infected in medium containing tunicamycin, it was likely that 
M2L-V5 ΔERret proteins were indeed N-linked glycosylated, and therefore entered the 
ER.  Notably, while some M2L-V5 ΔERret proteins still co-localized with PDI, a portion 
of the ΔERret proteins no longer co-localized, suggesting that only some of the mutant 
M2L proteins lost their ER association phenotype.  It is unknown why some of the 
mutant M2L proteins still remain in the ER.  Images of ΔERret proteins were obtained up 
to 4 h post-infection.  Whether the entire population may eventually migrate out of the 
ER at later times post-infection remains to be tested.  Nevertheless, even with this partial 
phenotype, the M2L-V5 ΔERret protein is compromised in its ability to inhibit NF-κB 
activity at early times post-infection.
 The ER comprises the large reticular network that not only acts as a storage site 
for calcium, but also regulates protein synthesis, protein modification, and the proper 
folding and transport of proteins (10).  Events germane to viral replication, namely high 
level production of viral proteins, will often cause ER stress, leading to at least two 
chemically distinct signal transduction pathways, termed the ER overload response 
(EOR) and the unfolded protein response (UPR) (18).  Not surprisingly, multiple viruses 
express proteins to regulate ER homeostasis (14, 29, 33-35, 47), thereby maintaining a 
productive cellular environment for viral replication.
 It is thought that EOR is an immediate cellular response to viral infection, 
presumably activating cellular genes whose products would limit virus infection. During 
EOR, calcium is released from the ER into the cytoplasm, proceeded by an increase in 
intracellular reactive oxygen species (ROS) (34).  Through undefined signal transduction 
mechanisms, this release of calcium and ROS results in NF-κB activation (33, 36).  
Given the requirement of ER localization for the M2L protein’s NF-κB inhibitory 
function, one speculation is that this viral protein blocks an early event in the EOR 
pathway, namely calcium release from the ER.  At least one cellular protein, RTN3HAP, 
is involved in triggering calcium release during EOR (22). Thus, M2L interaction with 
this or other similar ER-based calcium release channels, such as the ryanodine receptors 
and the INSP3 receptors (10) may exert this predicted effect. It was reported previously 
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that the M2L product also prevents ERK2 phosphorylation, an event necessary for MVA-
induced NF-κB activation of 293T cells (9).  Although the M2L and ERK2 proteins are 
not likely to be present in common cellular compartments (37), there is a body of 
evidence showing a causal relationship between cytoplasmic calcium increases (perhaps 
those triggered via the EOR) and MEK/ERK activation (20, 27), with calcium release and 
ERK activation intimately associated with NF-κB activation.  Thus, the M2L protein’s 
ability to prevent ERK2 phosphorylation may be linked with its ability to inhibit calcium 
release from the ER.
 In contrast to the EOR, the UPR occurs when there is an accumulation of 
improperly folded proteins in the ER. The UPR is characterized by the activation of 
cellular kinases such as ATF6 and IRE1, to stimulate the production of proteins that 
enhance the folding capacity of the ER, and PERK, which phosphorylates eIF2α to 
induce a translational arrest (13).  Historically, only the EOR was thought to trigger 
activation of NF-κB via the accumulation of proteins in the ER (18).  More recent 
publications, however, find that UPR and NF-κB activation occur concomitantly, with the 
inhibition of the UPR also preventing NF-κB activation (6, 26). Thus, assessing the role 
of M2L on the UPR as its mechanism for inhibiting NF-κB activation is warranted.
 Yet another important innate immune defense is Toll-like receptor (TLR) 
recognition of viral genomes, subsequently resulting in NF-κB activation.  For virus-
induced TLR signaling, TLRs 3, 7 and 9 are probably most important because they 
recognize viral components such as double-stranded RNA, single stranded RNA and 
unmethylated DNA, respectively (31).  Recently, these viral sensing TLR proteins were 
shown to interact with the cellular UNC93B ER membrane protein (5), with a point 
mutation in UNC93B abolishing this interaction.  In laboratory mice expressing mutant 
UNC93B proteins, the TNF cytokine, whose expression is dependent upon the activated 
form of NF-κB, is no longer produced in response to the natural ligands of TLRs 7 or 9 
(5, 44).  These studies infer that the ER localization of these TLRs, and their interaction 
with UNC93B, may be important for NF-κB activation.  Whether ER-localized vaccinia 
M2L proteins may be preventing such interactions is the subject of future studies.  If 
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future data support this hypothesis, then the M2L protein would utilize a different 
mechanism for inhibiting TLR-mediated NF-κB activation than those deployed by the 
previously characterized vaccinia A52R, A46R and N1L proteins (4, 7).
 The M2L protein is highly conserved amongst members of the Orthopoxvirus 
genus (www.poxvirus.org), suggesting that its function may be important for 
pathogenesis in vivo.  In addition, predicted proteins with approximately 50% similarity 
are also present in myxoma virus (gp120-like ORF) and rabbit fibroma virus (gp154L) 
(www.poxvirus.org).  Whether these viral products also localize to the ER and inhibit 
NF-κB activation remains to be determined.  Interestingly, there are two other poxviral 
proteins (vaccinia B7R and myxoma M-T4) that reside in the ER and are virulence 
factors (3, 39).  For instance, deletion of the B7R ORF from the vaccinia virus genome 
results in a genetically altered virus that is attenuated when administered intradermally to 
mice (39).  Similarly, removal of the myxoma M-T4 ORF results in a deletion mutant 
virus that produces an attenuated myxamatosis in rabbits (3).  Additionally, unlike the 
parental virus, this altered virus activates apoptosis in cultured and primary lymphocytes 
(3).  Whether either protein affects ER stress as its mechanism for virulence remains to be 
tested. Multiple viruses express mechanisms to regulate ER stress.  Given the importance 
of ER location to the M2L ability to inhibit NF-κB activation, it is interesting to speculate 
that poxviruses, like other viruses, may also express functionally similar proteins to 
purposefully regulate ER-mediated signaling pathways, thereby ensuring a productive 
infection in vivo.
 It was observed that either exposure to nonlethal quantities of PD 98059 or U0126 
or the overexpression of a dominant-negative, kinase-deficient form of ERK2 did not 
completely abolish MVA-induced NF-κB activation, as measured by luciferase reporter 
and electrophoretic mobility shift assays. One potential explanation for this observation is 
that ERK2 functions cooperatively with another protein to eventually activate NF-κB and 
that both participants must be inactivated to completely repress NF-κB activation. Two 
such candidate proteins are ERK1 and ERK5, since complexes of either with ERK2 can 
activate NF-κB (8, 12, 24, 26, 27, 47). In support of the possibility that the ERK2-ERK1 
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complex is responsible, the extent of ERK1 phosphorylation in MVA- or PMA-stimulated 
cells was reduced in the presence of the M2L protein (Fig. 2.9).  
 Alternatively, an MVA infection eliciting a second, ERK2-independent NF-κB 
activation pathway would explain the partial inhibition observed in dominant-negative 
ERK2 mutant-expressing cells (9).   Interestingly, we demonstrated that another VV 
protein, K1L, hampers NF-κB-controlled cellular and marker (luciferase) gene 
transcription in 293T cells (41). However, unlike M2L, K1L did not impede ERK2 
phosphorylation in cells stimulated with either MVA or PMA. Since infection with either 
MVA/M2L or MVA/K1L inhibited NF-κB-regulated luciferase activity similarly and to 
the same level as that during MVA/5.2kb infection (9), one possibility is that the K1L 
product functions downstream of ERK2 activation to prevent NF-κB activation. It is 
unlikely that K1L and M2L interact directly to inhibit ERK2, since no association 
between these two proteins was detected in a yeast two-hybrid system (24).  Yet another 
conclusion that can be drawn from the observed independence of K1L and M2L is that 
they each inhibit distinct signal transduction pathways to repress NF-κB activation. If VV 
infection does indeed antagonize a cell to employ more than one transduction pathway 
for NF-κB activation, then it would not be surprising that separate interactions between 
different host and virus proteins are necessary for complete inhibition of the NF-κB 
response. Whether this phenomenon occurs in 293T cells is currently unknown, but in 
establishing a molecular mechanism for K1L in these cells, we would rule out the 
involvement of p70S6 kinase, phosphatidylinositol 3-kinase, and p38 MAP kinase, since 
compounds that inhibit their activities did not reduce MVA-induced NF-κB activation (9). 
Future experiments that are designed to examine the effects of M2L and K1L gene 
expression on events after ERK phosphorylation and on other signal transduction 
pathways in a variety of cell lines will be necessary to establish the correct model.
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Figure 2.1 Temporal M2L protein expression in virus-infected cells. 293T cellular 
PRQROD\HUVZHUHPRFNLQIHFWHG81RULQIHFWHGZLWKHLWKHU:5у0/09$RU09$0/
(MOI=10). For some samples, absorption of virus and virus infection proceeded in medium 
containing Ara C (40 +g/ml medium). Cells were harvested and lysed in CE buffer at the 
indicated hours post-infection. 25 +g of cytoplasmic proteins from each sample were 
analyzed by SDS-12% PAGE and transferred to a PVDF membrane. Membranes were 
probed with anti-M2L antiserum. After development based on chemilluminescence, blots 
were re-incubated with anti-actin antiserum and subsequently developed to detect actin 
proteins. Identical blots were probed with anti-A11R antibodies, developed, and then 
re-probed for actin protein presence by using anti-actin antibodies. The relative positions of 
the molecular weight markers (MW) are indicated on the right hand side of the figure.
1      MVYKLVLLFCIASLGYS^VEYKNTICPPRQDY
32     RYWYFAAELTIGVNYDINSTIIGECHMSESYI
64     DRNANIVLTGYGLEINMTIMDTDQRFVAAAE
95     GVGKDNKLSVLLFTTQRLDKVHHNISVTITC
126   MEMNCGTTKYDSDLPESIHKSSSCDITINGS
157  CVTCVNLETDPTKINPHYLHPKDKYLYHNSEY
189   SMRGSYGVTFIDELNQCLLDIKELSYDICYRE 
Figure 2.2 The amino acid sequence of M2.  The 220 amino acid M2 vaccinia virus 
protein is depicted.  The signal peptide sequence is boxed, cleavage is indicated by a ^ 
between positions 17 and 18. The four putative N-linked glycosylation sites occur at 
positions 49, 79, 118, and 154.  The three putative ER retention/retrieval sites occur at 
positions 178, 199, and 209.  
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Figure 2.3 The effect of 
glycosylation inhibitors on M2 
protein mobility. 293T cell 
monolayers were mock-infected 
(UN) or infected with either MVA, 
09$0/:5RUу0/
(MOI=10) in medium that lacked 
any drug supplements (A), or 
contained 10 +g/ml tunicamycin 
(B), or 1 +M monensin (C). At 20 
h post-infection, cells were 
harvested, lysed, and 25 µg of 
each lysate was 
electrophoretically separated in a 
SDS-12% PAG. Proteins were 
transferred to PVDF membranes, 
and the membranes were probed 
with anti-M2 antiserum. Reactive 
proteins were detected by 
chemilluminescence. Blots were 
re-incubated with anti-actin 
antibodies and subsequent 
signals for the detection of actin 
proteins were developed. The 
relative positions of the molecular 
weight markers (MW) are 
indicated on the right hand side 
of the figure.
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Figure 2.4  Co-localization of the M2L and ER proteins during virus infection. 293T (A) or 
COS-7 (B) cell monolayers were mock-infected (UN) or infected with either MVA orMVA/M2L-V5 
(MOI=10). At 2 h post-infection, cell monolayers were fixed, permeabilized, and incubated with a 
mixture of mouse monoclonal anti-V5 and rabbit polyclonal anti-PDI antisera. After washing, 
samples were subsequently incubated with Alexa Fluor 488 dye-conjugated donkey anti-mouse 
or Alexa Fluor 647 dye-conjugated goat anti-rabbit secondary antibodies. Images were acquired 
using the Leica SP2 Laser Scanning confocal microscope.
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Figure 2.5  Cellular localization of an 
altered M2L protein lacking the 
N-terminal signal peptide sequence. 
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Figure 2.6  The effect of deleting the signal peptide signal on M2L protein-mediated 
LQKLELWLRQRI09$LQGXFHG1)ѣ%DFWLYDWLRQ293T cellular monolayers were infected with 
the indicated viruses (MOI=10) or mock-infected (UN). At 1 h post-infection, nuclei were 
isolated from the cells, lysed and clarified by centrifugation. The soluble fractions were 
incubated with 32P-labeled double-stranded oligonucleotides containing binding sites for the 
1)ѣ%WUDQVFULSWLRQIDFWRU,QRQHFDVH09$DQWLS+JRIPRQRFORQDODQWLSDQWLVH-
rum was included. Following incubation at room temperature, reactions were resolved 
HOHFWURSKRUHWLFDOO\LQDDFU\ODPLGHJHO,QYLWURJHQXQGHUQRQGHQDWXULQJFRQGLWLRQV2QH
reaction, indicated as “probe only” contained no cellular proteins. Afterwards, the gel was 
dried onto filter paper, exposed to a phosphorimager plate (Molecular Devices) and images 
ZHUHGHYHORSHG$QDVWHULVN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Figure 2.7  Cellular localization of an altered M2L protein lacking the C-terminal 
region containing ER retention and ER retrieval motifs. 7FHOOPRQROD\HUVZHUH
HLWKHUPRFNLQIHFWHG81RULQIHFWHGZLWKHLWKHU09$09$0/909$0/9у(5UHW
RU:502, $WKSRVWLQIHFWLRQ$FHOOVZHUHKDUYHVWHGDQGO\VHGDQGO\VDWHVZHUH
VHSDUDWHGE\XVLQJ6'63$*($IWHUHOHFWURSKRUHWLFWUDQVIHURIWKHSURWHLQVWRD
39')PHPEUDQHWKHPHPEUDQHZDVSUREHGZLWKDQWL0DQWLVHUXPIROORZHGE\LQFXED-
WLRQZLWKVHFRQGDU\+53FRQMXJDWHGJRDWDQWLUDEELW,J*%ORWVZHUHGHYHORSHGE\FKHPLO-
OXPLQHVFHQFHUHSUREHGZLWKDQWLDFWLQDQWLVHUXPDQGGHYHORSHG%0RFNLQIHFWHGFHOOV
RUFHOOVLQIHFWHGZLWKHLWKHU09$0/9RU09$0/9у(5UHW02, ZHUHLQFXEDWHG
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ZHUHZDVKHGDQGLQFXEDWHGZLWKHLWKHU$OH[D)OXRUG\HFRQMXJDWHGJRDWDQWLUDEELWRU
$OH[D)OXRUG\HFRQMXJDWHGGRQNH\DQWLPRXVHVHFRQGDU\DQWLERGLHV,PDJHVZHUH
DFTXLUHGXVLQJWKH/HLFD63/DVHU6FDQQLQJFRQIRFDOPLFURVFRSH
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ret, or WR (MOI=10) or mock-infected (UN). At either 1 or 2 h post-infection, nuclei were 
isolated from the cells, and soluble nuclear proteins were extracted, and then incubated with 
3ODEHOHGGRXEOHVWUDQGHGROLJRQXFOHRWLGHVFRQWDLQLQJELQGLQJVLWHVIRUWKH1)ѣ%
transcription factor. In one case (MVA+anti-p65), 1 +g of monoclonal anti-p65 antiserum was 
included in the reactions. Yet another sample (probe only) lacked nuclear-extracted proteins. 
Following incubation at room temperature, reactions were resolved electrophoretically in a 
6% acrylamide gel (Invitrogen) under non-denaturing conditions. The gel was dried onto filter 
paper, exposed to a phosphorimager plate (Molecular Devices) and images were developed. 
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Figure 2.9  Effect of autonomous expression of VV K1L, M1L, or M2L on ERK2 
phosphorylation in PMA-induced cells. Subconfluent 293T cell monolayers were 
either mock transfected (UN) or transfected with 1 +g of either pCI, M2L/pCI, M1L/pCI, 
or K1L/pCI. After 24 h, the cells were incubated in medium lacking or containing 125 nM 
PMA for 2 h, at which time they were harvested and lysed in CE buffer. Equal amounts 
ѥJRISUHSDUHGF\WRSODVPLFH[WUDFWVZHUHHOHFWURSKRUHWLFDOO\VHSDUDWHGLQ
SDS-polyacrylamide gels and transferred to PVDF membranes. Samples were analyzed 
by probing separate immunoblots with antisera recognizing the phosphorylated (top 
panel) and unphosphorylated (bottom panel) forms of ERK1 and ERK2.
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Figure 2.10  Effect of M2L gene expression on ERK phosphorylation in MVA-infected 
cells. 293T cell monolayers were mock infected (UN) or infected at an MOI of 10 with either 
MVA, MVA/M2L, MVA/K1L, or WR. At 2, 4 or 20 h postinfection, cells were collected and lysed 
in CE buffer. Equal amounts of prepared cytoplasmic extracts (25 +g) were electrophoretically 
separated in 12% SDS-polyacrylamide gels and transferred to PVDF membranes. Samples 
were analyzed by probing separate immunoblots with antisera recognizing the phosphorylated 
(top panel) and unphosphorylated (bottom panel) forms of ERK1 and ERK2.    
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Chapter III:  The Role of Glycosylation and Cellular 
Secretion in the Vaccinia Virus M2 Protein’s Ability to 
Inhibit ERK1/2 and NF-κB Activation
Introduction
 For the sake of clarity, the current and following chapters now follow the accepted 
nomenclature for vaccinia virus M2 as the protein, and M2L as the gene.  In Chapter 2, 
we demonstrated that the vaccinia virus M2 protein is N-linked glycosylated and also 
possesses an N-terminal signal peptide sequence necessary for its entry into the 
endoplasmic reticulum (ER).  M2 also possesses NF-κB & ERK1/2 inhibitory activity.  In 
this chapter, the requirement of each of the N-linked glycosylation sites and signal 
peptide cleavage in the expression and function of M2 was investigated.   
 Several poxviral proteins localize to the ER and evade the host immune response.  
Cowpox virus prevents the intracellular transport  of MHC I molecules (4).  The Myxoma 
virus M-T4 and M-T2 proteins induction of apoptosis, so that the virus can complete its 
replication and release new progeny from the cell it infected.  Poxviruses also encode 
secreted proteins that bind secreted IL-12, complement control protein homologs (8), 
IL-18, (23).  While several poxviral proteins have been demonstrated to localize to the 
ER and effect virulence, it is unknown how they function, nor the contribution of ER 
targeting or glycosylation status of each. 
 N-linked glycosylation is important for both correct protein folding and protein 
function (20).  For viral glycoproteins these functions include receptor binding, 
membrane fusion and penetration into cells, virulence, directing virus morphogenesis at 
the budding site and immune evasion (2, 19, 25).  The importance of glycosylation as it 
relates to virus infectivity, stability, and virulence is emphasized by the many viral 
proteins whose functions depend on glycosylation.  SARS-CoV, hepatitis, and West Nile 
depend on N-linked glycosylation for proper entry into host cells, proteolytic processing, 
and protein trafficking.  HIV and influenza express glycoproteins which help them evade 
the host immune response.  Recently, it was reported that the vaccinia B5 protein affects 
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the glycosylation and function of that of another envelope protein, A34 (3).  
Glycosylation may impact the ability of a viral protein to properly modulate host 
signaling pathways or molecules to the virus’ benefit. 
  According to the presence of the N-linked glycosylation sequence, Asn-X-Ser/
Thr (11), M2 has 4 potential N-linked glycosylation sites.  Alignment of the amino acid 
sequences of M2L species encoded by members of the Orthopoxvirus genus revealed that 
all of the N-linked glycosylation sites are conserved.  The strict conservation of N-linked 
glycosylation suggest that N-glycans are likely required for protein folding and biological 
functioning.  Mutagenesis of each of the N-linked glycosylation sites allowed creation of 
four different mutant viruses each lacking one of the four glycosylation residues present.  
This allowed the role of glycan moieties in the role of M2 function to be determined.  
 Investigation of the role of glycosylation in M2 functioning is important since 
glycoyslation sites in the M2 protein are conserved across orthopoxvirus species, 
suggesting an important role during infection.  The fact that other M2 variants which lack 
the signal peptide (∆sp) and C-terminal sequences (∆ERret) are impaired in their 
glycosylation ability and functioning suggests their contribution to M2 activity.   
Although our previous paper (Hinthong et. al., 2008) demonstrated that M2 is indeed 
modified by glycosylation, this data relied on the action of drugs to inhibit N-linked 
glycosylation.  Use of tunicamycin and endoH treatment reveals whether or not a protein 
is glycosylated, yet are disadvantageous in that these approaches may have secondary 
effects such as altering the innate cellular biochemistry of the glycosylation system (12).  
Hence, using glycosylation inhibitors does not provide information about the role that 
each glycosylation site contributes to the protein. Therefore, studies to verify and 
evaluate the usage of each glycosylation site in M2 were carried out using site-directed 
mutagenesis.  
 Signal peptides are located at the N-terminus of proteins and serve as key 
determinants for targeting and trafficking of glycoproteins to the secretory pathway.  
Glycoproteins rely on their signal peptides to direct them to their appropriate cellular 
destination.  Many viruses encode proteins that are secreted into the extracellular milieu; 
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the majority of these serve to modulate the host immune response.  VV blocks cytokine 
signaling by encoding secreted decoy receptors for TNF-alpha, IL-1β, IFN-α/β, and 
IFNγ (1). 
 Mutants were generated to address the question if certain motifs within M2 were 
responsible for NF-κB and/or ERK1/2 inhibitory functioning.  To evaluate the role of 
each individual N-linked glycosylation site or signal peptide cleavage site, a panel of 
recombinant viruses was generated (Fig. 3.1).  By expressing the M2L gene in the context 
of a virus infection, we are assured that M2L was expressed at the correct time and levels, 
so as not to perturb its inherent biological activity.   As M2 can inhibit 2 cytoplasmic 
signaling pathways, it was prudent to examine the molecular basis for this and it was 
hypothesized that this function lies within the protein itself.  Analysis of different M2 
mutant proteins would resolve if M2L had separate mechanisms of functioning for each 
separate pathway.  We demonstrate that certain amino acids substitutions at the four N-
linked glycosylation or signal peptide cleavage residues influence ERK1/2 or NF-κB 
inhibitory activity.
 
Materials and Methods
Cell Lines and Viruses  
 Human embryonic kidney (HEK) 293T cells were obtained form the American 
Type Culture Collection, and chicken embryonic fibroblast (CEF) cells were purchased 
from Charles River Laboratories.  Cells were cultured in Eagle’s Minimum Essential 
Medium supplemented with 2 mM L-glutamine, 10% fetal calf serum (FCS), 100 U/ml 
penicillin and 100 µg/ml streptomycin.  This is referred to as complete medium.  Medium 
used for virus infection is the same as complete medium, except only 2.5% FCS is 
present.  This is referred to as virus medium.  The wild type vaccinia virus strain Western 
Reserve (WR) and the attenuated strain modified vaccinia Ankara (MVA) (16) were 
provided by Dr. Bernard Moss (National Institutes of Health).  Recombinant virus MVA/
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M2L-V5 stably expresses a V5 epitope-tagged M2 protein and the green fluorescent 
protein (GFP) (13).
Recombinant Virus Construction
 Figure 3.1 illustrates the different mutant M2L proteins expressed in recombinant 
MVA viruses used in these studies.  Four viral constructs (N49Q, N79Q, N118Q, N154Q) 
had mutations in one of the predicted N-linked glycosylation sites of the M2 protein, 
while two constructs (S17I and S17F) had substitution mutations at residue 17 within the 
signal peptide sequence of M2.  All recombinant viruses were made by using homologous 
recombination, as described below. 
 Table 3.1 lists the plasmids utilized in creating the recombinant viruses expressing 
the mutant glycosylation constructs.  Plasmid pLW44/M2L-V5 contains the M2L gene 
with a V5 epitope tag at its C terminus, and also contains GFP (13).  This plasmid allows 
for the stable insertion of M2L-V5 and GFP into the deletion III region of the MVA 
genome, with GFP fluorescence of plaques utilized as a stable screening marker during 
isolation of recombinant MVA viruses (13).  pLW44/M2L-V5 was used as a template for 
site-directed mutagenesis using the QuikChange Site Directed Mutagenesis kit XL 
(Stratagene), resulting in plasmids pLW44/N49Q, pLW44/N79Q, pLW44/N118Q, and 
pLW44/N154Q.  The primer pairs used to introduce mutations into the M2L gene are 
listed in Table 1.  M2 proteins with mutations in potential glycosylation sites were 
constructed such that the resultant M2-V5 proteins expressed an asparagine instead of a 
glutamine at amino acid positions 49, 79, 118 or 154.  M2 proteins with mutations in the 
putative signal peptide cleavage sitewere constructed such that the mutant M2-V5 protein 
expressed either an isoleucine or phenylalanine instead of serine at amino acid position 
17, resulting in plasmids pLW44/S17I and pLW44/S17F.  Each plasmid-based mutated 
M2L gene was stably inserted into the MVA del III region by using homologous 
recombination (13).  The lack of parental virus (MVA) and the presence of the M2L gene 
in plaque-purified viruses were confirmed by PCR analysis of DNA isolated from virus-
infected cells.  
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Virus Infection  
 For virus infections, subconfluent 293T cellular monolayers (7.5 x 105 cells/well) 
in 6-well tissue culture dishes were either mock infected (UN) or infected with the 
indicated virus at an MOI of 10 PFU/cell.  During this adsorption phase, the viruses and 
cells were incubated in virus medium, and the tissue culture plates were rocked every 15 
min for 1 hr.  After this adsorption phase, virus-containing medium was removed, and 
infected cell monolayers were incubated in 1 ml fresh complete medium.  Infected cells 
were harvested at the times indicated post-infection.  
Preparation of Cytoplasmic and Nuclear Extracts
 Cytoplasmic and nuclear extracts from infected or transfected cells were prepared 
as described (Hinthong et. al, 2008).  Cells were collected by scraping and centrifuged at 
13,000 x g for 5 min.  The supernatant was aspirated and discarded.  The cellular pellet 
was resuspended in 50 µl cytoplasmic extract (CE) buffer [10 mM HEPES (pH 7.9), 10 
mM KCl, 0.1 mM EDTA pH 8.0, 0.1 mM EGTA (pH 8.0), 0.05% NP-40] (Oie and 
Pickup, 2001), supplemented with 1x HALT Protease Inhibitor Cocktail (Thermo 
Scientific) and 1 mM DTT (Promega).  The sample was incubated on ice for 5 min.  
Next, lysates were centrifuged at 13,000 x g for 2 min, and supernatants was transferred 
to new tubes for use as the cytoplasmic extract.  Remaining pellets was washed in 100 µl 
CE buffer and centrifuged at 13,000 x g for 2 min.  Supernatants were removed and each 
pellet was resuspended in 30 µl of nuclear extract (NE) buffer [20 mM HEPES (pH 7.9), 
0.4 M NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA (pH 8.0), 25% glycerol] (18), 
containing 1x  HALT Protease Inhibitor Cocktail (Thermo Scientific) and 1 mM DTT 
(Promega).  Samples were incubated on ice for 30 min, after which they were subjected 
to a 10 min centrifugation step at 13,000 x g and the supernatant taken as the nuclear 
extract portion. 
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Immunoblotting
 Briefly, 293T cellular monolayers (7.5 x 105 cells/well) in 6-well tissue culture 
plates were infected with indicated viruses at an MOI of 10 PFU/ml for the period of time 
indicated in the figure legends.  In some experiments, cellular monolayers were incubated 
in medium containing either tunicamycin (10 µg/ml; Sigma-Aldrich) or Brefeldin A (10 
µg/ml; MP Biomedicals).  Tunicamycin was present in medium during the adsorption 
phase of infection and post-infection, whereas Brefeldin A only was present 30 min prior 
to the adsorption phase of infection.  
 For ectopic expression of M2, sub-confluent 293T cellular monolayers (5 x 105 
cells/well) in 6-well tissue cultures plates were transfected with 4 μg of pCI, 2 μg pCI/
M2L-V5, or 2 or 4 μg of pLW44-M2L-V5 plasmid using FuGene 6 (Roche) transfection 
reagent per the manufacturer’s instructions.  Transfection proceeded for 24 hours prior to 
harvest or infection with virus.  
 For all cells, after the indicated times, cells were harvested from cell culture 
dishes by scraping and collected by centrifugation.  Cytoplasmic extracts were prepared 
as described above.  An equal amount of protein from each sample, as measured by a 
BCA assay (Pierce), was used for immunoblotting.  Briefly, extracted proteins were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
using either a 12% or 14% polyacrylamide gel, and were transferred to Immobilon P 
membrane (Millipore).  Membranes were blocked for 1 hr at room temperature in western 
blocking buffer, which consisted of 5% non-fat dry milk (Carnation) in TBST (0.05% 
Tween-20, 150 mM NaCl, 100 mM TrisCl, pH 7.5).  Membranes were incubated 
overnight at 4°C with either polyclonal anti-M2L antiserum (1:20,000), anti-V5 
antiserum (1:5,000; Invitrogen), anti-phospho-ERK1/2 antiserum (1:1,000; Santa Cruz 
Biotechnology), anti-ERK 1 antiserum (1:1,000; Santa Cruz Biotechnology), or anti-actin 
antiserum (1:1000, Santa Cruz Biotechnology).  Immunoblots were washed in TBST and 
incubated in western blocking buffer containing either horseradish peroxidase (HRP) 
conjugated goat anti-rabbit immunoglobulin G (IgG) (1:10,000 to 1:20,000; 
CalbioChem), or HRP-conjugated goat-anti-mouse IgG (1:10,000; Fisher Scientific).  
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Proteins were detected with the enhanced chemiluminescence (ECL) system (Amersham 
Biosciences).  Densitometry analysis was utilized to quantify the signals generated by 
ECL, using the histogram function in Photoshop CS3 (Adobe Systems Incorporated).  
The signal from the lane containing lysates from mock-infected cells was set to a value 
equal to one.  The relative intensity values from lysates of virus-infected cells were 
recorded and shown as a graph or given as direct numerical values.  
Electrophoretic Mobility Shift Assay (EMSA)
 Nuclear extracts were prepared from virus-infected cells as described above and 
were analyzed by EMSAs (Gedey et al., 2006).  Briefly, annealed double-stranded 
oligonucleotides containing a NF-κB consensus site (Promega) were labelled with [γ-32P] 
ATP.  6 µg of nuclear extract from each sample was incubated at room temperature for 20 
min in binding buffer (Promega) and 32P-labeled oligonucleotide probe.  When a 
supershift assay was performed with some samples, 1 µg of anti-p65 antibody (Santa 
Cruz Biotechnology) was present.  Next, samples were electrophoretically analyzed in a 
6% polyacrylamide gel under non-denaturing conditions.  Gels were dried and exposed to 
phosphorimager plates (Molecular Devices) and the images were developed and analyzed 
using the ImageGauge and ImageReader programs (Fuji).  For quantitation of the density 
of bands, images were analyzed using Photoshop CS3 (Adobe Systems Incorporated) to 
quantify pixel intensities.  The value obtained for mock-infected cells was set to a value 
equal to one and values from virus-infected cells were recorded.  
Quantitative NF-κB Activation Through Sandwich ELISA
 The PathScan Total NF-κB p65 Sandwich ELISA antibody Pair kit (Cell 
Signaling) was utilized to detect nuclear-translocated NF-κB using a 96 well Immunolon 
ELISA plate (Thermo Scientific) per manufacturer’s instructions.  Briefly, anti-p65 
capture antibody was incubated overnight in PBS at 4˚C with constant rocking to coat the 
bottom of each sample well.  The wells were then incubated using ELISA blocking buffer 
(1X PBS/0.05% Tween-20, 1 % BSA) for 2 h at room temperature.  2 µg of nuclear 
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extract from each sample was diluted in 100 µl blocking buffer and added to each well.  
After a 2 h incubation at room temperature, wells were washed with wash solution (1X 
PBS, 0.05% Tween-20) and incubated with a NF-κB p65 rabbit detection antibody 
(1:1000) for 1 h followed by anti-rabbit IgG HRP-linked secondary antibody (1:10,000) 
for 30 min.  The plate was washed in wash solution, and the HRP-linked anti-rabbit IgG, 
was detected by addition of TMB substrate.  The signal was quenched by addition of 
STOP solution (Cell Signaling) to the wells, and color development was immediately 
analyzed using a microplate reader (Bio-Rad) at an absorbance of 450 nm.  For the 
ELISA assay, each sample was analzyed in triplicate, with the results expressed as the 
mean ± SD. 
Immunoprecipitation  
 293T cellular monolayers were transfected or infected in  6-well plates.  In the 
case of virus infection, after the absorption phase, virus medium was removed and 1 ml 
of fresh complete media was added to the cell monolayer. For transfections, spent media 
was removed, and 1 ml of fresh complete media was added to transfected cell monolayers 
5 hrs after the onset of transfection.  Cellular supernatants from infected or transfected 
cells were collected 24 h later.  At the end of infection or transfection, 293T cellular 
monolayers were harvested by scraping and collected by centrifugation at 13,000 x g for 
1 min.  Cellular pellets were incubated in IP lysis buffer (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, and 5 mM EDTA with 1% NP-40) to lyse cellular and nuclear membranes.  
Clarified supernatants from total cellular extracts or supernatants from cellular 
monolayers were incubated with Protein G Sepharose 4 Fast flow beads (GE Healthcare) 
equilibrated 1:1 in PBS with HALT protease inhibitor.  Specifically, either 1 ml of 
supernatant or 500 µl total cellular extracts were each incubated with 50 µl of protein G 
Sepharose beads and either 1 µl anti-V5 antibody or 2 µl anti-M2 antibody.  After a 
rotating incubation for 4 h at 4˚C, immune complexes were precipitated by centrifugation 
(10,000 x g for 1 min).  The beads were washed three times in large volumes of IP lysis 
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buffer and resuspended in 30 µl 2x Laemmli buffer (Pierce) containing 5% 2-
mercaptoethanol, boiled for 5 min, and analyzed by immunoblotting as described above.  
 
Reverse Transcriptase PCR (RT-PCR)
 At 4 h post-infection, total RNA was isolated from 8.5 x 105 293T cells using the 
RNeasy Kit (Qiagen).  A portion of each RNA sample (1 µg) was subjected to RT-PCR 
analysis to measure the expression of M2L and GAPDH.  Briefly, contained 1 µg total 
RNA, was reverse-transcribed using ImProm-II Reverse transcriptase (Promega), which 
resulted in first strand cDNA synthesis.  Next, cDNA was PCR amplified using 
oligonucleotide primers specifically recognizing either the VACV M2L or the cellular 
GAPDH gene.  Primers used to amplify the M2L gene were sense (5’- ATG GTT TAC 
AAA TTA GTC TTA CTC TT-3’)  and antisense (5’-TTA CTC TCT ATA ACA AAT ATC 
ATA ACT TAG T-3’).  PCR conditions were 94 ˚C for 30 s, 48 ˚C for 45 s, and 72 ˚C for 
45 s for 25 cycles.  For amplification of GAPDH cDNA, sense (5’-AAG GTC GGA GTC 
AAC GGA TTT GGT-3’) and antisense (5’-ACA AAG TGG TCG TTG AGG GCA 
ATG-3’) primers were used.  PCR conditions for GAPDH amplification were 95˚C for 30 
s, 62˚C for 45 s, and 72˚C for 30 s for 25 cycles.  A portion of each reaction was analyzed 
by 1% agarose gel electrophoresis.  PCR amplicons were detected by staining gels with 
ethidium bromide.  
Results
Extracellular M2 Proteins Do Not Inhibit NF-κB Activation
 Although the M2 protein was reported to be cell-associated, it possesses a putative 
signal peptide sequence at its N-terminus, indicative of secretion of the protein.   In 
Chapter 2, M2 was shown to be devoid of O-linked glycosylation, a process which occurs 
exclusively within the Golgi, but some proteins that transit through the Golgi may not 
receive this modification.  To assess if M2 proteins were secreted, 293T cells were 
transfected with a plasmid containing M2L (M2-V5/pCI) and cellular supernatants were 
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assayed for M2 proteins by immunoprecipitation.  As shown in Figure 3.2A and 3.2B, M2 
was detected as both a cell-associated and secreted protein, with a majority of the M2 
protein population present in the cellular supernatants.  The mobility of the extracellular 
M2 was higher than its predicted molecular weight (25 kDa) and its cell-associated form 
of M2 (35 kDa), indicating that post-translational modifications, in addition to N-linked 
glycosylation, occurred.  As cells were transfected with increasing ng amounts of M2L-
containing plasmid, extracellular M2 proteins were detected in increasing amounts (Fig. 
3.2C).  M2 secretion also occurred during virus infection, as was evidenced by the 
presence of M2 from supernatants of M2L-V5-infected cells (Figure 3.3).  Extracellular 
M2 was no longer detected when M2L-V5 infections occurred in the presence of 
brefeldin A (BFA), indicating that the M2 protein trafficked through the Golgi apparatus 
before being secreted.   
 Given that the M2 protein inhibits MVA-induced NF-κB activation, it was queried 
whether extracellular M2 afforded this function.  To this end, the M2L gene was 
ectopically expressed, and supernatants from transfected cells were pre-incubated with 
293T cells, and evaluated for their ability to inhibit MVA-induced ERK1/2 activation.  
Results are shown in Figure 3.3B.  MVA infection of untransfected or pCI-transfected 
cells stimulated ERK1/2 activation 1.79- and 1.86-fold above mock-infected cells, 
respectively, as detected by phospho-ERK1/2 levels.  Supernatants from cells transfected 
with a plasmid containing M2L (pCI/M2L-V5) still allowed MVA-induced ERK1/2 
activation.  Phospho-ERK1/2 levels were at least 1.82-fold higher than mock-infected 
cells.  Similar results were obtained from pretreatment of cells with supernatants from 
virus infection (data not shown), suggesting that the extracellular M2 protein did not 
inhibit MVA-induced ERK1/2 activation.
Signal Peptide Cleavage Site Influence on MVA-Induced ERK1/2 and NF-κB 
Activation
 The above data suggested that the intracellular form of M2 is important for 
preventing MVA-induced ERK1/2 phosphorylation and NF-κB activation.  It is known 
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that signal peptides can have several additional functions apart from being responsible 
and essential to targeting glycoproteins to the secretory pathway (15).  For example, 
glycoproteins rely on their signal peptides to direct them to their appropriate cellular 
destination.  Since the M2 protein is N-linked glycosylated, it was queried how the signal 
peptide sequence would affect M2 glycosylation or function.  To further explore the role 
of the signal peptide sequence in M2 function, the serine 17 of the signal peptide 
sequence was mutated to either isoleucine or phenylalaline, yielding the S17I and S17F 
mutant viruses, respectively (Fig. 3.1).  The SignalP 3.0 program predicted that these two 
mutant M2 proteins no longer would be cleaved between residues 17 and 18.  When 
analyzing infected cells for intracellular S17I and S17F M2 proteins, S17I was detected at  
diminished levels amounts as compared to WT M2 or the S17F protein, at both early 
(Fig. 3.4A) and late (Fig. 3.4B) times post-infection.  While either the polyclonal anti-
M2L antiserum or the monoclonal anti-V5 antiserum recognized M2 proteins in 
immunoblots, more glycosylated forms of M2 were detected when using the polyclonal 
antiserum than anti-V5.  The mobility of the S17I or S17F mutant M2 proteins was 
identical/ slightly higher to the 35 kDa WT M2 protein, implying that each of the signal 
peptides were cleaved, despite the loss of the predicted signal peptide cleavage site.  The 
WT M2 protein from WR-infected cells did not possess a V5 epitope tag.  Because of this 
feature, the WT M2 had a lower molecular mobility (~30 kDa) than M2 from M2-V5-
infected cells (Fig. 3.4A), and was not detected when extracts were immunoblotted with 
anti-V5 antibody (Fig. 3.4B).  The upper bands present in the S17I and S17F are thought 
to be the uncleaved forms of these proteins.  
 The SignalP 3.0 program predicted that these two mutant M2 proteins no longer 
would be secreted due to the ablation of the signal peptide sequence.  However, the 
mobility of the mutant M2 protins were nearly identical to WT M2, indicating that the 
signal peptidase still cleaved the mutant M2 proteins. When each mutant protein was 
analyzed for its ability to be secreted, it was found that S17I and S17F were extracellular.  
Next, supernatants from virus-infected cells were analyzed for the presence of 
extracellular M2 by using immunoprecipitation.  As shown in Figure 3.5A, WT M2, S17I 
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and S17F were each detected in the supernatants of virus-infected cells.  While S17F was 
detected at levels similar to WT M2, S17I protein levels were lower.  A doublet was 
detected for each of the three proteins, indicating extracellular aggregates present in the 
extracellular media.  The doublet bands for S17I and S17F had a slightly higher mobility 
than WT M2, indicating that they retain more of a signal peptide accounting for the 
slightly higher molecular weight observed.  To compare the rates of M2 secretion, 
supernatants from infected 293T cells were immunoprecipitated at increasing times post-
infection, and immunoprecipitates were analyzed for the presence of M2 proteins by 
immunoblotting (Fig. 3.5B).  The WT M2 protein was detected in cellular supernatants as 
early as 30 min post- infection.  In comparison, the S17I mutant protein was not detected 
in extracellular medium until 4 hours post-infection.  Low levels of S17F were detected 
at 2 hours post-infection, but levels were similar to that of WT M2 at 4 and 6 hours post-
infection.  
 As the S17I and S17F mutant proteins were not detected in the supernatant 
abundantly until at least 4 hpi (Fig. 3.5B), our studies focused on a later time point to 
guarantee that these mutants were secreted outside the cell in order to assay for 
extracellular functioning.  The S17I and S17F mutants exhibited an impaired phenotype 
in terms of their ability to inhibit ERK1/2 activation compared to WT M2L (Fig. 3.6).  
These results are at a later time during infection, when it is certain S17I and S17F have 
been secreted into the extracellular space.  Similar results were obtained early in infection 
(data not shown).  Relative to wild-type M2, the S17F protein was more impaired in 
terms of inhibiting ERK1/2 activation.  This was also seen at early time points, times in 
which the mutant M2 proteins are not secreted.  
 To test if the intracellular form of M2 was sufficient to inhibit MVA-induced 
ERK1/2 and NF-κB activation, we tested the viruses encoding the S17I and S17F 
proteins for their ability to inhibit NF-κB activation.  NF-κB activation was detected at 2 
hours post-infection, a time in which the WT and mutant M2 proteins are cell-associated 
(Fig. 3.11).  Also at this time, the mutant M2 proteins were not present in abundance 
  84
extracellularly.  Thus, inhibitory function of these mutant proteins would imply that the 
intracellular form of M2 was sufficient to inhibit NF-κB activation.  
 293T cells were infected, an electromobility shift assay (EMSA) was used to 
detect and quantify the amount of nuclearly-translocated NF-κB as an indicator of NF-κB 
activation.  For EMSA analysis, the intensity of the NF-κB-containing band was depicted 
graphically and expressed as the intensity of the band relative to that of mock-infected 
cells (Fig. 3.11).  Mock-infected cells did not activate NF-κB as expected (Fig. 3.11).  In 
contrast, NF-κB nuclear translocation was evident in MVA-infected cells, as indicated by 
the presence of a unique mobility-shifted band that was about 4-fold more intense that 
that observed when using extracts from mock-infected cells.  Inclusion of a monoclonal 
p65 antibody in a separate reaction resulted in a super-shift of the NF-κB-containing 
band.  MVA/M2L-V5-infected cells reduced the intensity of the NF-κB-containing band.  
Impairment of the signal peptide cleavage site resulted in a 4.5-fold increase in NF-κB 
activation, indicating that the disruption of the signal peptide cleavage site was important 
for the intracellular function of M2.     
Stability and Electrophoretic Mobility of M2 proteins With Mutations in Predicted 
N-Linked Glycosylation Sites  
 The above data hint that the intracellular function and post-translational 
modifications to the M2 protein prior to secretion are important for M2 activity.  Signal 
peptides are located at the N-terminus of proteins and serve as key determinants for 
targeting and trafficking of glycoproteins to the secretory pathway (10).  Cleavage of the 
signal peptide is important for proper functioning of the protein (6).  Glycoproteins rely 
on their signal peptides to direct them to their appropriate cellular destination.  
 The VACV M2 protein is N-linked glycosylated.  M2 possesses 4 putative N-
linked glycosylation sites (N-X-S/T) located at the N at amino acid positions 48, 79, 118, 
and 154  (11).  Alignment of the M2 amino acid sequences from all sequenced members 
of the Orthopoxviridae genus revealed that all of the N-linked glycosylation sites are 
conserved.  To test the hypothesis that N-linked glycosylation was important for the 
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ERK1/2 and NF-κB inhibitory activity of M2, mutant M2 proteins were generated, in 
which each one of the N-linked glycosylation sites was abolished via the substitution of 
Q for N (Fig. 3.1 and Fig. 3.2).   
 The effect of each mutation on the stability and electrophoretic mobility of M2 
was determined by immunoblotting of infected cell lysates.  Immunoblotted lysates were 
probed with either polyclonal anti-M2L antiserum (Figure 3.7A) or monoclonal anti-V5 
antiserum (Figure 3.7B).  As previously published, the WT M2 protein was detected as 
31-35 kDa proteins, with the predominant form of M2 a 35 kDa band (Fig. 3.7A) when 
using the polyclonal anti-M2L antiserum.  Only the 35 kDa M2 protein was detected 
when anti-V5 antiserum was used for immunoblotting (Fig. 3.7B).  Since Q is very 
similar to N, these substitutions at each of the predicted N-linked glycosylation sites were 
predicted to minimally affect M2 stability.  Indeed, all mutant M2 proteins, with the 
exception of N79Q, were detected.  N154Q was detected at slightly lower levels than WT 
M2 at early times post-infection, but at levels similar to WT M2 protein at later times 
post-infection (data not shown).  N49Q and N188Q were detected at the same or higher 
levels as WT M2.  The observed molecular mobility of the N49Q, N118Q, and N154Q 
proteins was less than that of the wild-type (WT) M2 protein (Fig. 3.7A and 3.7B), 
implying that bona fide N-linked glycosylation sites indeed had been N-linked.  For the 
N49Q and N118Q proteins, three bands ranging from 29-31 kDa were detected.  In 
contrast, only two bands were detected in immunoblots containing lysates from N154Q-
infected cells.  The N49/118Q, N49/154Q, and N118/154Q double glycosylation mutants 
were detectable at a molecular mobility less than that of the single glycosylation mutants 
as predicted (Fig. 3.7A and 3.7B, right panels).  The N49/118/154Q mutant was resolved 
as a single band which migrated less than the double glycosylation mutants, but greater 
than the theoretical molecular weight of M2 (25 kDa), indicating that amino acid 79 is 
utilized for glycosylation.   
 The N79Q protein was not detected at early or late times post-infection when 
immunoblotting lysates with either anti-M2L or anti-V5 antiserum.  Two independently-
derived clones of the N79Q virus did not express the mutant M2 protein (data not 
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shown), implying that the M2 protein was unstable.  Furthermore, the transcription of the 
gene encoding N79Q occurred, as detected by reverse transcriptase PCR (Figure 3.8A).  
The double and triple glycosylation mutants were tested for their transcription profiles as 
well, and all were transcribed to the same extent as WT M2 (Fig. 3.8B).  
 To confirm that the decrease in molecular weights of the mutant M2 proteins 
reflected the loss of the glycosylation sites, we treated mock-treated (UN) or virus 
infected cells with tunicamycin, a drug which blocks N-glycosidic linkages (17).  The 
extent of glycosylation of M2 proteins was observed by comparing the electrophoretic 
mobility of M2 when infections proceeded in the presence of tunicamycin (Fig. 3.9).  WT 
M2 migrates at 25 kDa, its predicted molecular mass as an unmodified protein, when 
infections proceeded in the presence of tunicamycin.  In the absence of tunicamycin, WT 
M2 protein migrated ~ 35kDa, indicating that four N-linked glycosylations occured.  
(Usage of a single glycosylation site is predicted to account for 1-3 kDa in additional 
mobility.)  Mutant M2 proteins N49Q, N118Q and N154Q also migrated at 25 kDa when 
infections proceeded in the presence of tunicamycin.  Additional, less intense bands 
ranging from 25-35 kDa were observed when N118Q-infected cells were incubated with 
tunicamycin, demonstrating incomplete glycosylation observed for the protein.  Actin 
levels were consistent throughout all samples, indicating that protein loading was 
equivalent.  Due to sensitivity of tunicamycin treatment, N-linked glycosylation of the 
M2 protein does not impair the trafficking of these mutants into the ER.  
N-linked Glycosylation is Important for ERK1/2 Inhibitory Activity
 In 293T cells, MEK1/2 activation is required for MVA-induced NF-κB activation 
(7, 14).  The M2 protein inhibits MVA-induced NF-κB activation by preventing MEK1/2-
mediated phosphorylation of ERK1/2 (7).  In our previous study (13), we identified a 
mutant M2 protein (∆sp) that was not glycosylated and did not inhibit ERK1/2 
phosphorylation or NF-κB activation (13).  Recombinant viruses expressing mutant M2 
proteins were evaluated to determine if glycosylation was responsible for ERK1/2 
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inhibitory activity.  To this end, lysates from virus-infected cells were assayed for 
ERK1/2 activation (phosphorylation) by using immunoblotting. In mock-infected cells, 
there is a basal level of ERK1/2 activation, as detected by phosphorylation of ERK1/2 
(Fig. 3.10).  MVA infection induced ERK1/2 activation, as previously reported (14).  
When WT M2 was expressed in MVA/M2L-infected cells, phospho-ERK1/2 levels 
decreased to levels comparable to that of mock-infected cells.  Phospho-ERK1/2 levels, 
as measured by the intensity of the phospho-ERK1/2 bands, were either higher than MVA 
infected cells (N49Q infection) or similar to MVA-infected cells (N79Q, N118Q or 
N154Q infection), indicating that the loss of any N-linked glycosylation site dramatically 
affects M2’s ERK1/2 inhibitory function.  The levels of unmodified ERK1/2 levels were 
similar in mock- or virus-infected cells, indicating that loss of activation of ERK 1 and 
ERK2 is not due to degradation of these molecules.  
N-linked Glycosylation Impacts the NF-κB inhibitory function of M2  
 We next examined how the loss of a glycosylation site affected the M2 protein’s 
ability to inhibit MVA-induced NF-κB activation.  Since ERK1/2 activation is required 
for MVA-induced NF-κB activation, we hypothesized that none of the mutant M2 
proteins would inhibit NF-κB activation.  293T cells were infected, and an 
electromobility shift assay (EMSA) was used to detect and quantify the amount of 
nuclearly-translocated NF-κB as an indicator of NF-κB activation.  For EMSA analysis, 
the intensity of the NF-κB-containing band was depicted graphically and expressed as the 
intensity of the band relative to that of mock-infected cells (Fig. 3.11).  Mock-infected 
cells did not activate NF-κB as expected (Fig. 3.11).  In contrast, NF-κB nuclear 
translocation was evident in MVA-infected cells, as indicated by the presence of a unique 
mobility-shifted band that was about 4-fold more intense that that observed when using 
extracts from mock-infected cells.  Inclusion of a monoclonal p65 antibody in a separate 
reaction resulted in a super-shift of the NF-κB-containing band.  MVA/M2L-V5-infected 
cells reduced the intensity of the NF-κB-containing band.  Deletion of the third 
glycosylation site of M2 (N118Q) impaired the ability of M2 to inhibit NF-κB.  In 
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contrast, N154Q infection inhibited NF-κB translocation to the same extent as WT M2, 
indicating that the fourth N-linked glycosylation site was dispensable for NF-κB 
inhibitory function.  Virus N49Q was partially impaired in its ability to inhibit NF-κB 
activation, as observed by a slightly more intense NF-κB-containing band relative to 
M2L-V5 infections.  Thus, the N-linked glycosylation site at residue 49 affects the M2 
function.  Despite the fact that no mutant M2 protein was detected in N79Q-infected 
cells, NF-κB nuclear translocation was partially inhibited in these infected cells.   Similar 
results are obtained in Figure 3.12 for these single glycosylation mutants at a later time 
point.   
Discussion
 The M2L gene is highly conserved among orthopoxviruses, yet lacks homology to 
any known cellular or viral protein.  There is no known immunomodulatory protein that 
is shared by all poxviruses, thus immunomodulators are specific to the virus and the host 
it infects.   Immunomodulators such as M2 may confer a survival advantage when the 
virus moves to another host species.  We have validated that M2 is indeed a secretory 
protein and that glycosylation and signal peptide cleavage contribute to M2’s function as 
an immunomodulator.  Here we have described previously unknown and potentially 
important alterations to the M2 glycoprotein.  Our evidence shows that glycosylation and 
signal peptide cleavage of the vaccinia virus M2 protein has functional consequences.  
Consistent with conservation of glycosylation at positions 49,79,118,154, we show that 
for the most striking mutants, amino acid sugar residue 49 carries ERK1/2 inhibitory 
information and that sugar residue 118 carries NF-κB inhibitory information.  This data 
suggest that M2 acts on different cytoplasmic pathways in a different manner as protein 
modification of the protein confers proper functioning. 
 Figure 3.12 is an EMSA performed at a later time post-infection when these 
mutant proteins are expressed at their maximal levels.  Similar results were obtained for 
the signal peptide cleavage mutants and single glycosylation mutants to that of Fig. 3.11.  
The N49/118Q double glycosylation mutant was impaired nearly to the same extent as 
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the N118Q single glycosylation mutant.  Two of the double glycosylation mutants 
(N49/118Q, N49/154Q) gave an unexpected result of being able to inhibit NF-κB 
activation.  As can be seen in the free probe that is present on the bottom of the gel, the 
last 3 mutant samples have noticeably less protein loading than that of the other samples 
present.  Also, the titers of the N49/154Q and N118/154Q used during this assay was 2 
log folds less than that of the other mutants tested.  Therefore, conclusions drawn from 
this result are not indicative of equal protein expression of the mutants.  The triple 
glycosylation mutant, N49/118/154Q appears to inhibit NF-κB activation to the same 
extent as that as WT M2, but again, there appears to be less protein loading within this 
sample and may contribute to the diminished band that is observed.
 Usage of each glycosylation site by differential modification of glycosylation 
species can also account for differences seen in the activity of the M2L glycosylation 
mutants.  The first glycosylation sequence at amino acid residue 49 is NST, at position 
79, it is NMT, at position 118 it is NIS, and at position 154 it is NGS.  The usage of 
glycosylation sequence context can be important to influence not only function, but also 
topological orientation on the protein when the nascent polypeptide is synthesized in the 
ER.   In an in vitro study, it was demonstrated that NGS is the most efficient N-X-S 
consensus sequence for N-linked glycosylation (24).  Correspondingly, our data indicated 
that the N154Q mutation impacted protein expression, as this mutant has a stronger 
expression profile as infection proceeded (unpublished observations).  In another study, it 
was found that an NMT site account for dynamic reorientation of polypeptides within the 
translocon, altering the topology of the final protein (9), and may be an explanation as to 
why the N79Q is degraded and not detectable through western blotting.    
 Loss of glycosylation or impairment of signal peptide cleavage can disrupt 
disulfide bonding within M2.  This destabilizes the overall fold of the protein within M2L 
and can result in impaired functioning.  Perhaps M2L dimerizes with itself, as it contains 
10 cysteine residues.  The intracellular and extracellular forms of M2 contain cysteines in 
their oxidized (i.e. disulfide) form as they were sensitive to 2-mercaptoethanol treatment 
(data not shown).  As the signal peptide cleavage mutants and glycosylation mutants have 
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lost their ability to inhibit NF-κB and ERK1/2 activation to WT M2 levels, this 
explanation is a possibility.  
 The most intriguing finding of our analysis is the finding that the N79Q protein 
had a severe defect in protein expression, but still retained function.  Alteration to a single 
glycosylation site has been shown to completely abolish protein expression (26).  To test 
the possibility that M2 N79Q is unstable and thus being degraded, virus infection could 
have been carried out in the absence of presence of a proteasomal indicator such as 
epoxomicin.  Treatment of cells with proteasome inhibitors could boost accumulation of 
the mutant viral proteins seen.  Epoximicin is specific for the proteasome and does not 
inhibit nonproteasomal proteases such as trypsin, chymotrypsin, papain, cathepsin B, 
calpain, or tripeptidyl-peptidase II (22).  If N79Q was being degraded by proteasome, it 
would be expected that slight accumulation of M2L protein is seen when the inhibitor is 
present.  
 The ability of M2 to inhibit NF-κB and ERK1/2 pathways would be more easily 
understandable if M2 was strictly an intracellular protein.  M2 is not an ER-restricted 
glycoprotein and does not fully depend on glycosylation for cellular secretion.  Our data 
demonstrates that signal peptide cleavage between amino acid residues 17 and 18 allow 
for the proper trafficking of M2 to the supernatant.  It is unknown what the exact 
extracellular function of M2L is.  Viral proteins that act extracellularly are usually 
glycoproteins that act to competitively bind host cytokines and chemokines.  
 Based on our data, we propose that the extracellular secreted M2 glycoprotein is 
not critical during vaccinia virus infection to modulate either the ERK1/2 or NF-κB 
signaling pathways.  Immunofluorescence data (data not shown), demonstrated that M2 is 
not localized on the surface of cells, and may be binding to a secreted cellular or viral 
factor present during infection.  Since cytokines play a role in the development and 
progression of viral disease, it is likely M2 binds to such secreted proteins to dampen the 
immune response.  The fact that M2L is secreted and is thus soluble may counteract the 
activity of cytokines. This may have added to the virus’s success when infecting other 
cells and helped these orthopoxviruses replicate in several species.
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 Other possibilities for M2L function include the idea that M2L is acting as a 
competitive inhibitor in the cellular pathways it interacts with.  MAPKs require their dual 
phosphorylation at two conserved threonines (Thr/T) and tyrosines (Tyr/Y) (5, 21).  
These phosphoryaltion sites are separated by only one amino acid, thereby defining a 
tripeptide motif, Thr-X-Tyr.  M2L contains a TGY at amino acid positions 72-74, and a 
TKY sequence at amino acids 133-135.  M2L may therefore be acting as a substrate for 
an upstream kinase, and acting as a decoy substrate.  MVA infected cells do not proceed 
through an ERK1 mediated pathway as evidenced by a kinase dead mutant (7).  M2 is 
able to inhibit both ERK1 and ERK2 activation.  The preference for M2 to inhibit ERK1 
phosphorylation more severely than ERK2 activation is not currently understood.  M2L 
does not share homology to either ERK1 nor ERK2.  M2L may act as a phosphorylation 
substrate due to its ability to inhibit both MVA and PMA-induced ERK1/2 activation (7, 
13).  The possibility that M2L acting as a competitive inhibitor  is currently being 
investigated.   
 Besides potentially serving as a MAPK substrate, M2L contains other serine/
threonine sites which are candidates for phosphorylation, indicating a cytoplasmic 
localization and function.  We have not assessed whether M2L is phosphorylated under 
all conditions we have described in our study, but it is noteworthy that the N79Q 
mutation overlaps with a putative casein kinase II (CK2) phosphorylation site.  M2L has 
five putative casein kinase II sites (see Chapter 5, Fig. 5.1), which may serve to modulate 
casein kinase II induced activity as a means to downregulate ERK1/2 activity.
 The data presented in this chapter extend the results of previous studies into the 
mechanistic basis for M2L functioning in 293T cells.  M2 modulates the innate immune 
response by altering NF-κB and ERK1/2 activation.  This advances our knowledge of M2 
and improved our understanding of the host immune response to vaccinia virus and the 
relationship between molecular post translational modifications and function. 
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Figure 3.1  Schematic of the 
different M2 constructs.  The 
signal peptide sequence of M2 is 
indicated by a black box of amino 
acids 1-19.  N-linked glycosylation 
sites occur at positions 49, 79, 118, 
DQG(5UHWHQWLRQUHWULHYDO
sites at positions 178, 199, 209 
(SLWRSHWDJVGHQRWHGLQJUD\ER[HV
(V5).  
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Figure 3.2  Secretion patterns of M2 proteins in transfected cells.  293T cellular 
monolayers were transfected with the empty vector (pCI) or a construct expressing the M2 
protein (pCI/M2L-V5). (A) At 17 h pi, cell-free supernatants were collected and incubated 
with protein G-Sepharose beads and anti-V5 antiserum. 25 +g of cellular lysate from the 
transfected samples or a portion of the immunoprecipated (IP) sample was separated by 
12% SDS-PAGE and proteins were transferred to PVDF membranes by Western blotting.  
Immunoblots were probed with antibodies recognizing the M2 proteins.  (B) Same as in (A), 
with the exception that beads were incubated with anti-M2 polyclonal antisera. (C) At 17 h 
pi, cell-free supernatants were collected and incubated with protein G-Sepharose beads and 
anti-V5 antiserum.  A portion of the immunoprecipated sample was separated by 12% 
SDS-PAGE and proteins were transferred to PVDF membranes by Western blotting.  
Immunoblots were probed with antibodies recognizing the M2 proteins.  Molecular weight 
markers (MW) are indicated.  
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Figure 3.3  M2 protein secretion during infection is blocked with Brefeldin A and secreted 
M2 does not inhibit ERK1/2 activation.  (A) 293T cell monolayers were infected with the 
indicated viruses at an MOI=10.  At 17 h pi, cellular monolayers or cell-free supernatants or 
ZHUHFROOHFWHG&HOOVZHUHO\VHGLQ&(EXIIHUDQGѥJRISURWHLQIURPHDFKVDPSOHZDV
analyzed by immunoblotting for the presence of M2 protein.  Supernatants were 
immunoprecipitated (IP) with Protein G-sepharose beads pre-conjugated to anti-M2 antiserum.  
Immunoprecipitated samples were separated by 12% SDS-PAGE and the blot was 
subsequently probed with an anti-V5 antibody. In some cases, cells were incubated in medium 
FRQWDLQLQJ%UHIHOGLQ$ѥJPOLQZKLFKWKHGUXJZDVSUHVHQWIRUPLQSULRUWRLQIHFWLRQ
After 30 min, the drug-containing medium was removed and infections proceeded as normal.  
(B) 293T cells were transefected with pCI, M2L-containing plasmids or no DNA.  At 24 h 
post-transfection, supernatants were collected and added to fresh cellular monolayers.  After 2 
h, supernatants were removed and cells were inoculated with MVA (MOI  = 10).  At 1 h pi, cells 
were collected and lysed in CE buffer. Densitometry analysis was performed to quantify the 
p-ERK1 and p-ERK2 signals.  The signal from the lane containing cytoplasmic extracts from 
mock-infected cells (UN) was set as a value equal to one.  The amount of p-ERK1 and p-ERK2 
in lanes containing cytoplasmic extracts from virus-infected cells was determined and recorded 
under each lane of the immunoblot, represented as a fold-increase above that observed for UN 
cells.
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Figure 3.4  The effect of mutating the signal peptide cleavage sequence on M2 protein 
mobility and expression levels.  293T cellular monolayers were either mock-infected (UN) or 
infected with the indicated viruses (MOI =10).  At (A) 2 or (B) 20 h pi, cells were harvested and 
O\VHGLQ&(EXIIHU$QHTXDODPRXQWRISURWHLQѥJIURPHDFKVDPSOHZDVVHSDUDWHGE\
SDS-14% PAGE.  Proteins were transferred to PVDF membranes and membranes were probed 
ZLWK$DQWL0RU%DQWL9DQWLVHUXP$IWHUGHYHORSLQJWKHVLJQDOHDFKEORWZDVUHSUREHG
with anti-actin antiserum.  
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Figure 3.5  Secretion patterns of mutant M2 proteins in infected cells.  293T cellular 
monolayers were mock-infected (UN) or infected with the indicated viruses (MOI = 10).  
(A) At 17 h pi, cell-free supernatants were collected and incubated with protein 
G-Sepharose beads and anti-M2 antiserum. An equal amount of each sample was 
analyzed by 14% SDS-PAGE and proteins were transferred to PVDF membranes by 
Western blotting.  Immunoblots were probed with antibodies recognizing the M2 proteins.  
Molecular weight markers (MW) are indicated.  (B) At the times indicated post-infection, 
cell-free supernatants were incubated with anti-V5 monoclonal antibodies coupled to 
Protein G-Sepharose beads.  Immunoprecipitated samples were analyzed by 14% 
SDS-PAGE and proteins were transferred to PVDF membranes by Western blotting.  
Immunoblots were probed with anti-M2 antiserum.  Molecular weight markers (MW) are 
indicated. 
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Figure 3.6  The effect of mutating the signal peptide sequence on M2 protein!s ability to 
inhibit ERK1/2 activation.  293T cellular monolayers were mock-infected (UN) or infected with 
the indicated viruses (MOI = 10).  Infected cells were harvested at 24 h pi and cytoplasmic 
O\VDWHVZHUHSUHSDUHG$QHTXDODPRXQWRISURWHLQѥJIURPHDFKVDPSOHZDVVHSDUDWHGE\
6'63$*(3URWHLQVZHUHWUDQVIHUUHGWR39')PHPEUDQHV,PPXQREORWWLQJZLWK
SKRVSKR(5.S(5.DQWLERG\GHWHFWHGSKRVSKRU\ODWHG(5.DQG(5.6XEVHTXHQW
LPPXQREORWWLQJUHFRJQL]HGWKHXQPRGLILHGIRUPVRI(5.DQG(5.'HQVLWRPHWU\DQDO\VLVZDV
SHUIRUPHGWRTXDQWLI\WKHS(5.DQGS(5.VLJQDOV7KHVLJQDOIURPWKHODQHFRQWDLQLQJ
cytoplasmic extracts from mock-infected cells (UN) was set as a value equal to one.  The amount 
RIS(5.DQGS(5.LQODQHVFRQWDLQLQJF\WRSODVPLFH[WUDFWVIURPYLUXVLQIHFWHGFHOOVZDV
JUDSKLFDOO\UHSUHVHQWHGDVDIROGLQFUHDVHDERYHWKDWREVHUYHGIRU81FHOOV
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Figure 3.7  Protein expression of mutant M2 genes.  6XEFRQIOXHQW7FHOOXODUPRQROD\HUV
ZHUHHLWKHUPRFNLQIHFWHG81RULQIHFWHGZLWKWKHLQGLFDWHGYLUXVHV02, $WKSLFHOOV
ZHUHKDUYHVWHGDQGO\VHGLQF\WRSODVPLFH[WUDFW&(EXIIHU(TXDODPRXQWVRISURWHLQѥJ
IURPHDFKO\VDWHVZDVVXEMHFWHGWR6'63$*(DQGSURWHLQVZHUHWUDQVIHUUHGWRD39')
PHPEUDQH,GHQWLFDOPHPEUDQHVZHUHLQFXEDWHGZLWKHLWKHU$DQWL0RU%DQWL9DQWLVH-
UXP&KHPLOOXPLQHVFHQFHZDVXVHGWRGHWHFW0SURWHLQV(DFKEORWZDVVXEVHTXHQWO\
LQFXEDWHGZLWKDQWLDFWLQDQWLERGLHVDQGGHYHORSHGXVLQJFKHPLOOXPLQHVFHQFH7KHSRVLWLRQVRI
PROHFXODUZHLJKWPDUNHUV0:DUHVKRZQRQWKHOHIWRIHDFKLPDJH
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Figure 3.8  mRNA expression of glycosylation mutant M2L genes.  Subconfluent 
293T cellular monolayers were either mock-infected (UN) or infected with the 
indicated viruses (MOI =10).  At 2 hpi, cells were harvested and M2L or GAPDH 
cDNAs were PCR amplified.  Resultant DNA products from (A) the single 
glycosylation mutants or (B) double and triple glycosylation mutants were separated 
by electrophoresis in a 1% agarose gel and visualized with ethidium bromide. 
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Figure 3.9  The effect of tunicamycin on the mobility of wild-type and mutant M2 
proteins.  293T cellular monolayers were innoculated with the indicated viruses or 
PRFNLQIHFWHG81LQPHGLXPODFNLQJRUFRQWDLQLQJWXQLFDP\FLQWXQLFѥJPO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E\LPPXQREORWWLQJIRU0SURWHLQH[SUHVVLRQXVLQJDQWL0DQWLVHUXP(DFKEORWZDV
UHSUREHGZLWKDQWLERG\UHFRJQL]LQJDFWLQ0ROHFXODUZHLJKWPDUNHUVDUHLQGLFDWHG
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Figure 3.10  The effect of mutant M2 proteins on inhibiting MVA-induced ERK1/2 
activation.  293T cell monolayers were mock-infected (UN) or infected with the indicated 
viruses (MOI = 10).  Infected cells were harvested 2 h pi and cytoplasmic lysates were 
analyzed by immunoblotting, using antiserum simultaneously recognizing the phosphorylated 
forms of ERK1 and ERK2 (p-ERK1, p-ERK2).  Subsequent immunoblotting of the same 
membranes used antiserum specifcally detecting the unmodified forms of ERK1 and ERK2.  
Molecular weight markers (MW) are indicated.  Densitometry analysis was performed to 
quantify the p-ERK1 and p-ERK2 signals.  The signal from the lane containing cytoplasmic 
extracts from mock-infected cells (UN) was set as a value equal to one.  The amount of 
p-ERK1 and p-ERK2 in lanes containing cytoplasmic extracts from virus-infected cells was 
graphically represented as a fold-increase above that observed for UN cells.
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Figure 3.11  NF-gB activation in cells infected with single glycosylation mutant and 
signal peptide cleavage mutant viruses.  293T cellular monolayers were infected with the 
indicated viruses (MOI=10).  At  2 h pi, cells were harvested.  Each experimental sample was 
lysed in CE buffer and centrifuged.  Supernatants were removed and the remaining nuclei-
containing pellets were disrupted in NE buffer.  6 +g of nuclear extracted proteins from each 
sample were incubated with 32P-radiolabelled oligonucleotides that contain NF-gB binding sites. 
“Neg” indicates a reaction lacking nuclear extract present.  Reactions were analyzed via a gel 
electrophoretic mobility shift assay (EMSA).  Gels were dried and radioactivity was detected by 
phosphorimaging.  Shifted bands containing NF-gB are indicated with an asterisk.  In one 
reaction containing nuclear extracts from MVA-infected cells, anti-NF-gB antibody (p65) was 
present.  The mobility of the resultant super-shifted band is indicated by a double asterisk.  
Densitometry analysis was performed to quantify the NF-gB levels in the EMSAs.  The signal 
from the lane containing nuclear extracts from mock-infected cells (UN) was set as a value 
equal to one.  The amount of NF-gB in lanes containing nuclear extracts from virus-infected 
cells was graphically represented as a fold-increase above that observed for UN cells.  
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Figure 3.12  Preliminary results for an EMSA assesing the effect of the virally-
expressed M2 signal peptide cleavage and glycoslyation variants on MVA-mediated 
NF-gB nuclear translocation at 20 hpi.  293T cellular monolayers were infected with the 
indicated viruses (MOI=10).  At 20 hpi cells were harvested.  Each experimental sample was 
lysed in CE buffer and centrifuged.  Supernatants were removed and the remaining nuclei-
containing pellets were disrupted in NE buffer.  6 +g of nuclear extracted proteins from each 
sample were incubated with 32P-radiolabelled oligonucleotides that contain NF-gB binding 
sites.  “Neg” indicates a reaction lacking nuclear extract present.  Reactions were analyzed 
via a gel electrophoretic mobility shift assay (EMSA).  Gels were dried and radioactivity was 
detected by phosphorimaging.  Shifted bands containing NF-gB are indicated with an asterisk.  
,QRQHUHDFWLRQFRQWDLQLQJQXFOHDUH[WUDFWVIURP09$LQIHFWHGFHOOVDQWL1)ѣ%DQWLERG\
(p65) was present.  The mobility of the resultant super-shifted band is indicated by a double 
asterisk.  
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Chapter IV:  Assessment of M2’s Ability to Modulate 
ER-Based Cellular Signaling Pathways and Attempts to 
Identify Interactions With Cellular Host Proteins 
Introduction
 The endoplasmic reticulum (ER) is central to the secretory pathway and the site of 
protein folding, disulfide bond formation and glycosylation, as well as calcium uptake 
and storage.  Thus, it is crucial that the ER maintains the above mechanisms to respond 
rapidly to cellular stress.   The idea of  “quality control,” where proteins that transit to the 
ER and are monitored before exiting the ER and reaching their final destination within or 
outside of the cell, is critical for proper functioning of the cell (25). When the ER 
environment is altered/stressed, it burdens the normal function of the ER.  Regulation of 
ER stress genes occurs via two signal transduction pathways: the unfolded protein 
response (UPR) and the ER overload response (EOR) (20, 24).  
 The UPR consists of molecular signal transduction pathways that detect 
disturbances in the ER, such as misfolded proteins, and determine whether a cell survives 
or dies in response to the stress.  The UPR pathway involves up-regulation of glucose 
responsive genes such as Grp78 (BiP) in order to facilitate protein trafficking in the ER 
and the transcription factor CHOP/GADD153, which sensitizes cells to ER stress (24).  
ATF-6 is a member of the ATF/CREB basic-leucine zipper and a proximal transducer of 
both Grp78/Bip and CHOP/GADD153.  These protective responses are designed to 
relieve ER stress, however, when they are ineffective, the cell undergoes apoptosis.  
Initiation of the UPR is critical for cell survival and consequently for viral replication (7).  
However, prolonged/excessive UPR can lead to cell death.  Therefore, regulation of ER 
stress by viruses would dictate the balance between viral pathogenesis and replication.  
UPR signaling can result in cell protective responses, or involve mechanisms that lead to 
apoptosis induction, which ultimately, can lead to pathological states due to chronic ER 
stress. 
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 The endoplasmic reticulum is the predominant storage site for calcium (Ca2+) in 
the cell, and NF-κB is activated by changes in intracellular calcium levels (19).  The EOR 
is triggered, in part, by increased calcium levels.  Calcium participates in the regulation 
of phosphorylation/dephosphorylation of a variety of cellular proteins, thereby 
modulating basic cellular processes such as cell growth, differentiation, proliferation, and 
survival.  Activation of MEK/ERK pathway by calcium is well established  (1).  The 
EOR activates IKK, which causes activation of NF-κB (20).  This allows for activation of 
NF-κB, a transcription factor that induces the expression of genes encoding several 
proteins involved in death, survival and inflammatory responses.  This activation of NF-
κB was shown to occur due to the second messengers, calcium and reactive oxygen 
intermediates that are produced during EOR.  Although this pathway is also evoked in 
response to ER stress, EOR is distinct from that of the UPR (21).    
 As viruses seek to command all aspects of cellular pathways, they place 
considerable burden on the host cell.  Viral infection generates a considerable amount of 
intracellular stress.  In particular, the endoplasmic reticulum must adapt with the increase 
in viral protein load.  It is not known how poxviruses stabilize the ER for proper 
glycosylation of viral proteins in infected cells.  Data demonstrate that the vaccinia virus 
M2 localizes to the ER during infection.  We hypothesized that M2 would modulate an 
ER-based signaling pathway or an ER resident protein which would eventually inhibit 
NF-κB activation.  If this were the case, M2 may also modulate calcium release from the 
ER.  The effect of the M2 protein on EOR, URP and calcium release are included in the 
first part of this chapter.
 As M2 is not predicted to be a hydrophobic protein, nor does it have 
transmembrane region, and lacks homology to proteins with known function, we 
hypothesized that M2 could be interacting with a protein in the ER to inhibit NF-κB 
activation.  Two candidate proteins were UNC93B and STING.  Both are ER-resident 
proteins known to regulate upstream activators of NF-κB (6, 13).  UNC93B is a cellular 
protein that must interact with ER-localized Toll-like receptors 3,7 or 9 to stimulate NF-
κB.  It was thus hypothesized that M2 could interact with UNC39B to inhibit NF-κB 
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activation. Another ER resident protein, STING, activates NF-κB activation.  STING 
(stimulator of interferon genes) is a five transmembrane molecule, which contains an ER 
retention/ retrieval sequence (RIR) which retains the protein in the ER membrane and 
maintains its integrity (28).  Thus, we also hypothesized that the M2 protein interacted 
with STING to inhibit NF-κB.  While the first half of this chapter focuses on ER-based 
signaling pathways M2 may modulate, the latter half of this chapter evaluated the ability 
of the M2 protein to interact with UNC93B or STING, or other cellular proteins.  
Materials and Methods
Virus Infection
 For virus infections, subconfluent 293T cellular monolayers (7.5 x 105 cells/well) 
in 6-well tissue culture dishes were either mock infected (UN) or infected with the 
indicated virus at an MOI of 10 PFU/cell.  During this adsorption phase, the viruses and 
cells were incubated in virus medium, and the tissue culture plates were rocked every 15 
min for 1 hr.  After this adsorption phase, virus-containing medium was removed, and 
infected cell monolayers were incubated in 1 ml fresh complete medium.  Infected cells 
were harvested at the times indicated post-infection.  
Preparation of Cytoplasmic and Nuclear Extracts
 Cytoplasmic and nuclear extracts from infected or transfected cells were prepared 
as described (12).  Cells were collected by scraping and centrifuged at 13,000 x g for 5 
min.  The supernatant was aspirated and discarded.  The cellular pellet was resuspended 
in 50 µl cytoplasmic extract (CE) buffer [10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM 
EDTA pH 8.0, 0.1 mM EGTA (pH 8.0), 0.05% NP-40 (Oie and Pickup, 2001), 1x HALT 
Protease Inhibitor Cocktail (Thermo Scientific), 1 mM DTT (Promega)].  The sample 
was incubated on ice for 5 min.  Next, the lysate was centrifuged at 13,000 x g for 2 min, 
and the supernatant was transferred to a new tube for use as the cytoplasmic extract.  The 
remaining pellet was washed in 100 µl CE buffer and centrifuged at 13,000 x g.  The 
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supernatant was removed and the cell pellet was resuspended in 30 ul of nuclear extract 
(NE) buffer [20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA 
(pH 8.0), 25% glycerol (18), 1x  HALT Protease Inhibitor Cocktail (Thermo Scientific), 1 
mM DTT (Promega)].  Samples were incubated on ice for 30 min after which they were 
subjected to a 10 min centrifugation step at 13,000 x g and the supernatant taken as the 
nuclear extract portion. 
Immunoblotting
 Briefly, 293T cellular monolayers were infected with indicated viruses at an MOI 
of 10 PFU/ml for the period of time indicated in the figure legends.  In some experiments, 
cellular monolayers were incubated in medium containing either tunicamycin (10 µg/ml; 
Sigma-Aldrich) or Brefeldin A (10 µg/ml; MP Biomedicals).  Tunicamycin was present in 
medium during the adsorption phase of infection and post-infection, whereas Brefeldin A 
only was present 30 min prior to the adsorption phase of infection.  
 For ectopic expression of M2, sub-confluent 293T cellular monolayers (5 x 105 
cells/well) in 6-well tissue cultures plates were transfected with 4 µg of pCI, 2 µg pCI/
M2L-V5, or 2 or 4 µg of pLW44-M2L-V5 plasmid using FuGene 6 (Roche) transfection 
reagent per the manufacturer’s instructions.  Transfection proceeded for 24 hours prior to 
harvest or infection with virus.  
 For all cells, after the indicated times, cells were harvested from cell culture 
dishes by scraping and collected by centrifugation.  Cytoplasmic extracts were prepared 
as described above.  An equal amount of protein from each sample, as measured by a 
BCA assay (Pierce), was used for immunoblotting.  Briefly, extracted proteins were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
using either a 12% or 14% polyacrylamide gel, and were transferred to Immobilon P 
membrane (Millipore).  Membranes were blocked for 1 hr at room temperature in western 
blocking buffer, which consisted of 5% non-fat dry milk (Carnation) in TBST (0.05% 
Tween-20, 150 mM NaCl, 100 mM TrisCl, pH 7.5).  
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 Membranes were incubated overnight at 4°C with either polyclonal anti-M2L 
antiserum (1:20,000), anti-V5 antiserum (1:5,000, Invitrogen), anti-phospho-ERK1/2 
antiserum (1:1,000, Santa Cruz Biotechnology), anti-ERK 1 antiserum (1:1,000, Santa 
Cruz Biotechnology), or anti-actin antiserum (1:1000, Santa Cruz Biotechnology).  
Immunoblots were washed in TBST and incubated in western blocking buffer containing 
either horseradish peroxidase (HRP) conjugated goat anti-rabbit immunoglobulin G (IgG) 
(1:10,000 to 1:20,000; CalbioChem), or HRP-conjugated goat-anti-mouse IgG (1:10,000; 
Fisher Scientific).  Proteins were detected with the enhanced chemiluminescence (ECL) 
system (Amersham Biosciences).  
 Densitometry analysis was utilized to quantify the signals generated by ECL, 
using the histogram function in Photoshop CS3 (Adobe Systems Incorporated).  The 
signal from the lane containing lysates from mock-infected cells was set to a value equal 
to one.  The relative intensity values from lysates of virus-infected cells were recorded 
and shown as a graph or given as direct numerical values.  
Electrophoretic Mobility Shift Assay (EMSA)
 Nuclear extracts were prepared from virus-infected cells as described above and 
were subjected to a gel EMSA (11).  Briefly, annealed double-stranded oligonucleotides 
containing a NF-κB consensus site (Promega) were labelled with [γ-32P] ATP.  6 µg of 
nuclear extract from each sample was incubated at room temperature for 20 min in 
binding buffer (Promega) and 32P-labeled oligonucleotides probe.  When a supershift 
assay was performed with some samples, 1 µg of anti-p65 antibody (Santa Cruz 
Biotechnology) was present.  Next, samples were electrophoretically analyzed in a 6% 
nondenaturing polyacrylamide gel.  The gel was dried and exposed to a phosphorimager 
plate (Molecular Devices) and the images developed and analyzed using the ImageGauge 
and ImageReader programs from Fuji.  For quantitation of bands present in an EMSA, 
images were analyzed using Photoshop CS3 (Adobe Systems Incorporated) to quantify 
pixel intensities.  The value obtained for mock-infected cells was set to a value equal to 
one and values from virus-infected cells were recorded.
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Luciferase Assays
 293T cells were cotransfected with 450 ng pNF-κBluc (Stratagene), 50 ng-
pRLnull (Promega) and either plasmid M2L-V5/pCI or pCI.  pNF-κBluc contains the 
firefly luciferase gene under the control of an NF-κB-specific promoter.  pRL-null 
expresses constitutively low levels of sea pansy luciferase and accounts for differences in 
transfection efficiencies.  At 24 h post-transfection, cells were transfected with the 
adaptor molecule proteins are transfected with either the pNIK plasmid, the pRIP plasmid 
(gift from Dr. Preet Chaudhary, University of Texas Southwestern Medical Center), or the 
pMyD88, pTRIF, and pTRAM plasmids (gift from Dr. Richard Tapping, University of 
Illinois at Urbana-Champaign).  Cells were lysed and firefly and sea pansy luciferase 
activities of whole cells extracts were assayed by using the Dual Luciferase Reporter 
Assay Stystem (Promega).  Each experiment was performed in triplicate and firefly 
luciferase activity was divided by the sea pansy luciferase activity for each experimental 
point to normalize transfection efficiencies.  The resultant ratios were normalized to that 
of untreated, pCI-transfected cells, whose value was taken as one.  
Immunoprecipitation Analysis
 Protein A or Protein G beads (Invitrogen-Zymed) were utilized in 
immunoprecipitations and equilibrated in the buffer used to lyse cells in general IP Buffer 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 5 mM EDTA with 1% NP-40) or in 1% 
digitonin lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 5 mM EDTA with 
1% Digitonin).  After centrifugation, cell lysates  were incubated for 4 h or overnight at 
4˚C with 50 µl protein A or G-Sepharose beads and 1µl of anti-V5, 3 ul anti-M2, 2 ul 
anti-p65, 2 µl anti-phospho ERK1/2, or 2 µl anti-p38 antibodies.  The protein-bead 
complex was sedimented at 10,000 x g for 2 minutes, and pellets were washed three 
times with the same buffer used to lyse the cells.  Samples were then resuspended in 30 ul 
Laemmli Buffer and 5 µl of 2-me.  Samples were then subjected to SDS-PAGE.  
 For immunoprecipitation of the UNC-93B plasmid containing an HA tag, a rat 
anti-HA affinity matrix (Roche) was used.  These beads have HRP directly coupled to 
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them. Immunoprecipitation of UNC-93B HA construct was done in 1% digitonin lysis 
buffer.  The IP’d samples were not boiled, but rather left on the lab bench for 1 hr to 
denature, then loaded on a gel.  
Flow Cytometry
 293T cells were collected at 24 h after transfection or infection at 2 hpi.  Cells 
were infected with VV as described above and harvested for flow cytometry at the 
appropriate times.  Cells were detached from the plate with a Trypsin-Versene mixture 
(BioWhittaker, Lonza).  Cells were spun down and then incubated with 100 µl of 
complete media.  Samples were then transported to the flow cytometry facility (Edwin R. 
Madigan Laboratory, University of Illinois at Urbana-Champaign) in a styrofoam 
container with ice packs warmed in a waterbath.    
 For calcium mobilization kinetics, changes in dye fluorescence after stimulation 
with ionomycin, thapsigargin, H202 over time at 37 ˚C were determined by flow 
cytometry (FACScan; Becton Dickinson).  Cells were then stimulated with an inducer 
such as Ionomycin (Calbiochem) Thapsigargin (Sigma), H2O2 or left untreated in the case 
of virus samples.
 Cells were collected at 2,000 x g for 3 minutes and the cell pellet resuspended in 
100 ul calcium-free media. Changes in cytosolic Ca2+ concentration were measured using 
the calcium indicator Fluo-3AM, an acetomethylester whose fluorescence emission 
increases upon binding calcium, or dichlorodihydroflourescein diacetate (H2DCFDA) 
whose fluorescence emission increases upon binding reactive oxygen speicies.  Cells 
were incubated with the respective indicator dyes in low light conditions.  Samples were 
then incubated for 30 minutes in a 37 ˚C waterbath, with gentle shaking every few 
minutes.  
 At the end of the incubation period, cells were spun down and supernatants were 
aspirated off.   Cells were washed 2x with 1 ml PBS and then resuspended in 1000 µl 
PBS and analyzed by flow cytometry.  
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 Flow cytometry was performed with a FACSCalibur flow cytomer (BD 
Biosciences) and analyzed with FCS Express 3 software (De Novo Software, CA, USA).  
All samples were gated by forward scatter and side scatter to exclude dead cells and 
debris prior to analysis.  The 488 nm line of the argon laser was used to excite Fluo-3AM, 
or H2DCFDA, and fluorescence emission was collected through a long-pass 585 nm 
filter.
Silver-Staining
 2 wells of 1x107 cells were infected with the appropriate virus and then samples 
were immunoprecipitated as described above.  These samples were then used in the 
silver-staining method.  The method of running a large 12% SDS-PAGE gel casted on a 
large BioRad iix system was utilized.  The glass plates were washed with 70% EtOH to 
avoid keratin contamination.  The plates were then sprayed with an air duster to remove 
any residual dust.  The method of Blum et.al, 1987 was utilized (5), with all steps carried 
out at room temperature and using ultrapure water or solvents.
 The gel was fixed in 50% MeOH;12% AcOH; and 0.5mL 37% HCOH/L for 1 hr.  
The gel was then washed in 50% EtOH, a total of 3 times for 20 minutes each time.   The 
gel was then pretreated with Na2S2O3 •5 H2O (0.2g/L) for 1 minute.  The gel was 
promptly rinsed with ultrapure H20, 3 times for 20 seconds.  The cell was then 
impregnated with AgNO3 (2g/L); 0.75 mL 37% HCOH/L for 20 minutes.  The gel was 
again rinsed with water, two times for 20 seconds.  The gel was then developed using 
Na2Co3 (60g/L); 0.5 mL 37%  HCOH/L; Na2S2O3 • 5 H20 (4mg/L) for up to half an hour.  
The gel was again washed with H20 twice, for 2 minutes.  The development of gel was 
stopped by incubating the gel in 50% MeOH; 12% AcOH for 10 minutes.  As a final step, 
the gel was washed in 50% MeoH for 20 minutes and then the gel air dried using gel 
dryer cassettes.  
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Results
M2 Does Not Inhibit Overexpression of Adaptor Proteins Involved in Various 
Signaling Pathways
 It was observed that M2 inhibits NF-κB activation.  There are numerous 
intracellular signal transduction pathways that result in NF-κB activation.  Since it was 
observed that M2 affected the MEK/ERK pathway, it was prudent to examine other 
pathways leading to NF-κB activation to determine if M2 functioned globally or 
specifically on the MEK/ERK pathway in 293T cells.  To attempt to identify M2’s 
molecular function, we asked how M2 affected NF-κB activation induced by the over-
expression of prominent adaptor proteins from different pathways.  Different adaptor 
molecules from many independent signaling pathways known to trigger NF-κB activation 
were co-transfected with a M2L-V5/pCI plasmid to determine the impact on NF-κB 
activation, the results of which are shown in figures 4.1-4.4.  NF-κB activation was 
measured for these assays via a luciferase reporter assay in which the synthesis and 
activity of luciferase is indicative of NF-κB  activation.  
 Tumor necrosis factor receptor-I is a potent activator of NF-κB.  Binding of the 
TNF trimer to the extracellular domain of TNF-R1 results in the formation of a 
cytoplasmic receptor-proximal complex containing the important adaptor proteins 
TRADD, TRAF2, RIP, and FADD (8).  This signalsome then recruits and activates IKK 
to trigger NF-κB activation.  Not surprisingly, over-expression of any of these adaptor 
proteins also activates NF-κB.  To address if M2 inhibited this signal transduction 
cascade, NF-κB-induced luciferase activity was measured in cells over-expressing RIP.  
As a positive control, some cells were co-transfected with RIP and MC160/pCI, since it 
has been shown that MC160 inhibits RIP-induced NF-κB activation (17) .  As shown in 
Fig. 4.1, luciferase activity was high in cells transfected with HA-RIP, but low in pCI- 
transfected cells.  While over-expression of MC160 molecules decreased RIP-mediated 
luciferase activity about 5-fold, only a slight decrease in luciferase activity was observed 
in M2-expressing cells, implying that M2 did not inhibit this pathway.  NIK (NF-κB 
inducing kinase), is a MAPKKK-related protein kinase that associates with TRAF2 and 
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other members of the TRAF family and mediates TNF-induced activation of NF-κB 
through IKKs (14), but does not activate JNK or p38 (9).  Similar to the results in Fig. 
4.1, over-expression of M2 did not inhibit NIK-induced NF-κB activation, while activity 
was decreased in cells co-expressing NIK & MC160 (Fig. 4.2).  The effect of M2L on 
signaling via the adaptor molecules of other signal transduction pathways (i.e. Toll-Like 
Receptors) was tested using MyD88 (Fig. 4.3), TICAM-1 and TRAM (Fig. 4.4).  M2 
protein expression did not significantly decrease NF-κB activation induced by the 
expression of any of these proteins. Since M2 did not inhibit NIK- or RIP-1- induced NF-
κB activation, we hypothesize that M2 was specifically targeting MEK/ERK-induced 
NF-κB activation.  
M2 Does Not Have an Effect on the Unfolded Protein Response (UPR)
 To assess the role of M2 during the UPR, western blot analysis was performed to 
assess levels of phospho-eIF2-α, a marker of cellular stress.  Cells were mock-infected, 
infected with MVA, or infected with MVA/M2L-V5.  As seen in Figure 4.5A, there was 
no detectable difference in phospho-eIF2-α levels in MVA versus MVA/M2L-V5-infected 
cells compared to that of cells stimulated with thapsigargin, a drug used to induce the 
UPR.
 Another event that occurs during UPR is induction of Bip/Grp78 mRNA (24).  
The UPR involves up-regulation of the secretory pathway’s capacity to process proteins 
and transcriptional up-regulation of a coordinately expressed set of genes encoding ER 
chaperones, enzymes, and structural components of the ER.  The UPR pathway 
culminates in the expression of Grp78, which is a classical marker for UPR activation in 
mammalian cells.  As shown in Figure 4.5B, infection with MVA, MVA/M2L-V5 or WR 
does not dramatically alter Bip protein expression.  Similarly, cells treated with 
thapsigargin, a known ER agonist which increases Grp78/Bip protein levels, and 
tunicamycin, which inhibits protein glycosylation, also did not modulate Bip.  As shown 
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in Figure 4.6A, M2 expression did not alter PERK or PDI expression levels, two other 
cellular proteins known to be upregulated during ER stress (Fig. 4.6B).  
M2 Does Not Inhibit Intracellular Calcium Release Associated with the EOR 
Pathway
 Because the classical response to ER stress was not influenced by M2 expression, 
the lesser-known and less well-characterized pathway of the EOR was assessed for M2’s 
inhibitory involvement.  The choice of cell lines for flow cytometry included the 293T 
cells and Jurkat T cell lines.  293T cells were used for the data generated in characterizing 
the M2 protein, and continued to be utilized in this flow cytometry assay to stay 
consistent with data obtained for ER localization and ERK1/2 and NF-κB activation 
studies.  293T cells have been shown to support calcium signaling (4) and that ERK1/2 
activation follows calcium release (16). Jurkat T cells were used because these cells are 
known to respond to calcium signals.  A time point of 2 hours post-infection was 
investigated throughout these studies.  This correlated with the time M2 was observed to 
both localize to the organelle and also inhibit NF-κB and ERK1/2 activation.  
 The source of transient calcium increases in cells can be either intracellular 
(released from intracellular stores) or extracellular (enters the cell across the plasma 
membrane) (3).  To exclude the influence of extracellular calcium in samples, cells were 
incubated with calcium free media before labeling and induction steps.  
 In Figure 4.7 the amount of calcium release was assessed in UN-, MVA, MVA/
M2L-V5, WR-, and MVA/5.2kb infected 293T cells.  There was no detectable difference 
in the amount of calcium release as indicated by Fluo-3AM values.  This data suggested 
that vaccinia virus infection did not alter intracellular calcium levels, disproving our 
hypothesis.  In order to have a positive control to assess calcium mobilization, the 
pUl37x1 construct was obtained from the Children’s National Medical Center from Dr. 
Anamaris M. Colberg-Poley.  pUL37x1 is an ER-localized human cytomegalovirus 
protein expressed during the immediate-early stage in infection (26).  pUL37x1 induced 
the release of calcium from the ER into the cytosol, showing that the detection limits of 
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the assay were appropriate.  Cells were also incubated with ionomycin, a calcium inducer. 
As shown in Figure 4.8, M2-expressing cells did not have lower levels of ionomycin-
induced calcium levels than vector-transfected cells.  Similar results to the 293T cell line 
were obtained in Jurkat T cells ,which are another cell line that responds well to calcium 
signaling (Fig. 4.8).  
M2 and Reactive Oxygen Species Analysis
 High-resolution electron tomography has demonstrated that the ER and 
mitochondria are in close proximity and have numerous contacts (15).  Contacts between 
the ER and mitochondria provide sites for transfer of lipids (27) and potentially of Ca2+ 
(10, 22, 29, 31).  Mitochondria are often found localized very close to Ca2+ release 
channels on the ER and plasma membrane.  These microdomains of high local [Ca2+] 
allow released Ca2+ to be sensed by the electrogenic mitochondrial Ca2+ uniporter, 
resulting in Ca2+ sequestration in the mitochondria (23). 
 ROS are thought to act as modulators and costimulators of cytokine-mediated 
inflammatory responses including the stimulation of NF-κB transcription activation (2).  
ROS release is an event that occurs after calcium release from the ER.  As the EOR 
proceeds through calcium release at the ER, followed by reactive oxygen intermediate 
release from the mitochondria, reactive oxygen species release was analyzed in infected 
293T cells.  This experiment was done to confirm the results obtained in the calcium 
experiment.  Inducers of reactive oxygen intermediates include okadaic acid, hydrogen 
peroxide, tunicamycin, and PMA.  Hydrogen peroxide was chosen as a positive control to 
stimulate calcium release from the ER in these studies.  To directly examine whether 
M2L influences the cellular accumulation of ROS, intracellular levels were examined in 
293T cells infected with M2L versus that of other viruses and also if transfected M2L 
could inhibit ROS induced H2O2 treatment (data not shown).   Flow cytometry analysis 
was carried out, with similar results were obtained for this assay as for the calcium 
release assay, indicating that this event after calcium release was not affected by M2 
expression.  
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M2 Does Not Directly Associate With Known Signaling Molecules Involved in 
ERK1/2-Induced NF-κB Activation  
 Interactions between ERK1/2 and p38 where tested to determine whether M2 
interacted with these proteins as a mechanism to inhibit ERK1/2 activation.  Such 
interactions were measured by co-immunoprecipitation.  As shown in Fig. 4.9, there were 
no detectable interactions between M2 and either of these cellular signaling components.  
As M2 inhibits NF-κB activation, it was tested to see if M2 could physically associate 
with the p65 subunit of NF-κB.  Data in Fig 4.10 showed that M2-p65 interactions did 
not occur.  
UNC93B Does Not Interact With the M2 Protein During Infection  
 Because the above signaling proteins were present with the cytoplasm of the cell 
(a location different than the ER-associated M2), we next tested if ER-resident proteins 
interact with M2 during infection.  UNC93B was a candidate for M2 binding because of 
its ER localization and because of its role in modulating Toll-like receptor-induced NF-
κB activation from the ER.  As NF-κB activation is a downstream event of TLR 
signaling, it was hypothesized that M2 would interact with UNC93B to inhibit NF-κB.  
 To test such interactions, 293T cells were transfected with UNC93B-HA.  20 
hours post-transfection, cells were infected with MVA/M2L-V5.  Cells were lysed in 1% 
digitonin based buffer, and an immunoprecipitation was performed with anti-HA-
conjugated beads, and immunoprecipitates were probed for M2.  Alternatively, lysates 
were immunoprecipitated with anti-V5-conjugated beads to immunoprecipitate M2.  
Samples were then left to denature at room temperature for one hour (per Melanie 
Brinkmann’s suggestion), and resolved on a 12% SDS-PAGE gel. The membrane was 
then probed for the presence for UNC93B-HA.  Results demonstrate that UNC93B did 
not interact with M2L, and vice versa (Fig. 4.11).
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An ER-Localized Protein, STING, Does Not Interact With M2
 STING (STimulator of INterferon Genes), is a five transmembrane molecule, 
predominantly located in the endoplasmic reticulum and activates NF-κB activation.  
Over-expression of this molecule was shown to upregulate type I IFN signaling through 
IRF-3/IRF-7.  A plasmid expressing the STING construct, pCGaggs (obtained from Luis 
Sobrido Martinez from University of Rochester), was utilized to determine whether M2 
interacted with STING as a means to inhibit NF-κB activation.   Cells were transfected 
with the STING and then infected with viruses either expressing or lacking the M2 
protein,  M2-STING interactions were tested by immunoprecipitation.  Figure 4.12A 
shows that the STING-HA construct is detected using an anti-HA antibody.  The amount 
of STING-HA in the last lane on the blot which contains STING-HA+M2L-V5 is much 
more than that of STING-HA alone since proteins from 6 wells were used instead of 
proteins from 1 well in the other sample lanes.  As such, expression of more STING-HA 
is indicative of more protein loaded on the gel, rather an influence of pCI/M2L-V5 
present in the sample.  In transfected samples, as shown in Fig. 4.12B ectopically 
expressed M2 does not interact directly with STING.  
Cloning of a 6-His Tag Unto the C-terminus of the M2 protein Resulted in 
Undetectable M2-His Proteins
 To create a construct which would allow enrichment of a histidine tagged M2 and 
any interacting partners, an MVA-recombinant virus was created in order to facilitate 
identification of potential cellular binding partners for M2 during infection.  This mutant 
protein was able to be detected using an anti-M2 polyclonal antibody, but the histidine 
epitope was not able to be detected (data not shown).  
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Silver-Staining to Identify Potential Interacting Proteins
 In an attempt to identify binding partners for M2, immunoprecipitation with either 
an M2 polyclonal or anti-V5 monoclonal antibody followed by silver staining was 
performed to identify any potential substrates.  As seen in Figure 4.13, M2 was detected 
in the infected lanes, but barely detected in the transfected sample lane.  Two intense 
bands appeared in the MVA/M2L-V5 and WR- infected sample lanes when IP’d with 
antibody recognizing the M2 protein species, but these bands also gradually appeared 
over time in the mock and MVA-infected lanes, and may not be indicative of a true 
interacting partner for M2.  Another band of interest which migrated around 90 kDa, was 
observed in the WR-, but not MVA/M2L-V5 infected samples.  These observed proteins 
at the molecular weights identified as potential interacting partners for M2 have not been 
explored further.  It is also difficult to predict what these viral or cellular interacting 
proteins may be as molecular weight alone is not enough to predict the identity of such 
proteins.   
Discussion
 The data presented in this chapter reveal that M2 does not modulate ER stress 
pathways, and does not physically associate with the members of pathways known to 
activate NF-κB or ERK1/2.  
 Many RNA viruses utilize the ER as the intracellular primary site for protein 
expression and RNA replication.  These activities alter ER homeostasis and ER stress 
pathways are activation in order to alleviate this burden.  Vaccinia virus, a DNA virus, 
has not been demonstrated to activate transcription of classical ER stress markers, such as 
ATF6 and ER chaperone Grp78.  Our studies indicate that M2 has no involvement in the 
ER stress pathways tested and does not effect either calcium nor reactive oxygen species 
release.  Furthermore, M2 was not found to directly associate with UNC93B or STING, 
two prominent ER residents that are involved in cytoplasmic signaling.  Therefore, the 
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possibility that M2 acts at the site of the ER to downregulate ERK1/2 or NF-κB activity 
is ruled out.  
 The results indicating that M2 does not inhibit overexpression of known 
molecules known to activate the signaling pathways leading to NF-κB or ERK1/2, and 
lacks physical association with various members of pathways where it inhibits, suggests 
that M2 acts on a yet unidentified pathway which feeds into NF-κB and ERK1/2 
activation.  
 As experiments demonstrated that M2 did not interact with known resident ER 
proteins, it was thought that immunoprecipitating intracellular M2 during infection would 
reveal potential interacting partners.  As seen through the silver staining results, there 
were several bands which could be potential proteins for M2 interaction (Figure 4.13).  
After discussion with Peter Yau at the proteomics facility on campus, it was reasoned that  
these bands may be due to human skin keratin, accounting for the presence of the ~ 70 
kDa band present in cells.  However, there is a possibility that this band could be a 
cellular protein, as this band is present in samples which do not contain M2.  Candidate 
proteins are that of CK1 or CK2, as these are detected near 66 kDa on gels (30).  
 An attempt to create a virus expressing a histidine tagged version of M2 was not 
successful.  The codon sequence used to incorporate the histidine tag consisted of 6 
codons of CAC’s, and did not utilize the other codon, CAT, which also codes for 
histidine.  It is believed that codon usage in an eukaryotic system did not favor this 
sequence.  This may be due to the need to further codon optimize by alternating the CAC 
or CAT codons within the 6x histidine sequence, or introduce a flexible linker region 
(GSGGGGS) between M2L and the histidine tag itself. 
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)LJXUH7KHHIIHFWRIHFWRSLFDOO\H[SUHVVHG0/RQ+$5,3PHGLDWHG1)ѣ%
activation. 7FHOOVZHUHFRWUDQVIHFWHGZLWKWKHOXFLIHUDVHUHSRUWHUJHQHS1)ѣ%OXF
plasmid (450 ng), prLNull (50 ng), 250 ng of the HA tagged-RIP plasmid, and 500 ng of 
MC160/pCI or M2L-V5/pCI.  The amount of DNA was kept constant by including the “empty 
YHFWRUµS&,KRXUVSRVWWUDQVIHFWLRQFHOOVZHUHKDUYHVWHGLQѥOSDVVLYHO\VLVEXIIHU
DQGWKHQѥORIWKLVDOLTXRWZDVXVHGIRUOXPLQRPHWHUUHDGLQJV7KHVHH[SHULPHQWVZHUH
independently carried out three times, and the results represent the averages with standard 
GHYLDWLRQVIURPRQHUHSUHVHQWDWLYHH[SHUPHQW
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MC160/pCI + pCI
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Figure 4.2  The effect of ectopically expressed M2L on NIK mediated 
1)ѣ%DFWLYDWLRQ7FHOOVZHUHFRWUDQVIHFWHGZLWKWKHOXFLIHUDVHUHSRUWHUJHQHS1)ѣ%OXF
plasmid (450 ng), prLNull (50 ng), 10 ng of the NIK plasmid, and 1000 ng of MC160/pCI or 
M2L-V5/pCI.  The amount of DNA was kept constant by including the “empty vector”, pCI.  24 
KRXUVSRVWWUDQVIHFWLRQFHOOVZHUHKDUYHVWHGLQѥOSDVVLYHO\VLVEXIIHUDQGWKHQѥORI
this aliquot was used for luminometer readings.  These experiments were independently carried 
out three times, and the results represent the averages with standard deviations from one 
representative experment.  
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)LJXUH7KHHIIHFWRIHFWRSLFDOO\H[SUHVVHG0/RQ0\'LQGXFHG1)ѣ%DFWLYDWLRQ 
293T cells were mock-transfected or transfected with plasmids containg the M2L-V5, MC160 or 
MyD88-FLAG ORF.  To ensure equal transfection amounts, an empty vector (pCI) was included to 
make sure the total amount of DNA transfected amounted to 2000 ng.  24 hours post-transfection, cells 
ZHUHKDUYHVWHGLQѥOSDVVLYHO\VLVEXIIHUDQGWKHQѥORIWKLVDOLTXRWZDVXVHGIRUOXPLQRPHWHU
readings.  These experiments were independently carried out three times, and the results represent 
the averages with standard deviations from one representative experiment.
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Examining M2L's effect on TICAM-1 and TRAM mediated NF- B 
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Figure 4.5  Immunoblot to detect p-eIF2alpha or Bip protein expression at 
1 hpi.  293T cells were either mock-infected or infected with the indicated 
viruses. (MOI=10).  At 30, 60, or 120 minutes post-infection, cells were collected 
DQGO\VHGLQ&(EXIIHU(TXDODPRXQWVRIF\WRSODVPLFH[WUDFWSURWHLQVѥJ
were determined by a bicinchoninic acid assay (BCA) and subjected to 12% 
SDS-PAGE.  Immunoblotting was performed with an (A) anti-p-eIF2alpha or (B) 
Bip antibody.  
  129
20 
uM
 tha
psi
gar
gin
UN MV
A
M2
L-V
5
UN5 u
g/m
l tu
nic
am
yci
n
MV
A/5
.2k
b
75
50
UN MV
A
M2
L-V
5
50
75
MW
37
50
¨V
S
¨(
5
MV
A/5
.2k
b
:
5
Figure 4.6  PERK and PDI levels in virus-infected cells.  (A) 293T cell 
monolayers were infected with the indicated viruses at an MOI=10.  At 1 hpi, 
FHOOXODUPRQROD\HUVZHUHFROOHFWHG&HOOVZHUHO\VHGLQ&(EXIIHUDQGѥORIWKH
protein from each sample was analyzed by immunoblotting for the presence of 
PDI, and the same blot was reprobed for anti-actin for equal protein loading.    
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Figure 4.7  During infection, M2L does not affect calcium release from the ER, as 
compared to pUL37x1, a human cytomegalovirus protein known to mobilize 
calcium.  293T cells were left untreated, infected for 2 hours with the viruses indicated, 
or either transfected with pUL37x1 for 22 hours, and then infected with MVA/M2L-V5 for 
2 hours.  Cells were then trypsinized, rinsed with PBS, and loaded with 2 mM of Fluo-
$0IRUPLQXWHVLQDÝ&LQFXEDWRU&HOOVZHUHZDVKHGZLWK3%6DQGIORZDQOD\-
sis perfomed on samples.  Larger Fluo-3AM values on the x-axis indicate increased 
FDOFLXPUHOHDVHLQWRWKHF\WRSODVP/HIWSDQHO&RPSDULVRQRIYLUXVHVDQGWKHLUDELOLW\
to affect calcium release from the ER to the cytoplasm.  Right panel:  pUL37x1-mediated 
FDOFLXPUHOHDVHIURPWKH(5LVQRWDIIHFWHGE\WKHSUHVHQFHRI0/GXULQJLQIHFWLRQ
MVA
UN
MVA/M2L-V5
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V5
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Figure 4.8  Analysis of the intracellular variation of calcium concentration by flow 
cytometry.  293T cells were loaded with Fluo-3AM and treated with ionomycin at 40 seconds after 
the start of data collection (+ ionomycin).  Sample readings continued for 80 seconds thereafter for 
a total of 120 seconds per sample.   Calcium mobilization is indicated by the Fluo-3AM readings 
shown on the y-axis. 
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Figure 4.9  M2L does not interact with the activated form of ERK 1/2 or p38.  
(A) 293T cell monolayers were infected with the indicated viruses at an MOI=10.  At 
2 hpi, cellular monolayers were collected.  Cells were lysed in IP lysis buffer and 
1/10 of the protein from each sample was analyzed by immunoblotting for the 
presence of M2, phophorylated ERK 1/2, or the p38 protein.  (B) Cellular lysates 
from (A) were immunoprecipitated (IP) with Protein G-sepharose beads 
pre-conjugated to the antibodies indicated.  Immunoprecipitated samples were 
separated by 12% SDS-PAGE and the blot was subsequently probed with either an 
anti-M2L or anti-phospho ERK1/2 antibody. 
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Figure 4.10  Immunoprecipitation of M2 and the p65 protein subunit.  (A) 293T cells were 
either mock infected (UN) or infected with MVA- or M2L-V5 viruses at an MOI=10.  At 2 hpi, 
cells were lysed and incubated with an anti-V5 antibody conjugated to protein G-Sepharose 
beads.  Cellular lysates and immunoprecipitated samples (immunoprecipitates) were separated 
by 12% SDS-PAGE, and proteins were transferred to PVDF membrane.  Immunoblots were 
probed with anti-p65 antibody.  (B) 293T cells were either mock infected (UN) or infected with 
MVA- or M2L-V5 viruses at an MOI=10.  At 2 hpi, cells were lysed and incubated with an 
anti-p65 antibody conjugated to protein G-Sepharose beads.  Cellular lysates and 
immunoprecipitated samples (immunoprecipitates) were separated by 12% SDS-PAGE, and 
proteins were transferred to PVDF membrane.  Immunoblots were probed with anti-V5 antibody.  
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Figure 4.11  UNC93B, an ER-localized protein essential for signaling through TLR!s 3,7,9, 
does not interact with M2L during infection.  293T cells were transfected with 1000 ng of 
either empty vector (pCI), TLR3-FLAG, or UNC93B for 22 hours.  Some samples were then 
infected with MVA/M2L-V5 (MOI=10) for 2 hours and then lysed in 1% digitonin (Sigma).   
Immunoprecipitation was then performed with either anti-V5 antibody (Invitrogen) coupled to 
Protein-G sepharose beads (Zymed) or with an anti-HA high affinity matrix (Roche).  Lysates 
and immunoprecipitation products were then prepared by adding loading buffer and 
2-mercaptoethanol, and left to denature at room temperature for 1 hour.  Samples were then 
analyzed by 10% SDS-PAGE. 
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Figure 4.12  Immunoprecipitation testing for STING-HA and pCI/M2L-V5 
interactions. (A and B) 293T cells were transfected with 1000 ng of pCI alone, 
pCI/M2L-V5 alone, 1000 ng of STING-HA construct, or cotransfected with 1000 ng of 
STING-HA and 1000 ng of pCI/M2L-V5.  Samples containing pCI-, pCI/M2L-V5-, and 
STING-HA contained protein from 1 well of a 6 well plate, whereas the STING-HA + 
pCI/M2L-V5 sample lanes contain the amount of protein 6 wells of a 6 well plate 
combined.  At 24 h posttrasnsfection, cells were lysed and incubated with anti-V5 
antibody conugated to protein G-Sepharose beads. Either cellular lysates (A) or 
iImmunoprcipitated samples (IP) (B) were separated by 12% SDS-PAGE, and 
proteins transferred to a PVDF membrane.  Immunoblots (IB) were probed with the 
indicated antisera.
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Figure 4.13  Silver-stained SDS-PAGE for M2 interacing partners.  293T cells were infected with 
an MOI=10 of indicated viruses, or transfected with 2000 ng of indicated plasmid.  At either 20 hpi or 
23 hrs post-transfection, cells were harvested and lysed in 1% Digitonin buffer.  An immunoprecipita-
tion with Protein G Sepharose beads coupled to either an M2L polyclonal antibody or anti-V5 
antibody was peformed and beads resuspended in Laemmli Buffer w/ 2-Mercaptoethanol and loaded 
immediately on a gel.  After proteins were separated by SDS-PAGE, the protein bands were revealed 
through silver-staining.  
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Chapter V:  Identification of Casein Kinase II Sites 
Within the Vaccinia Virus M2 Protein and MVA 
Mediated ERK1/2 and NF-κB Activation Through a 
Casein-Kinase II Pathway
! Portions of the Materials and Methods, Results and Discussion section of this 
chapter have been published in “The Dependence of MVA-induced ERK1/2 and NF-κB 
activation on Casein Kinase 2 activity”, submitted as an undergraduate thesis in the 
Department of Biochemistry by Brian C. Wang, 2010.    
Introduction
! Casein kinase II (CK2) is a ubiquitous serine/threonine kinase whose activity 
differs from the majority of protein kinases and is constitutively active and independent 
of either second messengers or phosphorylation events such as cyclic nucleotides and 
calcium.  It remains as one of the most pleiotropic protein kinases existing in eukaryotic 
organisms, with over 300 known substrates (12, 14).  This kinase is involved in a number 
of cellular processes, including maintenance of cell viability, protection of cells from 
apoptosis, tumorigenesis, and virus infection (12, 13). 
 The main form of the protein kinase CK2 is a heterotetramer composed of two 
catalytic α - or α’-subunits and two regulatory β-subunits.  Disruption of both genes 
encoding α and α’ subunits of CKII in yeast results in a complete loss of cell viability, 
indicating that CK2 is essential.  
 CK2 phosphorylation is specified by multiple acidic residues located downstream 
from the phosphorylatable amino acid (serine being preferred over threonine), the one at 
position n+3 playing the most crucial function (10).  Therefore, the consensus motif for 
such as site is defined as S/T-X-X-E/D.  The serine or threonine is the amino acid residue 
that is phosphorylated by CK2.  
 CK2 inhibitors such as 4,5,6,7-tetrabromo-1H-benzotriazole (TBB) or 2-
dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) were developed and are 
specific for CK2 kinase activity.   TBB displays a high affinity to CK2 due to strong 
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hydrophobic and Van der Waals interactions with the large bulky residues in CK2’s 
binding pocket (3).  TBB has a higher affinity and selectivity toward CK2 (14). 
  Several viruses are known to be influenced by casein kinase II activity, but 
currently no evidence in the literature that poxviruses modulate this ubiquitious kinase for 
their benefit.  The MCMV UL99 protein contains a single CK2 target motif  (1).  The 
RNA polymerase transcriptional cofactor protein P protein of several nonsegmented 
negative-strand RNA viruses such as Borna disease, respiratory syncytial virus, vesicular 
stomatitis virus and canine distemper virus are phosphorylated by CK2 (12).  Many other 
viral proteins phosphorylated by CK2 (reviewed in (4)). 
 Protein kinase CK2 is found nearly everywhere in the eukaryotic cell.  Due to its 
ubiquitous nature, it is no surprise that many of its substrates are associated with the 
endoplasmic reticulum.  The protein kinase CK2 is present on the ER surface, and it 
actions are related to this localization.  CK2 was identified as an ER-associated protein 
kinase by virtue of the phosphorylation of its substrate calnexin, which itself is associated 
with the endoplasmic reticulum (18).  As M2L is located in the ER as well, it is located in 
the same cellular compartment as that of M2. 
 As stated in previous chapters, MVA lacks the ability to inhibit NF-κB activation, 
as has multiple deletion and substitutions in its genome that alter viral anti-host defense 
proteins. This activation in MVA was attributed to an early protein event (11).  As the 
ERK1/2 and NF-κB pathways can both be activated by MVA, and these pathways can be 
upregulated in CK2 signaling, these two pathways were investigated. 
 
Materials and Methods
Cells, Viruses, and Reagents
 Human cervical carcinoma (HeLa) and HEK293T (293T) cell lines were obtained 
from the American Type Culture Collection.  HeLa and 293T cells were maintained in 
Eagle’s minimal essential medium (EMEM) supplemented with 10% fetal calf serum 
(FCS; Hyclone).  This cellular media is referred to as complete medium.  The virus used 
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in this study is modified vaccinia Ankara (MVA), a highly attenuated vaccinia virus 
strain, which was graciously provided by Dr. Bernard Moss (National Institute of Health). 
The CK2 inhibitor, 4,5,6,7-tetrabromobenzotriazole (TBB; Sigma), was reconstituted in a 
solution of dimethyl sulfoxide (DMSO).  Aliquots of TBB stock were stored at -80oC.  
The plasmid p56.CK2αK68A_HA (CK2DN) that corresponds to the dominant negative 
CK2 construct was obtained from Dr. Odile Filhol-Cochet (Institutde Rescherches en 
Technologies et Sciences pour le Vivant).  The pCI/M2L-V5 plasmid was constructed by 
first PCR amplifying the complete open reading frame of M2L from WR (wild-type 
vaccinia virus) DNA.  Then, the M2L open reading frame was used as a template to add a 
V5 epitope to the C-terminus of M2L.  This was then inserted into the eukaryotic 
expression vector pCI (Promega) using PstI and EagI sites.  
Transfection
 HeLa or 293T cells were plated down on 6-well plates at 5.0 x 105 cells/well and 
allowed to incubate overnight at 37oC.  Next, 2000 ng or 4000 ng of CK2DN, or 2000 ng 
of pCI/M2L-V5 plasmid were transfected into the subconfluent monolayer of cells by 
using FuGene 6 transfection reagent (Roche).  At 24 hr post-transfection, medium was 
aspirated, and HeLa cells were treated with medium containing 150 µM of TBB, while 
293T cells were treated with medium containing 100 µM of TBB.  After the 30 min pre-
treatment with at 37oC, the cells were either mock-infected or infected with MVA at a 
MOI of 10 as described above.  TBB was present at the respective concentration during 
the adsorption phase and the rest of the infection.  Cells were harvested by scraping, 
collected by centrifugation, and the cytoplasmic or nuclear proteins were extracted as 
described above (13, 25).  The protein concentration in each sample was determined by 
using the BCA protein assay kit (Pierce).  The cytoplasmic extract samples were analyzed 
by using immunoblotting (see Immunoblotting section), while the nuclear extracts 
samples were analyzed by using electrophoretic mobility shift assay (see Electrophoretic 
mobility shift assay section).
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Immunoblotting
 HeLa or 293T cells were plated down in a 6-well plate at 8.5 x 105 cells/well and 
incubated at 37oC overnight.  After the overnight incubation, the media in each of the 
wells were aspirated and replaced with a 1 ml complete medium solution containing TBB 
(25 µM, 50 µM, 75 µM, 100 µM or 150 µM TBB).  The cells were pre-treated with TBB 
for 30 min at 37oC.  TBB at the individual concentrations listed above was also present 
in medium during the adsorption stage of infection and for the duration of the infection.  
After pre-treatment of cellular monolayers with TBB, the cells were either mock-infected 
or infected with MVA at an MOI of 10 PFU/cell.  During this adsorption phase, the 
viruses and cells were incubated in EMEM containing 1% FCS. The 6-well plates were 
rocked every 15 min for 1 hr.  After the 1 hr incubation at 37˚C, the virus-containing 
medium was removed and replaced with 1 mL fresh complete medium or complete 
medium containing TBB (at the concentrations listed above).  At 0.5 hr post-infection, the 
cytoplasmic protein extracts were harvested from infected HeLa cells as previously 
described (13, 25).  The HeLa or 293T cell monolayer was scraped from the cell culture 
plate and cells were collected by centrifugation (1 min at 14,000 xg) at 4˚C.  Next, the 
supernatant was aspirated off and discarded.  Then, the cellular pellet was resuspended 
and lysed in cytoplasmic extraction (CE) buffer [10 mM HEPES (pH 7.9), 10 mM KCL, 
0.1 mM EDTA (pH 8.0), 0.1 mM EGTA, and 0.05% NP-40] that contained the HALT 
protease inhibitor cocktail (Pierce) for 4 min at 4˚C.  After a brief centrifugation (2 min at  
14,000 x g) at 4˚C, the resultant supernatants were collected and transferred to new tubes, 
and the protein concentration in each sample was determined by using the BCA protein 
assay kit (Pierce).  Cytoplasmically extracted samples were stored at -20˚C.  
An equal amount of protein (30 µg) from each sample was mixed with 3 µl of 2x Laemilli 
buffer and 1 µl of 10% 2-mercaptoethanol, boiled for 5 min, and loaded into separate 
wells in a SDS-12% polyacrylamide gel.  The proteins were separated electrophoretically 
and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore).  Then, 
membranes were incubated in blocking solution (TBS containing 5% powdered milk and 
0.1% Tween-20) for 1 hr.  After the blocking step, the membranes were incubated with 
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primary antibodies in TBS-T (TBS containing 5% milk and 0.1% Tween-20).  To detect 
phosphorylated (phospho-) ERK1 and phospho-ERK2 levels, the membranes were 
incubated with rabbit anti-phospho-ERK antiserum (Santa Cruz Biotechnology) diluted 
to 1:1000 in TBS-T.  After an overnight incubation at 4˚C with primary antibodies, the 
membranes were washed in TBS-T to remove unbound primary antibodies.  Then, the 
membranes were incubated with HRP-conjugated goat anti-rabbit IgG (Calbiochem) 
diluted to 1:10,000 in TBS-T (TBS containing 0.5% milk and 0.1% Tween-20) for 1 hr.  
 After the incubation with secondary antibodies, the membranes were washed with 
TBS-T and developed using SuperSignal West Chemilluminescence, as per manufacture 
instructions (Pierce).  To detect ERK1 and ERK2 levels, the membranes were incubated 
with rabbit anti-ERK1 antiserum (Santa Cruz Biotechnology) diluted to 1:1000 in TBS-T 
(TBS containing 5% milk and 0.1% Tween-20).  This antibody also recognizes the highly  
similar ERK2 protein. After an overnight incubation at 4oC, the membranes were washed 
with TBS-T to remove unbound primary antibodies.  Then, the membranes were 
incubated with HRP-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology) diluted 
to 1:10,000 in TBS-T (TBS containing 0.5% milk and 0.1% Tween-20) for 1 hr.  In the 
transfection experiments, the blots were additionally incubated in anti-HA antiserum 
(Sigma) diluted to 1:500 in TBS-T (TBS containing 0.5% milk and 0.1% Tween-20).  
After an overnight incubation at 4˚C, the membranes were washed with TBS-T to remove 
unbound primary antibodies.  Then, the membranes were incubated with HRP-conjugated 
goat anti-mouse antiserum (Thermo Scientific) diluted to 1:10,000 in TBS-T (TBS 
containing 0.5% milk and 0.1% Tween-20) for 1 hr.  After the 1 hr incubation with 
secondary antibodies, the membranes were washed with TBS-T and developed using 
SuperSignal West Chemilluminescence (Pierce). 
Electrophoretic Mobility Shift Assay
 HeLa or 293T cells were plated down in 6-well cell culture plates at 8.5 x 105 
cells/well.  The next day, medium was replaced with 1 ml of complete medium either 
lacking or containing TBB (25 µM, 50 µM, 75 µM, 100 µM or 150 µM TBB).  TBB was 
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present at the respective concentrations during the adsorption phase of infection and for 
the duration of the infection.  After a 30 min pre-treatment with TBB at 37˚C, HeLa or 
293T cells were either mock-infected or infected with MVA (MOI = 10) as described 
above.  At 0.5 hr post-infection, the cellular monolayers were collected by scraping and 
the nuclear proteins were extracted as described previously (13, 25).  First, cells were 
collected by centrifugation (1 min at 14,000 x g) at 4˚C.  Then, the supernatant was 
discarded, and the pellets were resuspended in CE buffer [10 mM HEPES (pH 7.9), 10 
mM KCL, 0.1 mM EDTA (pH 8.0), 0.1 mM EGTA, and 0.05% NP-40] that contained 
HALT protease inhibitor cocktail. The CE buffer lyses the cellular membrane while 
keeping the nuclear membrane intact.  After incubating for 4 min at 4˚C, the cytoplasmic 
proteins were separated from the cell lysate by centrifugation (2 min at 14,000 x g).  The 
resultant supernatant containing the cytoplasmic proteins were transferred to new tubes 
and stored at -20˚C.  Then, the remaining nuclear pellet was resuspended and washed in 
100 µl of CE buffer and centrifuged down to remove excess cytoplasmic proteins from 
the pellet.  The resultant supernatant was discarded, and the pellet was resuspended in 30 
µl nuclear protein extraction (NE) buffer [20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM 
EDTA (pH 8.0), 1 mM EGTA pH 8.0, 25% Glycerol].  After an incubation of 30 min at 
4oC, the nuclear portion was separated from the cell lysate by centrifugation (10 min at 
14,000 x g) at 4˚C.  The supernatant containing the nuclear proteins were kept as samples 
and stored at -80˚C. 
 Six µg of each extract was incubated in 0.35 pmol of 32P-labeled double-stranded 
oligonucleotides containing binding sites for the NF-κB transcription factor (Promega) in 
Gel Shift Assay System Binding buffer (Promega) as per manufacturer's directions.  In 
some reactions, 1 µg of monoclonal anti-p65 antiserum (Santa Cruz Biotechnology), 
which recognizes the p65 subunit of the p65:p50 NF-κB heterodimer, was included.  
Following incubation at room temperature, the samples were resolved electrophoretically 
in a 6% acrylamide gel (Invitrogen) under non-denaturing conditions, using TBE buffer.  
Afterward, the gel was dried, exposed to a phosphorimager plate (Molecular Devices), 
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and the images were developed and analyzed using the ImageGauge and ImageReader 
programs, respectively (Fuji).
Results
The Amino Acid Sequence of M2 Contains 5 Putative CK2 Phosphorylation Sites
 Infection of cells with MVA has been shown to activate the ERK1 and ERK2 
proteins, as measured by the level of phosphorylation of each protein (5, 11).  This 
increase in phosphorylated ERK1 and ERK2 (ERK1/2) levels is required for the 
activation of NF-κB, an important transcriptional regulator of anti-viral and immune 
genes in the host (5-7, 17).  CK2 activity is known to activate both ERK1/2 and NF-κB.  
Substrates that inhibit CK2 activity contain consensus sequences which serve to dampen 
activation of molecules within these pathways.  
 To identify potentially phosphorylated M2 amino acids, we searched for the 
consensus sequences of CK2 within M2. As shown in Fig 5.1, the CK2 consensus 
sequence [(S/T)XX(E/D)] revealed there are 5 potential sites for CK2 phosphorylation.  
Because M2 inhibits ERK1/2 activation and is only known to inhibit NF-κB activation 
through the MVA pathway, it was important to examine if MVA infection proceeded 
through a CK2 dependent pathway.  
 
TBB, a Drug That Inhibits CK2 Activity, Reduces ERK1/2 Activation During MVA 
Infection
 As MVA infection is known to both activate NF-κB, and ERK1/2, it was possible 
that MVA could be inducing a casein kinase II mediated pathway.  We and others have 
reported a strong induction of ERK1/2 activation early during infection (2, 11).  It was 
shown previously that CK2 can activate the ERK1 and ERK2 proteins and NF-κB (9, 16). 
Thus, we hypothesize that MVA-induced ERK1/2 and NF-κB activation is dependent on 
CK2 activity.
 An initial concentration course determined that a TBB concentration of 100 µM 
for 293T cells and 150 µM for HeLa cells was sufficient to inhibit MVA- mediated 
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ERK1/2 activation (data not shown).  This level of drug treatment also did not induce cell 
death as assessed by visual inspection of the cell monolayer.  
 To assess the dependence of MVA-induced ERK1/2 activation on CK2 activity, 
TBB, a CK2 inhibitor, was used during MVA infection (Fig. 5.2) in HeLa cells.  Under 
these conditions, the activation (phosphorylation) of the ERK1 and ERK2 proteins was 
detected by using immunoblotting, probing cytoplasmically extracted proteins for the 
phospho- forms of the ERK1 and ERK2 proteins.  In regular medium, phospho-ERK1 
and ERK2 levels remained relatively low in mock-infected cells (Fig. 5.2B; “UN”). 
However, upon infection with MVA (lane “MVA”), the levels of phospho-ERK1/2 were 
elevated, as expected, at both 0.5 and 1 hr post-infection (hpi) (Fig. 5.2B).  This pattern 
was disrupted when TBB was present during infection.  When TBB was included in the 
presence of a MVA infection, the levels of phospho-ERK1 and phospho-ERK2 decreased 
relative to the “MVA” lanes for both time points (Fig. 5.2B).  This decrease of phospho-
ERK1/2 levels in the presence of TBB indicated the dependence of ERK1/2 activation on 
CK2 activity.  Additionally, there was a concentration dependent inhibitory effect: 150 
µM TBB inhibited ERK1/2 activation to a greater extent than 25 µM TBB (Fig. 5.2B) 
during MVA infection.  The decreased levels of phospho-ERK1/2 were not due to low 
protein levels in cytoplasmically extracted samples because similar amounts of ERK1 
and ERK2 were detected in each immunoblotted sample (Fig. 5.2B).  As would be 
expected, the presence of TBB during a mock infection did not alter either inactive or the 
activated forms of ERK1 or ERK2 (Fig. 5.2B, lane “150 µM TBB”).
 Similar results were observed in a second human cell line, 293T cells (Fig. 5.2A).  
It was also noted that TBB is more toxic in these cells than in HeLa cells for reasons that 
are not yet completely understood.  Thus, when performing experiments with 293T cells, 
the highest concentration of TBB used was 100 µM.  As expected, MVA-infected cells 
displayed an increase in phospho-ERK1/2 levels relative to uninfected cells (Fig. 5.2A, 
lane “MVA” and “UN”).  Treatment of MVA-infected 293T cells with 100 µM of TBB 
inhibited phospho-ERK1/2 levels, indicating that MVA-induced ERK1/2 activation in 
293T cells is dependent on CK2 activity (Fig. 5.2A).  However, at both 0.5 and 1 hpi, the 
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ability of TBB to inhibit ERK1/2 activation decreased along with decreasing 
concentrations of TBB (Fig. 5.2A, lanes “50 µM TBB” and “25 µM TBB”).  The 
decreased levels of phospho-ERK1/2 were not due to low protein levels in 
cytoplasmically extracted samples because similar amounts of ERK1 and ERK2 were 
detected in each immunoblotted sample (Fig. 5.2A).  As would be expected, the presence 
of TBB during a mock infection did not alter either inactive or the activated forms of 
ERK1 or ERK2 (Fig. 5.2A, lane “100 µM TBB”).
The Expression of a Dominant Negative CK2 Protein Reduces ERK1/2 Activation 
During MVA Infection
 The p56.CK2αK68A_HA plasmid encodes a dominant negative CK2 (CK2DN) 
construct.  Over-expression of the dominant negative CK2 protein will out-compete 
endogenous CK2 for substrate binding, effectively inhibiting endogenous CK2 activity.  
It was hypothesized that the transfection of cells with the CK2DN plasmid should result 
in an inhibition of MVA-induced ERK1/2 activation, similar to the results seen above 
with TBB, if CK2 activity is required for ERK1/2 activation.  The ability of the CK2DN 
construct to inhibit ERK1/2 activation was assessed in HeLa (Fig. 5.3B) and 293T cells 
(Fig. 5.3A).  Another plasmid, pCI/M2L-V5, was also transfected into cells. When the 
pCI/M2L-V5 plasmid is transfected into cells, it stably expresses the viral M2L protein 
which is known to inhibit ERK1/2 and NF-κB activation (6). 
 293T cells were assessed for the effect of a DN CK2 construct on ERK1/2 
activation (Fig 5.3A). Phospho-ERK levels were decreased by the over-expression of 
CK2DN constructs (Fig. 5.3A).  At 0.5 hpi, phospho-ERK1/2 levels were decreased to a 
greater degree with TBB than with the over-expression of the CK2DN construct. At 1 
hpi, the inhibitory effect was lost (Fig. 5.3A).  
 Similar results were obtained in HeLa cells (Fig 5.3B) In uninfected HeLa cells, 
transfection of cells with the pCI/M2L-V5 and CK2DN plasmids resulted in a decrease in 
phospho-ERK levels relative to the untransfected cells (UN) lane (Fig. 5.3B).  HeLa cells 
that were infected with MVA displayed higher levels of phospho-ERK1/2 in comparison 
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to uninfected cells. However, MVA-infected cells that were previously transfected with 
the pCI/M2L-V5 or CK2DN plasmids displayed a decreased level of phospho-ERK1/2 in 
comparison to the untransfected lane for time points 0.5 and 1 hpi (Fig. 5.3B).  In 
addition, the transfection of 4000 ng of CK2DN plasmid had a greater inhibitory effect on 
ERK1/2 activation than the transfection of 2000 ng of CK2DN plasmid (Fig. 5.3B).  
These results indicated a dependence of MVA-induced ERK1/2 activation on CK2 
activity.  The decrease in phospho-ERK1/2 levels was not due to low protein 
concentrations in cytoplasmically extracted samples as evidenced by the similar amounts 
of ERK1/2 detected in each immunoblotted sample (Fig. 5.3B).  It should be additionally 
noted that TBB appeared to be a stronger inhibitor of CK2 activity than the CK2DN 
construct (Fig. 5.3A and 5.3B). 
 It has been shown previously that ERK1/2 activation is required for NF-κB 
activation (5).  Therefore, we hypothesized that if TBB is able to inhibit ERK1/2 
activation, it should also inhibit NF-κB activation.  When NF-κB is inactive, it remains in 
the cytoplasm, while when NF-κB is active, it translocates to the nucleus.  Consistent 
with previous data (5), infection of 293T cells with MVA induces NF-κB activation, as 
evidenced by the presence of a unique dark band (Fig. 5.4, lane “MVA”).  To verify that 
this band did indeed represent an NF-κB-oligonucleotide complex, nuclear extracts from 
MVA-infected cells were incubated with radiolabeled oligonucleotides and an antibody 
recognizing the p65 subunit of the NF-κB heterodimer. Under these conditions, the band 
was super-shifted to a higher molecular weight (Fig. 5.4, lane “MVA + p65”).  As shown 
in Fig. 5.4, when MVA-infected cells were treated with 100 µM of TBB (lane “100 µM 
TBB/+MVA”), there was a relative decrease in NF-κB activation as compared to 
untreated MVA-infected cells (lane “MVA”).  These results indicate that MVA-induced 
NF-κB activation is dependent on CK2 activity. It was also noted that the inhibitory effect 
of TBB on NF-κB activation decreased along with decreasing concentrations of TBB 
(Fig. 5,.4 lanes “50 µM TBB” and “25 µM TBB”).
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The Expression of a Dominant Negative CK2 Protein Reduces NF-κB Activation 
During MVA Infection
 To assess the ability of CK2DN construct to inhibit NF-κB activation, the nuclear 
extracted proteins from transfected and MVA-infected cells were assayed for the presence 
or absence of NF-κB.  Inactive NF-κB remains localized to the cytoplasm, while active 
NF-κB translocates to the nucleus.  It was hypothesized that the CK2DN construct will 
inhibit NF-κB activation because it is also able to inhibit ERK1/2 activation, which is 
required for NF-κB activation.  As expected from previous studies (5), infection of HeLa 
cells with MVA induces NF-κB activation, as evidenced by the presence of a unique dark 
band (Fig. 5.5, lane “MVA”).  To verify that this band did indeed represent an NF-κB-
oligonucleotide complex, nuclear extracts from MVA-infected cells were incubated with 
radiolabeled oligonucleotides and an antibody recognizing the p65 subunit of the NF-κB 
heterodimer. Under these conditions, the band was super-shifted to a higher molecular 
weight (Fig. 5.5, lane “MVA + p65”). In n addition, ectopic expression of the vaccinia 
M2 protein, which inhibits NF-κB activation, resulted in a decrease in NF-κB activation 
during both time points, as evidenced by lighter bands in comparison to the “MVA” lanes 
(Fig. 5.5, lane “pCI/M2L-V5”).  At 0.5 hpi, transfection with 2000 ng of CK2DN plasmid 
resulted in a slight decrease in relative activated NF-κB levels (Fig. 5.5, lane “CK2DN 
2000ng”).  However, transfection with 4000 ng of CK2DN plasmid resulted in a loss of 
the observed inhibitory effect (Fig. 5.5, lane “CK2DN 4000ng”).  The loss of the 
inhibitory effect with 4000 ng of transfected CK2DN plasmid can be attributed to cellular 
stress from transfecting large amounts of plasmids into the HeLa cells.  At 1 hpi, the 
inhibitory effect of the CK2DN constructs on NF-κB activation was considerably lower 
than at 0.5 hpi (Fig. 5.5).  In addition, the TBB drug possessed the ability to inhibit NF-
κB activation in MVA-infected HeLa cells at 1 hpi (Fig. 5.5, lane “150 µM TBB”).  These 
results indicate the dependence of MVA-induced NF-κB activation in HeLa cells on CK2 
activity.
 In contrast to HeLa cells, 293T cells are more susceptible to the inhibition of NF-
κB activation by the CK2DN construct (Fig. 5.6).  At 0.5 hpi, there is a noticeable 
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decrease in NF-κB activation in MVA-infected 293T cells transfected with 4000 ng of 
CK2DN relative to untransfected MVA-infected 293T cells (Fig. 5.6, lanes “CK2DN 
4000ng” and “MVA”).  At 1 hpi, transfection of the MVA-infected cells with 2000 ng 
(lane “CK2DN 2000ng”) and 4000 ng (lane “CK2DN 4000ng”) of CK2DN plasmid 
resulted in a relative decrease in NF-κB activation when compared to untransfected 
MVA-infected cells (Fig. 5.6).  However, there was, in comparison to cells transfected 
with 2000 ng of CK2DN plasmid, a lesser amount of activated NF-κB in cells transfected 
with 4000 ng of CK2DN plasmid (Fig. 5.6).  Again, this effect can be explained by the 
cellular stress that resulted from transfecting large amounts of plasmids into the 293T 
cells.  Furthermore, at both 0.5 and 1 hpi, the TBB drug possessed the ability to prevent 
NF-κB activation (Fig. 5.6, lane “150 µM TBB”).  Based on these results, MVA-induced 
NF-κB activation in 293T cells seemed to be dependent on CK2 activity.
Discussion
 Results from this study further characterized the signaling pathways involved in 
activating ERK1/2 and NF-κB upon infection with MVA.  In a previous study, MVA-
induced activation of NF-κB seemed was dependent on co-activation with ERK1 and 
ERK2 (10).  Furthermore, in unperturbed cells, the activation of NF-κB and ERK1/2 is 
dependent on casein kinase 2 (CK2) activity (8, 15).  To assess the dependence of MVA-
induced ERK1/2 and NF-κB activation in HeLa and 293T cells, TBB, a CK2 inhibitor, 
and a CK2DN plasmid, which expresses a dominant negative CK2 construct, were used.
 TBB is an effective drug to use when assessing the dependence of MVA-induced 
ERK1/2 and NF-κB activation on CK2 activity.  TBB is a competitive inhibitor of CK2 
that interacts strongly with CK2 via hydrophobic interactions and Van der Waals 
interactions with the large bulky residues in the binding pocket of CK2 (3).  In the 
presence of TBB, cells that require CK2 enzymatic activity are unable to proceed along a 
CK2-dependent pathway because the TBB drug is bound to the active site of TBB, 
preventing the binding of natural target substrates.  The TBB drug effectively inhibits 
  152
MVA-induced ERK1/2 (Fig. 5.2A and and Fig. 5.2B) and NF-κB activation (Fig. 5.4 and 
Fig. 5.5) in both HeLa and 293T cells. 
 To confirm the results seen with the TBB drug, cells were transfected with 
CK2DN plasmid and expressed a dominant negative CK2 construct.  The expression of a 
dominant negative CK2 construct should inhibit native CK2 activity in that it will 
compete with native CK2 for binding of target substrates.  Moreover, the dominant 
negative CK2 construct has no catalytic activity. Cells that are transfected with the 
CK2DN plasmids exhibit a reduction in both ERK1/2 (Fig. 5.3A and Fig. 5.3B) and NF-
κB activation (Fig. 5.6 and Fig. 5.7).  This reduction in ERK1/2 and NF-κB activation 
upon transfection of the dominant negative construct indicates that MVA-induced 
ERK1/2 and NF-κB activation requires CK2 involvement.  
 While both TBB and the CK2DN construct are able to inhibit MVA-induced 
ERK1/2 and NF-κB activation, the TBB drug has a greater ability to inhibit.  TBB 
directly interacts with CK2 by binding to the CK2 active site, thereby preventing the 
binding of natural substrates.  On the other hand, the CK2DN construct indirectly inhibits 
CK2 activity by binding to the natural substrates, thereby limiting the amount of natural 
substrates that native CK2 can bind to.  The stronger inhibitory effect seen with TBB can 
be attributed to the ability of the drug to occupy most of the active sites of CK2.  The 
expression of the CK2DN construct does not inhibit as strongly as TBB probably because 
the active sites of the native CK2 is still available for substrate binding.  Thus, the 
inhibitory effect with CK2DN constructs is lesser than with TBB.
 M1L, another member of the MVA/5.2kb region was found to inhibit ERK1/2 
(Figure 2.10 from Chapter 2), but is unable to inhibit NF-κB activation.  MVA/M1L -
infected 293T cytoplasmic lysates had lesser amounts of ERK1/2 activation compared to 
MVA and MVA/M2L infected cells.  M1L has one ankyrin repeat, but also 6 putative 
casein kinase II sites.  This indicates that different vaccinia virus proteins modulate 
ERK1/2 and NF-κB pathways through distinct mechanisms not yet defined. 
 Interestingly, the second glycosylation mutant in M2 prevents expression of the 
M2L protein (Chapter 3, Fig. 3.7), and may have destabilized the 3D conformation of the 
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protein.  The tyrosine within the second glycosylation site, NMT at position 79 in M2 
shares the second putative casein kinase 2 site present within M2 (compare Fig. 5.1 to 
Chapter 2 Fig.2.2).  This could explain why loss of this important glycosylation site/CK2 
site impacts protein functioning and total loss of expression.
 The above experiments demonstrated that MVA-mediated ERK1/2 activation 
proceeds through a CK2 mediated pathway.   As it is known that M2L inhibits ERK1/2 
activity, it was hypothesized that M2L could act as a substrate for phosphorylation by 
CK2.  To assess whether M2L can be directly phosphorylated by CK2, an in vitro 
phosphorylation assay will need to be performed to determine whether M2 is a substrate 
for CK2- mediated MVA activation of ERK1/2 or NF-κB activation.  
 Due to high levels of endogenous CK2, within cells, CK2 may be ubiquitious 
pathway vaccinia virus modulates.  No data in the literature suggests modulation of 
poxviruses by the CK2 pathway.  If M2 is found to inhibit CK2 activity through an in-
vitro kinase assay, this would be the first report of such a molecule that is able to inhibit 
CK2 activity in poxviruses.  In turn, this would open possibilities for therapeutics, as 
CK2 is implicated in cancer and other disease pathogenesis. 
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Figures
Figure 5.1 The CK2 phosphorylation sites within the amino 
acid sequence of M2.  The 220 amino acid M2 vaccinia virus 
protein is depicted with the amino acid available for CK2 
phosphorylation circled in black at positions 61, 81, 133, 147, 
197.  The five putative CK2 sequences are highighted in red.
MVYKLVLLFCIASLGYSVEYKNTICPPRQDYRY 
WYFAAELTIGVNYDINSTIIGECHMSESYIDRNA 
NIVLTGYGLEINMTIMDTDQRFVAAAEGVGKDN 
KLSVLLFTTQRLDKVHHNISVTITCMEMNCGT 
TKYDSDLPESIHKSSSCDITIGSCVTCVNLETD 
PTKINPHYLHPKDKYLYHNSEYSMRGSYGVTF 
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Figure 5.2  The effect of TBB drug treatment on MVA-induced ERK activation in 293T 
or HeLa cells.  Cellular monolayers of 293T (A) or HeLa (B) cells were treated with TBB at 
the indicated concentrations for 30 minutes.  Following TBB pretreatment, each cellular 
monoloayer was infected with MVA (+MVA) and the cytoplasmic protein extracts were 
harvested at 0.5 and 1 hpi.  Cytoplasmically extracted protesins were separated by 12% 
SDS-PAGE and transfered to PVDF membranes and incubated with either phoshpo-
ERK1/2 or unmodified ERK 1/2 antisera.  
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Figure 5.3  The effect of dominant negative CK2 construct on MVA-induced ERK 
activation in 293T or HeLa cells.  Cellular monolayers of 293T (A) or HeLa (B) cells were 
tarnsfected with pCI/M2L-V5 (2000 ng) or CK2DN (2000 or 4000 ng) plasmids.  At 24 h 
post-transfection, cells were mock-infected (MVA) or infected with MVA (MOI=10).  At 0.5 
or 1 hpi, cells were harvested and lysed.  Cytoplasmically extracted protesins were sepa-
rated by 12% SDS-PAGE and transfered to PVDF membranes and incubated with either 
phoshpo-ERK1/2 or unmodified ERK1/2 antisera.  
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activation in 293T cells.  293T cellular monolayers were transfected with pCI/M2l-V5 
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RULQIHFWHGZLWK09$02, DQGKDUYHVWHGDWKSLRUKSLѥJRIQXFOHDU
extracted proteins from each sample were incubated with 32P-radiolabelled oligonucleotides 
WKDWFRQWDLQ1)ѣ%ELQGLQJVLWHV´1HJµLQGLFDWHVDUHDFWLRQODFNLQJQXFOHDUH[WUDFWV
Reactions were analyzed via a gel electrophoretic mobility shift assay (EMSA).  Shifted bands 
FRQWDLQLQJ1)ѣ%DUHLQGLFDWHGZLWKDQDVWHULVN,QVRPHUHDFWLRQVFRQWDLQLQJQXFOHDU
H[WUDFWVIURP09$LQIHFWHGFHOOVDQWL1)ѣ%DQWLERG\SZDVSUHVHQW7KHPRELOLW\RIWKH
UHVXOWDQWVXSHUVKLIWHGEDQGLVLQGLFDWHGE\DGRXEOHDVWHULVN
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Chapter VI:  Summary and Future Directions
Summary
  This work encompasses several novel findings about the vaccinia virus M2 
protein.  Although M2 is not essential for viral growth and replication in cultured cell 
lines,it is expressed early during infection and acts as an immunomodulator.  
 Results presented in this dissertation demonstrate that M2 proteins are synthesized 
in the ER, post-translationally modified, and trafficked through the secretory pathway.  
Mutational analyses has demonstrated that M2 relies on its N-terminal signal peptide 
sequence and its 4 putative N-linked glycosylation sites to function fully.  The C-terminus 
of M2 also plays a role in M2 functioning, and may be due to the putative ER-retention/
retrieval sequences present.  M2 is secreted, but is not present on the surface of cells, and 
its extracellular function is currently unknown.  A portion of M2 proteins are intracellular, 
and it is proposed that this form of M2 is responsible for ERK1/2 and NF-κB inhibitory 
activity.  M2 has not been shown to physically associate with any members of the NF-κB 
or ERK1/2 pathways, nor is it able to degrade these proteins (unpublished observations).  
M2L may potentially modulate another protein(s) involved in these cytoplasmic signaling 
pathways.  
 While other poxviral proteins are known to inhibit NF-κB activation, these 
proteins have not been characterized to be heavily reliant on ER localization and 
glycosylation for their activity (12).  M2 differs in molecular functioning from that of 
other poxviral NF-κB modulators.  For instance, K1 inhibits PKR activation, thereby 
preventing eIF2alpha phsophorylation.  Therefore, M2 increases the repertoire of 
vaccinia virus proteins that inhibit NF-κB.
 The M2L gene is highly conserved among orthopoxviruses, yet lacks homology to 
any known cellular or viral protein.  There is no known immunomodulatory protein that 
is shared by all poxviruses, thus immunomodulators are specific to the virus and the host 
it infects (15).   Immunomodulators such as M2 may confer a survival advantage when 
the virus moves to another host species.  We have validated that M2 is indeed a secretory 
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protein and that glycosylation and signal peptide cleavage contribute to M2’s function as 
an immunomodulator. The fact that M2 is secreted and is thus soluble may counteract the 
activity of cytokines. This may have added to the virus’s success when infecting other 
cells and helped these orthopoxviruses replicate in several species. 
 Summarized in Table 6.1 are the M2 mutant protein phenotypes that have been 
fully characterized within this thesis.  Data presented in this body of work demonstrate 
that single glycosylation and signal peptide alteration to the vaccinia virus M2L protein 
has functional consequences. The ability of M2 to inhibit both the ERK 1/2 and NF-κB 
activation pathways is due to two distinct mechanisms that are not precisely defined at 
this point in time.  The double and triple glycosylation mutants have not been fully tested 
at the time of this writing, but it is predicted that these mutants would be impaired in their 
NF-κB and ERK 1/2 inhibitory activity as well.  
 The M2 gene product has no homology to any other protein existing in either the 
cellular or viral realm, making it an attractive therapeutic target for poxvirus infection.  
M2 may have potential for the development of antiviral strategies against a wide variety 
of viruses, including highly virulent emerging viruses. Implications of the loss of 
glycosylation sites in vaccinia virus are intriguing.  It may prove fruitful to ameliorate 
poxvirus disease by finding ways to modulate glycosylation of viral proteins which may 
prevent passage to other hosts.  Interruption of sugar-lectin interactions for antiviral 
treatment has been recently described (1).  Recent experiments in the poxvirus field have 
focused on engineering vaccinia virus proteins to elicit more robust neutralizing antibody 
reaction from the host (16).  As M2 is secreted, it may be acting as a cytokine mimetic, 
with the glycosylation sites shielding M2 from immune surveillance.  This provides 
future prospectives into developing therapeutics against poxviruses. 
 The ability to effectively target poxviral proteins for therapeutic intervention 
requires an understanding of all the intricacies that govern their activity.  Other 
researchers have highlighted the role of M2L in vivo.  Loss of the M1L-K2L region, 
including that of M2L in the vaccinia Tian Tian strain resulted in loss of virulence in 
BALB/c mice (21).  Another study demonstrated that the M2L epitope of 38-46, 
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comprising amino acids AELTIGVNY, was a peptide recognized by vaccinia-specific 
CD8+ T cells from the HLA allele B*4403 (11).  These findings underscore the role that 
M2 plays in poxviral diseases, and the need to target its activity.  
 Because the interaction between the signal peptide and its glycoprotein seems to 
be highly specific, inhibiting this interaction may be of therapeutic relevance.  As shown 
in Fig. 3.6 and 3.11 (Chapter 3), disruption of M2’s signal peptide cleavage impairs its 
proper functioning.  Inhibitory peptides or peptidomimetics that suppress the interaction 
between the signal peptide and glycoprotein would prevent cleavage of the protein and 
thus the production of infectious virus, or a viral protein which inhibits the host immune 
response.
 The data presented in this report extend the results of previous studies into the 
mechanistic basis for M2L functioning in 293T cells.  The evidence that M2L affects both 
NF-κB and ERK1/2 signaling adds yet another degree of complexity as well as another 
potential target to modulate the host response to poxviruses.   This advances our 
knowledge of M2 and improved our understanding between molecular post translational 
modifications and function.  This has improved the understanding of the host immune 
response to vaccinia virus.  Given that M2L is glycosylated, this underscores the 
importance of understanding virally encoded glycoproteins and their contribution to 
disease in the infected host.  Further investigation of this issue may provide new insights 
into the role of N-linked glycosylation for viral and cellular glycoproteins. Further studies 
are needed to address the intricate mechanisms of M2 action, and the following future 
studies outlined will aid in this understanding.
Future Directions
Extracellular Function for M2
 Secreted proteins are of particular interest as they theoretically have the highest 
potential for processing by the proteasome and presentation of peptides in associated with 
MHC class I molecules (5).  By interacting with specific cellular receptors, many viral 
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glycoproteins stimulate cells directly to secrete cytokines and chemokines.  In addition, 
viral RNA and a number of viral proteins with an intracellular location interfere with 
cellular signal transduction and transcription factor activity, thus promoting viral 
replication and expression of proinflammatory proteins.  
 As the secretory pathway is now emerging as a future target for anti-cancer 
therapy, it helps to understand processes viruses utilize as potential avenues for action 
(18).  Curiously, the M2 protein, although secreted outside of cells, was not found to 
confer function to naive cells exposed to the secreted form of M2L.  This may indicate 
that M2L possesses the ability to bind to secreted cellular or viral proteins induced during 
infection and modulates the infection in this manner.  Attempts to identify an extracellular 
binding partner for M2 is currently in progress.  
 M2 does not have any homology to any secreted protein, but it is conceivable that 
M2 may influence the activity of other secreted proteins, for instance that of cellular 
secreted MAPK inhibitors such as CCDC134 (10).  M2L may increase the activity of 
such molecules by binding to their active site and thus increasing their activity.  This 
possibility has not been explored.
 Our signal peptide cleavage mutants demonstrate that impairment of signal 
peptide processing may delay ultimate secretion of the protein.   It is known that 
alteration of the length of a signal peptide sequence manipulates the translation rate of ER 
targeted proteins, and that this rapid translocation step influences the ultimate fate of 
protein translation and impacts physiological functioning (8).  Our studies did not address 
the topology of M2L synthesis into the ER membrane and the time of synthesizing the 
polypeptide.  The exact time required for signal peptide processing during the 
intracellular transport of M2L into the ER lumen cannot be deduced from our current 
analysis.  Knowledge of this regulation for signal peptide cleavage functioning would add 
to the understanding of its influence on activity.
 As many disease states are associated with improper processing of signal peptide 
proteins, or delay in trafficking, understanding which steps the M2 protein utilizes sheds 
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light on mechanisms that may be important for correct targeting and functioning within 
cells.  
Creation of a Histidine-Tagged Version of M2 and Identification of Intracellular or 
Extracellular Binding Partners
 Previous attempts to identify an intracellular binding partner for M2 were 
unsuccessful.  It is thought that the secreted form of M2 interacts with either a cellular or 
viral secreted factor, thus inhibiting an unknown target protein that is causing ERK 1/2 
and NF-κB activation in cells. 
 Reattempts at a C-terminal histidine-tagged version of M2 in order to purify the 
tagged protein and assay for interacting partners will need to be constructed.  To identify 
any possible proteins that interact with M2, M2 will be expressed as a polyhistidine-
tagged protein in E. coli.   Evidence of data presents point to a cellular protein which M2 
may modualte, and thus it is prudent to examine if M2 physically interacts with this 
protein(s).  As the various glycosylation mutants have shown, M2 may modulate both the 
ERK1/2 and NF-κB activation pathway in a different manner.  
 The expressed proteins will be bound to a histidine column and incubated with 
whole-cell extract derived from 293T cells.  After washing the column and eluting, the 
sample will be run on a SDS-gel and silver-staining performed to visualize any potential 
interacting proteins. It will also be prudent to examine if any proteins that could bind to 
M2 after stimulating cells with different agonists such as PMA, as M2 can inhibit PMA-
induced ERK1/2 activation. 
 Viral proteins have been known to associate with cellular proteins and thus 
change their normal cellular destination (3).  Burger et. al showed that adenoviruses 
E3/19K associate with HLA antigens, but by doing so, inhibited the correct glycosylation 
pattern of the HLA antigen.  This in turn affected proper cell surface expression of the 
HLA antigen.  This mechanism delayed or escape the cellular immune system of the host.  
It is conceivable that M2L could divert pools of  proteins away from their proper location 
within the cell, thus ultimately impacting their correct functioning.  
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 The goal of future experiments will be to identify and characterize binding 
partners (viral or cellular) of M2L.  If a binding partner for M2 is identified, use of M2 
mutants described in this paper will facilitate understanding of its function in vivo.   
 
In Vitro Kinase Assays to Determine Whether M2 is a Substrate for Upstream 
Kinases such as MAPK or CK2 Which Lead to ERK 1/2 and NF-κB Activation
 M2 is observed to inhibit MVA-induced, and PMA-induced ERK 1/2 activation 
(Chapter 2).  It also inhibits MVA-induced NF-κB activation.  It is speculated that M2 
inhibits the activity of an upstream kinase that results in the activation of NF-κB and 
ERK 1/2.  
 It is known that MAPK signaling occurs through various intracellular 
compartments in the cell, including that of the ER (2, 6).  However, studies on ER-based 
signaling pathways and molecules demonstrated that M2L was not acting directly at the 
level of ER signaling to prevent either ERK1/2 or NF-κB activation (Chapter 4).  
Therefore, other possibilities may exist for M2 functioning.  Understanding virus 
induced/utilized signals may lead to successful strategies for targeting specific signaling 
molecules to develop anti-viral strategies.  Drugs targeting the MAPK pathways represent 
a promising new class of antiviral agents to treat poxvirus infections (5, 19).   
 ERK1 and ERK2 are co-expressed in nearly all tissues, and contain extensive 
amino acid identity, and have similar spatio-temporal regulation.  Emerging evidence 
show that ERK1 and ERK2 may be regulated differently in different cell lines (17).  
Increasing evidence shows extensive cross talk between distinct MAP kinase pathways.  
Notably, it was shown in HEK293 and HeLa cells that p38 interacted with ERK1 and this 
was dependent on p38 activation status.  p38 phosphotransferase activity was crucial for 
this interaction, and that two MAP kinases in two distinct signaling cascades physically 
interacted with each other (20).  Interestingly, it was reported by the same group that 
activated p38 can form a complex with casein kinase 2 in HeLa cells (14).  
 M2 was shown to affect both ERK2 but ERK1 activation, and there is preliminary 
evidence demonstrating that M2 may affect IL-1β stimulated p38 activation as well (Fig. 
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6.1).  As such, the influence on M2 on p38 expression or stability should be further 
investigated.  Preliminary data suggest (Fig 2.10 and Fig 6.1) that M2 may act as a 
substrate for the ERK and p38 MAPK family members.  
  M2 may be acting as a competitive inhibitor in the cellular pathways it interacts 
with.  MAPKs require their dual phosphorylation at two conserved threonines (Thr/T) 
and tyrosines (Tyr/Y) (4, 13).  These phosphoryaltion sites are separated by only one 
amino acid, thereby defining a tripeptide motif, Thr-X-Tyr.  M2 contains a TGY at amino 
acid positions 72-74, and a TKY sequence at amino acids 133-135.  M2L may therefore 
be acting as a substrate for an upstream kinase, and acting as a decoy substrate.  M2 
contains a motif indicative for p38 MAPK phosphorylation, but no direct interaction with 
p38 was observed (Fig. 4.9).  However, M2 inhibition of p38 activity was only observed 
when cells were stimulated with a p38 agonist, IL-1β (Fig. 6.1). Studies are therefore 
needed to determine if M2 is acting as a phosphorylation substrate for both ERK1/2 and 
p38 MAPK activation.  
 Why ERK1 phosphorylation is more heavily impacted in cells where M2 is 
expressed is unknown.  M2L does not share homology to either ERK1 nor ERK2.  This 
makes it likely that M2L is merely acting as a phosphorylation substrate due to the fact 
that it is able to inhibit both MVA- and PMA- induced ERK1/2 activation (7, 9).  
 Besides potentially serving as a MAPK substrate, M2 contains various other 
serine/threonine sites which are candidates for phosphorylation.  We have not assessed 
whether M2 is phosphorylated under all conditions we have described in this dissertation, 
but it is intriguing to note that the N79Q mutation overlaps with a putative casein kinase 
II (CK2) phosphorylation site.  M2 has five putative CK2 sites, which may serve to 
modulate casein kinase II induced activity as a means to downregulate ERK1/2 activity.   
The use of a an in-vitro kinase assay will resolve whether M2 is a substrate for such 
activity.  If results demonstrate that M2 is a substrate for upstream kinases involved in 
ERK 1/2 and NF-κB activation, then further studies will need to address if the CK2 
involved is catalytically active in the presence of M2 during infection. 
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Tables and Figures
viruses expression secretion NF-țB inhibition ERK 1/2 
inhibitionearly late
M2L WT +++++ +++++ 
(0.5 h.p.i)
+++++ +++ +++++
¨Vp + No + + +
¨(5 ++++ ? can’t tell, 
antibody issues
+++ +++ ++
N49Q +++ +++++ ++ ++ +
N79Q ------ ----- ++ ++ ++
N118Q +++++ +++++ + ++ ++
N154Q + -----> ++++ 
expression increases 
as infection pro-
ceeds
++++ ++++ ++ ++
S17I ++ ++++ (4 h.p.i.) + ++ ++
S17F ++++ ++++ (4 h.p.i) + ++ +
Table 6.1  Summary of M2 mutant protein phenotypes.  (+++++) denotes 
strongest activity noted, (+) weakest activity noted, (------) denotes no detectable 
activity at all.   
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• western blotting • silver and coomassie staining • in-vitro kinase assays • mammalian cell culture • 
transient transfection • cloning
Computer competency in both PC and Mac platforms: 
Confocal image acquisition software:  Leica SP2 and Zeiss LSM 510 confocal microscopes
NIH Image J • FCS Express 3 • FlowJo • BLAST • SignalP 3.0 • Adobe CS3 - Illustrator and Photoshop • 
Microsoft Word, Excel, and Powerpoint • Apple Keynote • basic HTML and website design
ACADEMIC RESEARCH EXPERIENCE
Graduate Research Assistant, Department of Microbiology
University of Illinois at Urbana-Champaign                       January 2005- October 2010
My project focuses on determining the molecular mechanism the vaccina virus M2L protein uses to inhibit 
the activation of the eukaryotic transcription factor NF-κB.  
 • Characterized the phenotype of the vaccinia virus M2L protein’s ability to localize to the 
  endoplasmic reticulum (ER) during infection
  • Demonstrated the intracellular ER-localization, glycosylation, and extracellular secretion of protein
 • Created recombinant viruses expressing wild-type and mutant constructs of the M2L protein
 • Coordinated generation of a polyclonal antibody against the M2L protein 
 • Investigated ER-based signaling pathways such as the unfolded protein response and calcium
 dependent pathway
 • Conceptualized and carried out experiments pertaining to the extracellular function of M2L 
• Developed protocol for confocal microscopy of virally-infected samples
Olivia Hinthong
1005 WEST STOUGHTON APT. 207   URBANA, IL 61801 
TEL  217-719-0000  EMAIL olivia@oliviahinthong.com
WEBSITE: www.oliviahinthong.com
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• Initiated studies using flow cytometry to access for calcium release in infected cells
    • Acquired plasmids and other reagents important for project’s progress
    • Refined protocol for harvesting and titering viruses
 • Presented research data at yearly departmental seminars and conferences 
Other responsibilities: 
  • Validated various methods to optimize gel electromobility shift assays 
•  Developed website for annual Department of Microbiology conference (Fall 2006)
    •  Handled troubleshooting and communication of broken lab equipment to facilities operations
• Monitored biological, chemical and radioactive waste flow and handled disposal of generated waste
•  Served as projectionist for weekly departmental seminars for visiting faculty speakers
•  Presented data at various conferences around the world
• Collaborated with a variety of researchers from exchanging DNA constructs,
 and other reagents supplying either our antibodies or helpful discussion related to projects
• Mentored various undergraduate students in the laboratory
Undergraduate student, Laboratory of Dr. James Weyhenmeyer 
University of Illinois at Urbana-Champaign                         2002-2004
Worked on the G-protein coupled receptor signaling pathway involved in inhibiting insulin-induced ERK-2 
phoshorylation due to expression of the human angiotensin II type-2 receptor in CHO cells.  
 • Contributed to the project by performing western-blotting, liquid scintillation counting, 
          DNA preparation, and cell culture
INDUSTRY EXPERIENCE
Research Specialist, Kim Laboratories, Inc.
Champaign, IL (now in Rantoul, IL)                                              2003-2004
Kim Laboratories Inc. focuses on developing food safety technology that quickly and accurately detects 
bacterial or viral contamination and focuses on the production of monoclonal norovirus antibodies.
•  Awarded Employee of the Year, 2004  
• Undergraduate worker trusted to join the company at its inception  
•  Extracted and purified LPS from candidate serotypes  
•  Performed oral and peritoneal inoculation of mice 
•  Attained knowledge regarding establishing a hybridoma cell line, monoclonal antibody production,    
   ELISA, and NIH small-business grant writing proposals
PUBLICATIONS
1. Hinthong, O., Jin, X.L., and Shisler, J.L.  (2008).  Characterization of wild-type and mutant vaccinia 
      virus M2L proteins’ abilities to localize to the endoplasmic reticulum and to inhibit NF-κB activation 
      during infection. Virology. 373(2):248-262.
2. Gedey, R., Jin, X.L, Hinthong, O., & Shisler, J.L. (2006). Poxviral regulation of the host NF-kappaB 
 response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2    
     pathway in virus-infected human embryonic kidney cells. Journal of Virology, 80 (17): 8676-8685.
3.  Moore, S. A., Huang, N., Hinthong, O., Andres, R. D., Grammatopoulos, T. N. & Weyhenmeyer, J.A. 
 (2004). Human angiotensin II type-2 receptor inhibition of insulin-mediated ERK-2 activity via a G-
 protein coupled signaling pathway. Molecular Brain Research, 124, 62-69. 
HONORS AND AWARDS
Deboer Fellowship               Summer 2010
University of Illinois at Urbana-Champaign                
Departmental fellowship support in virology.                                      
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James R. Beck Fellowship 
University of Illinois at Urbana-Champaign Fall 2008 & 2009 
Awarded to the most promising graduate student in their class, based on research accomplishments and 
potential in the field of microbiology.  A committee selects the most deserving candidate.  
Travel Award
17th Annual International Poxvirus and Iridovirus Conference                        June 2008 
Received full funding for the poxvirus conference, including registration, travel and accommodation fees.     
Teachers Ranked as Excellent by their Students
University of Illinois at Urbana-Champaign Fall 2005 & 2007
This campus-wide award is based on student evaluations during the course of the semester.  Achieved 
criteria to be ranked within the top 30% of instructors during the semester based upon teaching 
effectiveness and quality of instruction.  
CONFERENCE PRESENTATIONS
1.  “Understanding the molecular mechanism the ER-localized vaccinia virus M2L protein utilizes to 
       inhibit NF-κB activation.” Olivia Hinthong and Joanna Shisler.  28th Annual American Society for 
       Virology Meeting. Vancouver, BC. July 11-15, 2009.  
2.  “Understanding the molecular mechanism the ER-localized vaccinia virus M2L protein utilizes to 
      inhibit NF-κB activation.” Olivia Hinthong and Joanna Shisler.  17th Annual International 
      Poxvirus and Iridovirus Conference.  Grainau, Germany. June 7-12, 2008.  
3.  “The Vaccinia Virus M2L Protein inhibits NF-κB  and localizes to the Endoplasmic Reticulum.”  Olivia 
      Hinthong and Joanna Shisler. 26th Annual American Society for Virology Meeting. Oregon State  
      University, July 14-18, 2007.
4.  “Molecular Mechanisms the Vaccinia Virus M2L protein uses to Inhibit NF-κB.”  Olivia Hinthong, 
      Xiao-Lu Jin, Roderick Gedey, and Joanna Shisler. SEB Summer Research Conference on 
      Poxviruses. Indian Wells, CA.  June 3-8, 2006. 
TEACHING EXPERIENCE
Teaching Assistant, MCB 300 and 301
University of Illinois at Urbana-Champaign                                                                     Spring & Fall 2010
This introductory course focuses on microbial concepts and techniques.  
• Graded worksheets, lab reports, and homework assignments and proctored exams  
Teaching Assistant, MCB 250 - Molecular Genetics 
University of Illinois at Urbana-Champaign                                                            Fall 2005 & 2007
This course focused on genetic variation, gene organization, gene expression, and gene regulation in a 
variety of organisms.
 • Independently instructed molecular biology concepts to over 180 students
 • Taught in a meaningful manner, relating biology concepts to current events
 • Provided unbiased feedback to foster student progress
 • Designed and prepared interactive Powerpoint presentations to reinforce lecture material, used  
    “Jeopardy!” style game to review for exams
 • Provided supplementary help/practice through office hours and one-on one meetings
 • Ranked as one of the “List of Teachers Ranked as Excellent By Their Students” 
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TUTORING EXPERIENCE
Tutor, Irwin Academic Center
University of Illinois at Urbana-Champaign                                                      October 2008-December 2010
• Tutored all tracks of molecular and cellular biology to student-athletes
MENTORING EXPERIENCE
Trained and mentored various undergraduate students in experimental techniques and primary literature 
readings in a laboratory setting.  
Matthew Welzenbach, Undergraduate Student                                             December 2009- December 2010
Calvin Wang, Undergraduate Student     Summer 2010
Brian Wang, Undergraduate Student June 2009-May 2010
REFERENCES
Joanna Shisler, Ph.D., Associate Professor of Microbiology
University of Illinois at Urbana-Champaign
217-265-6450, jshisler@illinois.edu
Dr. Shisler has been my dissertation advisor.  She can elaborate on my research capabilities and academic 
potential.
Myung L. Kim, Ph.D., CEO, Kim Laboratories, Inc.
Champaign, IL
217-337-6666, mkim@kimlaboratories.com
Dr. Kim was my boss at Kim Laboratories, Inc. and can address my research capabilities in an industrial 
setting.  
Richard Tapping, Ph.D., Associate Professor of Microbiology
University of Illinois at Urbana-Champaign
217-244-7940, tapping@illinois.edu
Dr. Tapping has served as my committee chair during the course of my graduate career.  He is able to 
comment on my research quality and scientific reasoning and knowledge.
Barbara Pilas, Ph.D., Director of Flow Cytometry Facility
Carver Biotechnology Center
University of Illinois at Urbana-Champaign
217-244-6743, pilas@illinois.edu
Dr. Pilas knows me from when I performed flow cytometry studies, and is able to comment on my technical 
ability and understanding in a shared use facility. 
Annie L. White, Academic Counselor
217-265-4069, alwhite@illinois.edu
Irwin Academic Center, University of Illinois at Urbana-Champaign
Annie is the academic counselor at the Irwin Academic Center.  She can comment on my tutoring ability 
and effectiveness.
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